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 Abstract 
The immediate antiviral defense residing in the innate immune system of multicellular 
organisms critically determines the outcome of viral infection. This dissertation presents a study 
of the “effectors” and “receptors” of porcine innate immunity in infection caused by porcine 
reproductive and respiratory syndrome virus (PRRSV), which is the most devastating pathogen 
impacting the swine industry.    
In the first investigation, eleven novel porcine host defense peptides (HDPs), β-defensins 
(pBDs), were identified and characterized. All of these peptides have a consensus β-defensin 
motif and phylogenetically are similar to orthologs from other species. A differential expression 
pattern for these 11 newly identified genes was found. For example, pBD-2 and pBD-3 were 
expressed in bone marrow, lung, skin and other lymphoid tissues. pBD-2 and pBD-3 were further 
characterized for their gene structure, and antimicrobial activity of synthetic peptides.  
The second study was conducted to evaluate PRRSV-induced differential expression of 
porcine HDPs and direct antiviral activity of selected HDPs against PRRSV. In vitro incubation 
of PRRSV with synthetic pBD-3 or protegrin-4 (PG-4) significantly inhibited viral infectivity. 
Using nine protegrin-derived peptides, it was determined that cyclization of PG-4 increased anti-
PRRSV activity and mutation of some residues in PG-4 diminished some of the activity. These 
findings suggest the potential role of porcine HDPs as a group of innate antiviral effectors.  
In the third and fourth investigations, porcine Toll-like receptor (TLR) 3 and TLR7 were 
identified and functionally expressed. Increased expression of TLR3 was observed in PRRSV-
infected porcine lungs. Stimulation of porcine alovelar macrophages with poly (I:C), a synthetic 
TLR3 ligand, increased expression of interferon-β  and suppressed PRRSV infectivity. Activation 
of porcine TLR3 overexpressed in a PRRSV-sensitive cell line, elicited antiviral responses to 
PRRSV infection. Partial silencing of TLR3 in PAMs resulted in increased PRRSV infection. In 
summary, these data provide molecular information on porcine TLR3 and TLR7, and their 
involvement in PRRSV pathogenesis, which may elicit new strategies to prevent this costly 
swine disease. 
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Abstract 
The immediate antiviral defense residing in the innate immune system of multicellular 
organisms critically determines the outcome of viral infection. This dissertation presents a study 
of the “effectors” and “receptors” of porcine innate immunity in infection caused by porcine 
reproductive and respiratory syndrome virus (PRRSV), which is the most devastating pathogen 
impacting the swine industry.    
In the first investigation, eleven novel porcine host defense peptides (HDPs), β-defensins 
(pBDs), were identified and characterized. All of these peptides have a consensus β-defensin 
motif and phylogenetically are similar to orthologs from other species. A differential expression 
pattern for these 11 newly identified genes was found. For example, pBD-2 and pBD-3 were 
expressed in bone marrow, lung, skin and other lymphoid tissues. pBD-2 and pBD-3 were further 
characterized for their gene structure, and antimicrobial activity of synthetic peptides.  
The second study was conducted to evaluate PRRSV-induced differential expression of 
porcine HDPs and direct antiviral activity of selected HDPs against PRRSV. In vitro incubation 
of PRRSV with synthetic pBD-3 or protegrin-4 (PG-4) significantly inhibited viral infectivity. 
Using nine protegrin-derived peptides, it was determined that cyclization of PG-4 increased anti-
PRRSV activity and mutation of some residues in PG-4 diminished some of the activity. These 
findings suggest the potential role of porcine HDPs as a group of innate antiviral effectors.  
In the third and fourth investigations, porcine Toll-like receptor (TLR) 3 and TLR7 were 
identified and functionally expressed. Increased expression of TLR3 was observed in PRRSV-
infected porcine lungs. Stimulation of porcine alovelar macrophages with poly (I:C), a synthetic 
TLR3 ligand, increased expression of interferon-β  and suppressed PRRSV infectivity. Activation 
of porcine TLR3 overexpressed in a PRRSV-sensitive cell line, elicited antiviral responses to 
PRRSV infection. Partial silencing of TLR3 in PAMs resulted in increased PRRSV infection. In 
summary, these data provide molecular information on porcine TLR3 and TLR7, and their 
involvement in PRRSV pathogenesis, which may elicit new strategies to prevent this costly 
swine disease. 
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CHAPTER 1 - Literature Review: Mammalian Antiviral Innate 
Immunity 
 
1.1.  Introduction 
The immune system in higher vertebrates comprises both innate and adaptive immunity 
(Pancer and Cooper, 2006). Either sensitized by vaccination or evoked latter during infections, 
adaptive immunity consists of immune responses characterized by the arrest of B cells and T 
cells to exert pathogen-specific protection via secretion of humoral antibodies and activation of 
cell-mediated cytotoxicity. Conversly, innate immune mechanisms provide immediate frontline 
protection against infections (Beutler, 2004; Pancer and Cooper, 2006). In previously 
unvaccinated individuals, it may take 1-2 weeks to establish antibody levels and T cell responses 
(i.e. adaptive immune responses) post viral infection. Hence, without efficient protection from 
innate immunity, this time gap could potentially leave viruses unchecked and cause lethal 
consequences in animals (Pichlmair and Reis e Sousa, 2007; Takeuchi and Akira, 2007).  
Notably, despite being less specific than adaptive immunity, the promiscuity of innate immune 
recognition broadly extends its capacity for surveillance of pathogens. This is especially 
important for viruses, which keep changing their antigenic epitopes specifically recognized by 
neutralizing antibodies and T-cell receptors (TCR) in the adaptive immune system (Beutler, 
2004; Pancer and Cooper, 2006). Evidences from both host and virus indicate that early invoking 
of appropriate innate immune responses determines the outcomes of viral diseases, whether the 
infection is controlled or developed into a persistent status resulting in serious diseases (Beutler, 
2004; Pancer and Cooper, 2006). For the host per se, mutations which cause inefficiencies of the 
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innate immune response in viral sensing, signaling transduction or expression of antiviral 
effectors, often significantly elevate susceptibility or mortality to infection of multiple viruses 
(Akira et al., 2006; Pichlmair and Reis e Sousa, 2007). Virus isolates or species, which have the 
ability to suppress or evade innate immune surveillance, are likely to cause chronic infection 
leading to pandemic diseases (Haller and Weber, 2007; Loo and Gale, 2007). The critical role of 
innate immune cells and components not only obligates to early antiviral activity, but also 
potentiates the adaptive system for viral clearance (Hoebe et al., 2004; Kabelitz and Medzhitov, 
2007; Wen et al., 2008).       
 
1.2.  Afferent and Efferent Arms of Innate Antiviral Immunity 
Similar to adaptive immunity, the innate immune system also comprises both afferent and 
efferent arms to discriminate and kill pathogens (Fig. 1.1) (Beutler, 2004). This capability is 
intensified when dealing with viruses, which use host cellular metabolism to facilitate their own 
life cycles. Although innate immune sensors are diversified to distinguish between viral and 
cellular molecules, components of the efferent arm are also specialized to convey virus-
dependent activity. For example, interferon (IFN)-inducible proteins such as human tripartite 
motif protein (TRIM)-5α targets capsids of invading retroviruses, and Mx proteins target 
nucleoproteins of bunya- and orthomyxoviruses (Pichlmair and Reis e Sousa, 2007). In contrast, 
antibacterial proteins (such as lysozyme and bactericidal/permeability-increasing protein (BPI)) 
are less diversified and are generally active against most bacteria. Nevertheless, some 
components in both afferent and efferent arms of innate immunity are “universally” functional 
against bacteria, fungi, protozoa and viruses; however, only the activity in antiviral immunity 
will be discussed in this review. To focus on the main theme of this dissertation, examples 
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related to respiratory viral infections are primarily used. In Fig. 1.1, major components of innate 
antiviral immunity in higher vertebrates, mainly exemplified with that of humans and mice 
(Beutler, 2004), are illustrated. Like that of adaptive immunity, innate antiviral immunity also 
consists of humoral and cellular parts, in which each part contains afferent (sensing) and efferent 
(effector) arms. To some extent, both sensor and effector molecules in the humoral part of innate 
immunity may have a role in inactivation of viral infectivity. In contrast, the afferent and efferent 
arms of the cellular part are more specialized, as sensors are not killing but recognizing 
pathogen-associate molecular patterns (PAMPs) and effector molecules mainly function to 
inactivate viruses (Pichlmair and Reis e Sousa, 2007; Zuniga et al., 2007). Most steps of the viral 
lifecycle are limited within cells with short intervals of intercellular dissemination; therefore, 
innate immune mechanisms for virus determination/inactivation are evolutionally concentrated 
in the cellular arm. Accordingly, the components of afferent and efferent arms in the cellular part 
will be mainly discussed in this review. Type I interferons (IFNs) and host defense peptides 
(HDPs), which are primarily secreted by immune cells into the humoral system after synthesis, 
will be extensively discussed to highlight their central role as effectors and regulators in antiviral 
immunity (García-Sastre and Biron, 2006; Klotman and Chang, 2006; Pestka, 2007). In addition, 
two exceptions listed in Fig. 1.1 include natural antibodies (NAb) and micro RNA (miRNA). 
Although NAbs (secreted from B1 cells) belong to the “combinatorial system” adjunctive to 
specific immunity, they show innate-like characteristics and often work together with 
complement, a prominent humoral innate immune system, to perceive and to promote killing of 
viruses or virus-infected cells (Cummings, et al., 2007; Dörner and Radbruch, 2007). Micro 
RNA and related RNA interference is a prominent antiviral defense mechanism in invertebrates 
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such as Drosophila; the role of miRNA in antiviral immunity of vertebrates is emerging but still 
controversial (Kumar, 2008).               
 
1.3.  Innate Immune Cells  
All nucleated cells, to some extent, are capable of mounting innate immune responses upon 
exposure to viral infection (Beutler, 2004). Nevertheless, a highly differentiated immune system 
is an evolutionary advantage in higher vertebrates and the specialized immune cells are involved 
in eliciting and coordinating immune responses (Pancer and Cooper, 2006).  Mammalian innate 
immune cells, which are specialized to fulfill requirements in pathogen recognition, immune 
surveillance, and/or effector killing, include hematopoiesis-derived granulocytes, natural killer 
(NK) cells, macrophages and dendritic cells (DCs), as well as epithelial and endothelial cells 
which line the the cavities/surfaces of stuctures throughtout the body. Other immune cells, such 
as γδ T cells and CD1d-restricted T cells, exert innate immune function (such as pattern 
recognition with their restricted T cell receptors (TCR)) as well, but their TCR diverge by 
rearranging TCR genes and they can also develop a memory phenotype --- the marker events of 
adaptive immune cells. Thus, they are considered as belonging to adaptive immunity (Beutler, 
2004; Pancer and Cooper, 2006; Yamagata et al., 2006). On the one hand, granulocytes, 
macrophages and NK cells are known for their role as effector cells in engulfing and digesting 
trapped microorganisms or promoting active death of infected cells (Appelberg, 2007; Ludwig et 
al., 2006; Takeuchi and Akira, 2007; Vivier et al., 2008). DCs, epithelial and endothelial cells, 
pertaining to their special anatomical locations, are among the first group of cells contacting the 
initial load of the virus (Barchet et al., 2005; Hammad et al., 2008; Opitz et al., 2007; Wen et al., 
2008); therefore, their ability in viral recognition and immune surveillance are augmented such 
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as in coordinating subsequent immune responses and linking to adaptive immunity. On the other 
hand, all innate immune cells are dually functional as “sensors” and “effectors” to pathogens. 
Even the professional killer cells (eg. neutrophils of granulocytes) are facilitated somehow for 
immune surveillance with TLRs (Borregaard et al., 2007; Haselmayer et al., 2006), and the 
professional antigen presenting cells (i.e. cDC) potently inactivate engulfed pathogens through 
autophagy (Lee and Iwasaki, 2008; Schmid et al., 2006). This kind of functional combination is 
best illustrated in macrophages, which are a diverse group of professional phagocytes lethal to 
most trapped pathogens and behave as critical immunoregulatory cells in production of type I 
IFN and antigen presenting cells after activation (Fig. 1.2) (Hashimoto et al., 2007; Kumagai et 
al., 2007; Randolph et al., 2008).  Nevertheless, upon viral infection the overall immune response 
is dependent on coordination of these immune cells to exert immune surveillance and to produce 
immune effectors. Quite often, innate immune cells (esp. epithelial and endothelial cells) are 
initial footholds for viruses to begin infections. Thus, innate immune cells represent an 
unequivocal platform for examining virus-host interaction, viral recognition, signaling 
transduction and function of antiviral effectors (Hammad et al., 2008; Opitz et al., 2007; Wen et 
al., 2008). Innate immune cells are also important because of their situation at the interface of 
innate and adaptive immunity to shape specific antiviral immune responses (Fig. 1.2) (Hammad 
et al., 2008; Hoebe et al., 2004; Opitz et al., 2007; Wen et al., 2008).    
                            
Epithelial cells: Distinct types of epithelial cells and secretory cells cover the body’s 
external and internal surfaces all over. Mucosal surfaces are classified into two categories, type I 
mucosae are lined by simple epithelia of one cell-layer thickness and type II mucosae are 
covered by stratified squamous epithelia (keratinocytes) (Holgate, 2007;  Iwasaki 2007). The 
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primary role of the epithelia in type I mucosae, represented by those that cover alimentary, 
respiratory and most parts of reproductive tracts, is to perform absorptive, respiratory, excretory, 
and reproductive functions. On the other hand, type II mucosae include those that line skin, 
cornea, oroesophagus, and lower female reproductive organs (ectocervix and vagina). The 
epithelia that line type II mucosal surfaces (esp. skin keratinocytes) do not have absorptive or 
respiratory functions, and primarily serve as a physical barrier with intensified innate immune 
mechanisms. Clearly, epithelia lining external and internal surfaces are at the first line in 
contacting with viruses and are frequently used by the virus as initial footholds for infection 
(Holgate, 2007; Iwasaki 2007; Schleimer et al., 2007; Turner 2006). For example, viruses 
implicated in various respiratory viral syndromes, including influenza, parainfluenza, 
enterovirus, adenovirus, respiratory syncytial virus (RSV), rhinoviruses (RV), and coronaviruses, 
are all capable of infecting airway epithelial cells (Bousse et al., 2006; Fernandez-Sesma, 2007; 
Guillot et al., 2005; Holgate, 2007; Schleimer et al., 2007; Shi et al., 2007). Therefore, epithelial 
cells are well equipped for immune surveillance in addition to their primary physiological 
functions (Schleimer et al., 2007). For example, epithelial cells express most identified pattern 
recognition receptors (PRRs) including Toll-like receptors (TLRs) and RIG-like receptors 
(RLRs) (Table 1.1) (Behera et al., 2002; Fu et al., 1999;  Message et al., 2004; Schleimer et al., 
2007; Takaoka et al., 2006). In regard to the effector system, all mucosal epithelial cells are 
covered by a viscous layer of mucus, which is produced by the adjacent mucus-secreting cells 
and effectively impedes virus access to epithelia. The important effectors produced by epithelial 
cells after responding to viral infection include IFNs, proinflammatory cytokines/chemokines,  
nitric oxide (NO) and host defense peptides (HDPs), incompletely listed in Table 1.1 (Alp et al., 
2005; Duits et al., 2003; Klotman and Chang, 2006; Pestka, 2007; Stroinigg et al., 2005; Sun et 
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al., 2005; Takaoka et al., 2006). Type I IFNs produced by virus-infected epithelial cells in turn 
induce surrounding cells to express hundreds of IFN-stimulated genes (ISG) including IFNs 
themselves, which have antiviral potency. These ISGs include the dsRNA-activated protein 
kinase K (PKR), which reduces cellular activity in translation and transcription, two enzymes, 2', 
5'-oligoadenylate synthetase (2'5'OAS) and RNase L, which promote viral mRNA degradation, 
the myxovirus resistance (Mx) proteins, and RNA-specific adenosine deaminases, which are 
involved in RNA editing to interfere with genomes of RNA viruses (García-Sastre and Biron, 
2006; Sen and Sarkar, 2007; Zuniga et al., 2007). The activation of epithelial cells also produces 
a variety of proinflammatory cytokines and chemokines which recruit other immune cells 
including lymphocytes and neutrophils to infection sites for development of overall antiviral 
immune responses (Holgate, 2007; Message et al., 2004; Schleimer et al., 2007; Shi et al., 2007; 
Takaoka et al., 2006).    
 
Endothelial cells: Another main route of viral entrance into animal bodies is through blood 
infection, either via arthropod vectors, contaminated needles or blood transfusion (Valbuena and 
Walker, 2006). The formation of primary and secondary viremia is a critical step for viruses to 
establish systemic infection. Endothelia, composed of specilizazed epithelial cells that line 
serous cavities and blood vessels, are among the first cells coming into contact with viruses 
entering the bloodstream. Rationally, endothelial cells are equipped with both transmembrane 
and cytosolic surveillance systems capable to sense viral PAMPs (Table 1.1) (Opitz et al., 2007; 
Warke et al., 2003; Chaudhuri et al., 2007; Frantz et al., 2005). Similar to epithelial cells, 
endothelial cells are likely capable of producing a variety of antiviral effectors in triggering 
immune protection. However, there are limited studies providing related information in 
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endothelial cells and there is no direct evidence about the existence of TLR7-9 and cytosolic 
RLRs in endothelial cells.     
  
Dendritic cells: In higher vertebrates, an additional role of the innate immune system is to 
evoke specific immunity in preparation for the pathogens escaping from non-specific 
surveillance (Beutler, 2004; Pancer and Cooper, 2006; Yamagata et al., 2006). If a viral disease 
is developed, productive adaptive immunity is crucial for hosts to systemically eliminate viruses. 
In this context, dendritic cells (DCs) represent a primary group of innate immune cells to bridge 
innate and adaptive immune responses (Iwasaki, 2007; Hammad and Lambrecht, 2008; Wen et 
al., 2008). DCs develop in bone marrow, exist in blood in an immature state and migrate to 
peripheral tissues as tissue-specific DCs including skin Langerhans cells and various mucosal 
DCs underneath the epithelial layers, where they are ready to sample antigens including those 
from infective viruses (Iwasaki, 2007; Hammad and Lambrecht, 2008; Wen et al., 2008). Two 
major types of dendritic cells are classified as conventional and plasmacytoid dendritic cells 
(cDCs and pDCs, respectively). cDCs are prominently antigen-presenting cells with high activity 
for autophagy, a process to uptake the antigen. After activated by antigen-uptake, DCs follow the 
gradient of chemokines (CCL19/CCL21) migrating to the adjacent lymph nodes, where they 
undergo a maturation process evidenced by the expression of surface molecules for co-
stimulation (CD80/CD86) and antigen presentation (CD1, ICAM-1, LFA-3, and MHC class I 
and II). Meanwhile, the cells are reshaped with long extensions (dendrites) which facilitate 
interaction with naïve T cells.  Although cDC are important in antigen presentation for training T 
cells in secondary lymphoid tissues, no direct antiviral role of periphery cDCs has yet been 
defined in a primary viral infection (Iwasaki, 2007; Hammad and Lambrecht, 2008). The pDCs 
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are known as natural IFN-producing cells because of their capacity for high-level production of 
IFN-α, which is essential for inducing a series of antiviral ISGs and establishing an antiviral state 
in surrounding cells (Barchet et al., 2005; Sen and Sarkar, 2007; Zuniga et al., 2007). To a lesser 
extent, pDC also produce IL-12, which is thought to influence T cell skewing towards a Th1 
response (Barchet et al., 2005).  Hence, DCs constitute a special group of innate immune cells 
with particular function in linking innate and adaptive immunity.  For efficient immune 
surveillance, DCs express a complete repertoire of PRRs including cytosolic RLRs in cDCs and 
TLRs in all DCs (Takeuchi et al., 2007; Zilliox et al., 2006; Kato et al., 2006; Rodríguez-García 
et al., 2007; Schlender et al., 2005). However, seldom do viruses infect DCs, it is suggested that 
cytoplasm-localized receptors in DCs might engage viral PAMPs leaked from the autophagy 
process (Pichlmair and Reis e Sousa, 2007). In addition, it was reported that activation of 
antigen-presenting activity in DCs requires TLRs localized in both DCs and stromal cells (eg. 
epithelial cells) (Sato et al., 2004). Some effectors secreted from surrounding stromal cells may 
play a role in activation of TLRs in DCs (Hammad and Lambrecht, 2008; Iwasaki, 2007). In this 
context, human β-defensin-3 (hBD3), a HDP secreted from epithelia, was reported to activate 
DCs through TLR1 and TLR2 signaling (Funderburg et al., 2007). It is not clear how hBD3 
engages the TLR1/TLR2 complex, possibly by serving as an endogenous ligand like murine β-
defensin 2 to TLR4 (Biragyn et al., 2002). In another case, the human cathelicidin LL-37 
activation of pDCs is through the formation a complex with nucleic acid and presention to TLR9 
(Lande et al., 2007). Thus, antiviral surveillance of DCs is possibly composed of receptors in 
DCs and effectors secreted from infected stromal cells. 
Macrophages:  Macrophages, similar to dendritic cells, belong to the monocyte lineage of 
myeloid cells (Randolph et al., 2008).  In adult animals, they originate from bone morrow stem 
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cells, progress through the stages of monoblasts and promonocytes, and differentiate into 
peripheral monocytes and tissues macrophages. Thus, macrophages are composed of groups of 
very heterogeneous populations according to their locations, such as blood monocytes, peritoneal 
macrophages, pulmonary macrophages, Kupffer cells in liver and microglia in brain (Naito, 
2008; Randolph et al., 2008; Taylor et al., 2005). Even in the same organ, macrophages are 
further diversified with regard to different micro-anatomical locations. For example, pulmonary 
macrophages can be divided into three subgroups in respect to their contacting microenviroments 
in lung, which are alveolar macrophages (AMs), interstitial macrophages (ISMs), and 
intravascular macrophages (IVMs) (Naito, 2008; Randolph et al., 2008). AMs are the most 
abundant pulmonary immune cells in the alveolus located at the interphase between air and lung 
tissues; substantial numbers of ISMs are detected within the lung stroma despite not easily to be 
isolated as AMs; and IVMs are mature phagocytes adhering to capillary endothelial cells within 
lung, which may cover about 16% of lung capillary surface in animal species such as pigs and 
ruminants (Chitko-McKown and Blecha, 1992).   
      The ubiquitous presence of macrophages adjacent to the basement membrane of epithelia and 
endothelia implicates their essential role in immune defenses such as scavenger cells and 
immunoregulatory cells (Fig. 1.2) (Naito, 2008; Randolph et al., 2008; Taylor et al., 2005). In 
respect to airborne viral infections in lungs, AMs are foremost among the immune cells to be 
early activated for scavenging and killing mucus-trapped viral particles (or virus infected cells) 
through phagcytosis. To fulfill this task, AMs are equipped with a variety of surface/internal 
receptors to detect the antibody/complement-engaged viral particles (by surface Fc or 
complement receptors) and to recognize viral components by membrane-associated or cytosolic 
PRRs such as TLRs or RLRs (Table 1.2) (Beisswenger et al., 2005; Daffis et al., 2007; Fantuzzi 
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et al., 2003; Kumagai et al., 2007). AMs are very active killer cells to inactivating trapped 
viruses with both oxidative and non-oxidative mechanisms and lowering the chance of airborne 
viruses initializing infections on pneumocytes and pulmonary endothelial cells (Naito, 2008; 
Randolph et al., 2008; Taylor et al., 2005). Either activated through phagocytosis or PRR 
recognition of viral components, AMs are active producers of type I IFNs and other 
proinflammatory cytokines, which lead to antiviral responses including the regulatory loop by 
type I IFNs and recruitment of other immune cells to infection sites (Kumagai et al., 2007; 
Takeuchi and Akira, 2007). Normally, AMs represent >90% of immune cells in the 
bronchoalveolar lavage (BAL) fluid with an increase of granulocytes in BAL fluid indicating 
infection (White et al., 2007).  Recently, AMs, not DCs, were implicated to be the primary IFN-
α producer in murine models upon respiratory viral infections (Kumagai et al., 2007; Takeuchi 
and Akira, 2007). Compared to AMs, ISMs are less phagocytic and more likely to become 
antigen presenting cells and to secrete cytokines for priming T cells in bronchial lymph nodes. 
Pulmonary IVMs are important for clearance of pathogenic particles in the lung by their high 
cytolytic potency (Chitko-McKown and Blecha, 1992). The importance of macrophages in 
antiviral immune response is shown in that virus escaping the first-line surveillance of tissue 
macrophages has a much higher chance of escaping from innate immune defenses and causing 
persistent infections (Table 1.2). Quite a few viruses have adapted the ability to directly infect 
and undermine immune responses (such as production and signaling of type I IFNs) of 
macrophages. Such as in the cases by HIV-1 and PRRSV, the infected macrophages are 
functionally compromised in many ways including cytokine production, receptor expression, 
phagocytosis, and function as accessory cells (Ieong et al., 2000; Luo et al., 2008; Martinelli et 
al., 2007; Sanders et al., 2007; Thibault et al., 2007). In this regard, virus-infected macrophages 
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and cell traffic of infected macrophages are kidnapped by the viruses as footholds and “viral 
reservoirs” for spreading and forming systemic infections (Table 1.2).        
Natural killer cells: Natural killer (NK) cells and CD8+ cytotoxic T cells are major effector 
cells with ability to kill malignant cells and virus-infected cells. Although CD8+ T cells belong to 
the adaptive immune system, NK cells bear no antigen-specific receptors derived from somatic 
gene recombination (so named “null cells” as well) and are activated prior to antigen 
sensitization and thus are a part of the innate immune system (Lanier, 2008a; Vivier et al., 2008). 
Upon viral infection, NK cells are activated through two pathways. The first one is by innate 
cytokines (eg. IFN-α/β, IL-12, and IL-15) secreted from other cells such as pDCs viral infected 
cells. The binding of these cytokines to receptors on NK cell surface stimulates NK cells to 
proliferate (by IL-15), to produce IFN-γ (by IL-12), and to obtain cytotoxic functions (by IFN-
α/β) (Lanier, 2008b). The alternative way of NK cell activation is elicited through their surface 
receptors to detect the changes in virus-infected cells including presence of viral proteins, 
increase of cell stress proteins and the combination of viral peptides with MHC class I 
molecules. On human and mouse NK cells, there are three distinct receptor families: human 
killer-Ig-like receptors (KIRs), murine Ly49 lectin-like receptors, and NKG2 lectin-like 
receptors found in both species. These receptors can be functionally stimulatory or inhibitory 
depending on the intracellular signals and cell status elicited following ligand binding. To 
prevent NK cells from exerting cytoxicity to normal cells, the inhibitory aspect is dominant; 
seemingly the absence of inhibitor signaling allows activation to kill. Hence, the activation (or 
inhibition) of NK cells is a fine-tuned balance of stimulatory and inhibitory signals received 
during interaction of NK and target cells (Lanier, 2008b; Vivier et al., 2008). Several TLRs have 
been detected in NK cells (Table 1.2) (Al-Khatib et al., 2004; Alter et al., 2007; Saikh et al., 
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2003), but the question of how TLR-mediated viral molecule recognition contributes to NK cell 
activation is still open. Treatment of NK cells with viral mimics of the ligands to TLR3, TLR7, 
TLR8 or TLR9 were reported to activate NK cell cytokine production and cytotoxicity to tumors 
or virus-infected cells (Alter et al., 2007; Lauzon  et al., 2006; Sivori et al., 2004, 2007; Sawaki 
et al., 2007). In some cases, aggregation of TLRs by their ligands appeared efficient to activate 
NK cells, but in some other experiments, TLR-engagement had to be combined with existence of 
pDCs or cytokines such as IL-12 to effectively activate NK cells (Girart et al., 2007). One 
plausible explanation for this difference is that the status of NK cells varied among samples, such 
as difference in animal donors and expression levels of different receptors (Sivori et al., 2007). 
 
The overwhelming evidence about the importance of NK cells in antiviral resistance has been 
well reviewed elsewhere (Biron et al., 1999; Walzer et al., 2005; Golden-Mason et al., 2006; Lee 
et al., 2007; Lanier, 2008a; Vivier et al., 2008) and can be grouped in two categories.  The first 
group manifests that NK cell-mediated cytotoxicity and cytokine production are stimulated in 
some viral infections and NK cell deficiencies resulting from genomic defects or purposeful 
depletion increase host susceptibility to a wide range of virus infections. The incomplete list of 
viruses reported includes about 30 viruses in 12 virus families (Biron et al., 1999; Lee et al., 
2007). The second category of evidence indicates that NK cell receptors, including KIRs, Ly49s 
and NKG2 in humans and mice, interact with several viral proteins, and this interaction leads to 
resistance to the particular virus in addition to NK cell activation (Lee et al., 2007).   The first 
effector aspect of NK cells is production of cytokines especially IFN-γ, which exerts direct 
inactivation activity toward many viruses and enhances antiviral states in adjacent and distal 
cells. Second, NK cells mediate killing of target cells through releasing and delivering cytolytic 
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granules, which contain pore-forming proteins of perforin and granzyme, into target cells, in turn 
triggering a cell death process. Thus, NK cell-promoted death process on target cells could be a 
“specific” killing mechanism of innate immunity to combat intracellular pathogens like viruses.   
 
Granulocytes: With the presence of cytoplasmic granules and multi-lobed nuclei, 
granulocytes constitute a major portion (70%) of white blood cells and are the first group of cells 
migrating to the sites of infection (Hartenstein, 2006). Neutrophils, the primary subgroup of 
granulocytes, are highly motile phagocytic cells that provide early defenses against infectious 
microorganisms and orchestrate the inflammatory response (Segal, 2005). Neutrophilic killing 
was previously thought to be caused mainly by reactive oxygen intermediates generated through 
oxidase-related mechanisms (NADPH oxidase and myeloperoxidase). This concept is now 
expanded with the new insights of the following five points (Appelberg, 2007; Segal, 2005). (1) 
The activity of the membrane-associated NADPH oxidase promotes trans-membrane movement 
of ions to form an alkaline and hypertonic condition in phagocytic vacuoles for activation of 
granule contents (Appelberg, 2007; Segal, 2005). (2) The primary neutrophil killing mechanism 
is the granule polypeptide contents released into phagocytic vacuoles including neutrophil 
elastase, cathepsin G and antimicrobial peptides (Borregaard et al., 2007). (3) Both NADPH 
oxidase activity and granule peptide contents (especially the neutral proteases) are required for 
microbial killing (Appelberg, 2007; Segal, 2005). (4) Neutrophil extracellular traps (NET), 
formed by activated neutrophils attaching DNA backbones from rapidly dead cells (mainly 
neutrophils) plus embedded antimicrobial peptides and enzymes, function in filtering and killing 
pathogens in inflammation sites (Wartha et al., 2007). (5) A series of receptors and 
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transmembrane proteins have been recently found in secretory vesicles (eg. TLRs and cytokine 
receptors) and granules (eg. pentraxin 3 in specific granules) of neutrophils (Borregaard et al., 
2007; Haselmayer et al., 2006; Hattermann et al., 2007; Lee et al., 2006), and this indicates that 
neutrophils routinely communicate with the microenvironment and other cells like pDCs in 
mediation of immune responses (Ludwig et al., 2006). Neutrophils are essential for resistance to 
bacterial and fungal infections; however, the direct involvement in antiviral infection is not well 
documented. The emerging role of neutrophils is reflected in antiviral activity of granule 
antimicrobial peptides, such as human neutrophil α-defensins (HNPs) and non-human primate θ-
defensins (Buck et al., 2006; Chang et al., 2004, 2005; Wang W et al., 2003, 2004; Wu et al., 
2005). Besides its main activity against parasitic helminthes, emerging evidence indicates 
another type of granulocyte, eosinophils, also have an in vivo protective role against RNA 
viruses, such as respiratory syncytial virus (RSV) and pneumonia virus of mice (PVM) 
(Rosenberg and Domachowske, 2001; Rothenberg and Hogan, 2006). Interestingly, eosinophil 
granules contain abundant eosinophil-associated ribonucleases (EARs) that may degrade single-
stranded RNA containing viruses. Consistent with the feature of some innate immune genes (e.g. 
HDPs), humans and mice have very diverse genomic sequences encoding multiple isoforms of 
EARs, potentially targeting different species of ssRNA viruses (Rosenberg and Domachowske, 
2001; Rothenberg and Hogan, 2006).     
1.4. Cell-Based Viral Recognition Mechanisms  
1.4.1. Toll-Like Receptors (TLRs) and TLR-Dependent Viral Recognition 
 
Host cells use various receptors to perceive viral infections by recognizing pathogen-
associated molecular patterns (PAMPs) and subsequently induce antiviral responses (Akira et al., 
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2006; Kabelitz and Medzhitov, 2007; Pichlmair and Reis e Sousa, 2007). Prominent among these 
receptors are Toll-like receptors (TLRs), which are vertebrate homologues revealed and named 
after Drosophila Toll receptors (Lee and Kim, 2007; Takeuchi and Akira, 2007; West et al., 
2006). TLRs are critical for innate immune recognition and for inducing immune responses to 
most microorganism-caused infections (Beutler, 2004; West et al., 2006). The progress of 
mammalian genome projects indicates that each mammalian species has approximately 10 TLRs, 
which are functional for detection of a multitude of molecular ligands derived from various 
microorganisms as “danger signals” of infections (Gay and Gangloff, 2007; West et al., 2006). 
Six of these TLRs have been implicated in response to viral infection through sensing viral 
components (Akira et al., 2006; Pichlmair and Reis e Sousa, 2007; Takeuchi and Akira, 2007). 
Among them, TLR2 and TLR4 hinged on cell cytoplasmic membranes were found to recognize 
several viral proteins (Bieback et al., 2002; Kurt-Jones et al., 2000; Rassa et al., 2002); and 
especially the functional group of TLR3, TLR7, TLR8 and TLR9 was characterized to sense 
viral nucleic acid, either virus-derived RNA or DNA molecules (Alexopoulou et al., 2001; 
Diebold et al., 2004, 2006; Forsbach et al., 2008; Gay and Gangloff, 2007; Heil et al., 2004; 
Hemmi et al., 2002; Lund et al., 2004). Accordingly, these nucleic acid-sensing TLRs are 
responsive mainly in acidified intracellular compartments including late endosomes and 
lysosomes, where most viruses undergo a de-coating process during infection (Table 1.3) 
(Pichlmair and Reis e Sousa, 2007). All TLRs belong to a family of class I transmembrane 
receptors. Each TLR consists of an extracellular domain (ectodomain) to form a ligand-binding 
structure, a membrane-spanning α-helix to hinge on the membrane, and a cytoplasmic Toll-
interleukin receptor (TIR) domain to transduce postreceptor signaling via interaction with 
cytoplasmic adaptor proteins (Lee and Kim, 2007; West et al., 2006).  
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 TLR2 and TLR4: Prominently implicated in perceiving ligands derived from bacteria, 
fungi and stressed host cells, TLR2 and TLR4 also have been demonstrated to mediate antiviral 
responses via detection of viral proteins (Gay and Gangloff, 2007). In the reports, hemagglutinin 
(H) protein of wild-type measles virus induced the production of proinflammatory cytokines 
such as interleukin-6 (IL-6) in a TLR2-dependent manner in both human and murine monocytes. 
It was shown that wild-type H protein did not induce IL-6 release in macrophages from TLR2-
deficient mice, and mutation of a single amino acid (asparagine at position 481 to tyrosine) of 
wild-type H protein abolished its ability to activate TLR2 (Bieback et al., 2002).  Infection by 
lymphocytic choriomeningitis virus (LCMV) was recently demonstrated to induce the production 
of chemokines, such as MCP-1, RANTES and TNF-α in a similar TLR2-dependent manner in 
glial cells of the central nervous system (CNS). In this case, mice deficient in TLR2 or its 
downstream adaptor proteins (MyD88 and Mal described late) did not produce any of these 
chemokines upon LCMV infection; however, LCMV induced a similar chemokine response in 
both TLR3 and TLR4 knockout glial cells (Zhou et al., 2008). On the other hand, TLR4 was 
found to detect viral fusion protein and to mediate innate immune responses to human respiratory 
syncytial virus (RSV) (Kurt-Jones et al., 2000). TLR4 is also capable of detecting envelope 
proteins of retroviruses including mouse mammary tumor virus (MMTV) and murine leukemia 
virus (MLV) and, thereby, mediating murine B-cell or dendritic cell activation (Burzyn et al., 
2004; Rossa et al., 2002). One notable phenomenon is that activation of TLR2/4-dependent 
signals by viral proteins not only induces immune protection in host cells but also may be 
exploited by viruses to augment infection through upregulating viral receptors on infected cells, 
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which were indicated in interactions of TLR2-measles virus and TLR4-MMTV (Bieback et al., 
2002; Burzyn et al., 2004). 
  
TLR3:  As a set of universal viral PMAPs, double stranded (ds)-RNA is produced either as 
an intermediate of viral replication or as part of the viral RNA genome (Jacobs and Langland, 
1996). TLR3 was the first TLR implicated in antiviral responses (Alexopoulou et al., 2001). 
Besides its high preference for recognition of synthetic RNA analogs (e.g. polyinosinic acid-
cytidylic acid (poly(I:C) and especially Ampligen [poly(I)-poly(C12U)]) (Gowen et al., 2007), 
TLR3 recognizes viral dsRNAs derived from dsRNA viruses (such as reovirus), ssRNA viruses 
(such as West Nile virus, respiratory syncytial virus, hepatitis C virus and encephalomyocarditis 
virus) or DNA viruses (such as herpes simplex virus) (Schröder et al., 2005; Vercammen et al., 
2008).  Whereas there is no doubt about TLR3 recognition of dsRNA, the immune protective 
role of TLR3 in viral infection is controversial and dependent on different virus-host cell 
interactions.  
 TLR3 is expressed in the respiratory tract, and its expression is markedly upregulated in 
epithelial cells by infection of either influenza A virus or respiratory syncytial virus (RSV). In 
wild-type mice, pulmonary upregulation of TLR3 post influenza A infection caused acute 
pneumonia, whereas TLR3-decifient mice developed less severe pneumonia and had an 
unexpected survival advantage despite higher viral titer in lungs of TLR3-decifient mice. Thus, 
murine TLR3 signaling contributes to pulmonary clearance of influenza A virus but meanwhile 
results in detrimental inflammation (Guillot et al., 2005; Le Goffic et al., 2006). In contrast,  
TLR3 signaling is necessary to maintain proper immune protection in RSV infection because 
TLR3-deficient mice accumulate much higher T helper 2 cytokines resulting in mucus 
 18
overproduction in lungs, a pathological feature of RSV infection (Groskreutz et al., 2006; Rudd 
et al., 2006).  TLR3 has been shown to be expressed in glial and neuronal cells and proposed to 
be involved in intrinsic antiviral mechanisms in the central nervous system. During infection 
with influenza A virus, TLR3 showed a protective role of ameliorating influenza A virus-induced 
encephalopathy, as symptoms are profoundly developed in the patients with a missense mutation 
of the TLR3 protein (Hidaka et al., 2006). However, TLR3-dependent inflammatory responses 
were shown to facilitate West Nile virus (WNV) disruption of the blood–brain barrier and spread 
from the peripheral system into the brain. Once inside the brain, WNV infection initiated TLR3-
independent detrimental responses causing lethal encephalitis (Wang T et al., 2004). In skeletal 
and cardiac muscle infected by encephalomyocarditis virus, dsRNA released from infected dying 
cells engaged TLR3 leading to cross-priming of myeloid dendritic cells and activation of 
cytotoxic T cells. All of this plus IFN-β release from infected cells positively affected the 
infection by encephalomyocarditis virus (Le Bon et al., 2003). Indeed, compared to wild-type 
mice TLR3-deficient mice were more susceptible to encephalomyocarditis virus infection and 
had a significantly higher viral load in the heart (Hardarson et al., 2007). Similarly, dsRNA 
activation of TLR3 in the female genital tract was implicated in protection against herpes 
simplex virus type 2 infection (Ashkar et al., 2004). Again, the protective role of TLR3 signaling 
is controversial in virus-caused liver and kidney diseases. TLR3 upregulation was associated 
with excessive production of IL-6 in liver infected with a hepatotropic phlebovirus (Gowen et al., 
2006). The over-production of IL-6 was detrimental to the liver and associated with viral 
etiology for some hepatitis infections. In addition, a significant increase of TLR3 mRNA was 
associated with hepatitis C virus-positive kidney inflammation (i.e. glomerulonephritis) possibly 
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resulting from stimulation of local synthesis of chemokines including RANTES and monocyte 
chemotactic protein 1 (MCP1) (Wornle et al., 2006).  
Apart from the paradox of TLR3 in response to viral infections, it is clear that TLR3 
signaling is critical for mediation of a multitude of viral diseases despite leading to pathological 
complications in some cases. The importance of TLR3 signaling is shown by viruses which have 
evolved multiple ways to modulate TLR3 signaling (Schröder et al., 2005; Vercammen et al., 
2008). Several viruses, including measles virus, influenza A virus, hepatitis C virus (HCV), 
RSV, HIV and SIV, augment TLR3 expression and sometimes modulate TLR3 cellular 
localization (Groskreutz et al., 2006; Sanghavi et al., 2005; Tanabe et al., 2003; Vercammen et 
al., 2008). This kind of modulation of TLR3 was hypothesized to sensitize cells to subsequent 
viral or dsRNA exposure, which may skew TLR3 signaling to induce pathological inflammation 
in addition to antiviral responses (Vercammen et al., 2008). Interestingly, some virus-derived 
mechanisms, including vaccinia virus A46R (Stack et al., 2005) and A52R (Harte et al., 2003) 
proteins and HCV NS3/4A protease (Li et al., 2005), directly interfere with components in the 
TLR3-signaling pathway leading to suppression of IFN synthesis, thereby to allow escaping 
from the host immune response. On the other hand, a RNA-dependent RNA polymerase NS5B 
of HCV functioned to induce IFN-β production probably through catalyzing synthesis of dsRNA 
to engage TLR3 in host cells. This viral “trick” is thought to facilitate maintenance of a low and 
nonlethal level of HCV, which may distract the host defense system and enable persistent 
infection (Naka et al., 2006). Therefore, host-beneficial TLR3 signaling is case-dependent. To 
make the issue more complicated, cellular location of TLR3 is dependent on different cell types, 
such as localizing on the cell surface of fibroblasts and endosomes in cDCs; and TLR3 location, 
which affects TLR3 signaling, is modulated by some viruses (Groskreutz et al., 2006; Sanghavi 
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et al., 2005; Tanabe et al., 2003; Vercammen et al., 2008). Clearly, we have a long way to go 
before comprehension of the role of TLR3 signaling in virus-host interaction and manipulation 
of this process to augment host immune responses.    
 
TLR7-9: TLR7, 8 and 9 belong to the same functional subfamily based on similarities in 
their genomic sequences, cellular locations and interacted agonists. TLR7 and 8 are closely 
related and colocalized on X chromosomes in some mammalian species including humans, pigs 
and cattle, which have both functional TLR7 and 8. TLR7 and 9 are mainly expressed in pDCs, 
neutrophils and eosinophils; in contrast, TLR8 mRNA is highly expressed in cDCs, monocytes 
and macrophages.  Before the identification of viral ligands, murine TLR7 and human TLR7 and 
TLR8 were found to recognize imidazoquinoline compounds, such as imiquimod (R837) and 
resiquimod (R848), and guanosine analogs such as loxoribine, which have potent antiviral and/or 
anti-tumor activities (Akira et al., 2006;  Hemmi et al., 2002; Ito et al., 2002). Recent evidence 
showed that human and murine TLR7 mediates pDC responses to ssRNA viruses including HIV, 
vesicular stomatitis virus (VSV), Sendai virus and influenza virus (Diebold et al., 2004; Lund et 
al., 2004) and to genomic ssRNA purified from influenza virions (Diebold et al., 2004; Diebold 
et al., 2006; Heil et al., 2004). TLR7 engaging activity by these viral ssRNA has been 
reproduced with synthetic ssRNA oligonucleotides mimicking guanosine (G)/uridine (U) repeats 
in viral genomes. These U or GU repeats derived from viral RNA genomes were also extensively 
analyzed as agonists for human TLR8 in PMBCs (Forsbach et al., 2008). In contrast, TLR9 in 
pDCs detects unmethylated CpG motifs in DNA viruses such as adenovirus, HSV-1 and -2 or 
murine cytomegalovirus (MCMV). The CpG-containing DNA of HSV-2 engages TLR9 
signaling to induce IFN-α production in murine pDCs. TLR9-deficient mice lose resistance to 
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MCMV infection, suggesting that TLR9 signaling is responsible for antiviral responses by 
sensing the CpG-containing DNA of DNA viruses (Hochrein et al., 2004; Iacobelli-Martinez and 
Nemerow, 2007; Krug et al., 2004a, 2004b; Tabeta et al., 2004). 
  
1.4.2.  TLR-Mediated Antiviral Signaling Transduction 
TLR ectodomains contain multiple leucine-rich repeats forming hosrseshoe-shaped 
solenoids of ligand-binding structures. Different composition of LRR motifs on each TLR seems 
to create unique ligand specificities of respective receptors, such as LRR 12 and 20 in TLR3 
forming a convex loop suitable for dsRNA binding (Gay and Gangloff, 2007). In order to 
conform into a functional ligand-binding pocket, two (or three in TLR1/2/6) homogenous or 
heterogeneous TLR molecules may undergo multimerization upon ligand binding. The 
intermolecular combination expands the capacity of TLRs to detect numerous PAMPs, and 
cooperation among dimers may significantly increase ligand specificity/affinity over a mono-
TLR. In addition, several membrane-anchored proteins including MD2, CD14, CD36 and dectin-
1 have been implicated as co-receptors to TLRs such as TLR2, 3, and 4 and may function in 
membrane-targeting and enhancing ligand-binding (West et al., 2006) (Table 1.4). Ligand-TLR 
interaction promotes TLR dimerization and formation into a functional complex, which thereby 
induces conformation changes in the cytoplasmic TIR domains to recruit adaptor proteins. 
Functional TIR domains are essential for TLR signaling, as site-mutation (e.g. Pro712 in murine 
TLR4) and sequence truncation of TIR domains eliminate the capability of murine TLR3 and 
TLR4 to recruit downstream adaptor proteins including myeloid differentiation primary response 
gene 88 (MyD88), TIR-domain-containing adapter-inducing interferon-β (TRIF), TIR-domain-
containing adaptor protein (TIRAP) and TRIF-related adaptor molecule (TRAM). Dependent on 
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different adaptor proteins attached to the TIR domain, the so called MyD88-dependent and –
independent (mainly TRIF-dependent discussed herein) signaling transduction pathways are 
hereby bifurcated respectively leading to cytoplasmic signaling cascades and nuclear responsive 
gene expression (Fig. 1.3 and Table 1.4) (Gay and Gangloff, 2007; Lee and Kim, 2007; West et 
al., 2006).   
 
MyD88-dependent signaling: MyD88-deficient mice and cells showed drastically 
decreased or ablated responses to ligands of TLR2, 4, 7/8, and 9, indicating that these TLRs 
signal exclusively through the MyD88-dependent pathway. The adaptor proteins like MyD88 
contain a C-terminal TIR domain, a sequence similar to TIR domains of TLRs, and a N-terminal 
death domain. Therefore, the recruitment of MyD88 to a TLR cytoplasmic tail leads to a 
homotypic association between their TIR domains. The death domain of MyD88, thereby, 
interacts with the IL-1 receptor–associated kinase-4 (IRAK-4) and recruits and phosphorylates 
IRAK-1. This promotes IRAK-1 autophosphorylation and further recruits tumor necrosis factor 
receptor–associated factor-6 (TRAF6) to the MyD88/IRAK-4/IRAK-1 complex. Activated 
IRAK-1 and TRAF6 subsequently dissociate from the receptor complex and interact with 
additional molecules including transforming growth factor-β-activated kinase-1 (TAK1), which 
leads to the activation of c-Jun N-terminal kinase (JNK) and inhibitor of κB kinase (IKK). The 
downstream transcription factors including activator protein-1 (AP-1), NF-κB and IRF5  are 
activated, which translocate into nuclei and promote the transcription of genes encoding 
proinflammatory cytokines and chemokines such as TNFα, IL-6, IL-8, IL-12 and IL-1β (Lee and 
Kim, 2007; West et al., 2006). Thus, the current revealed signaling stream of MyD88-dependent 
pathway flows through: PAMP/TLR → MyD88/IRAK4/(IRAK1)/(TRAF6) → TAK1 → 
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JNK,IKK,p38 → AP-1, NF-κB, IRF5 → proinflammatory cytokines, where the complex of 
signaling components are clustered together and separated with slashes and the components in 
the parentheses may disassociate from the complex to activate downstream signaling. In the case 
of TLR7/8/9, two signaling streams are bifurcated after TRAF3/TRAF6 joining in the MyD88 
complex thus leading to transcription factor activation. These two signaling streams are through 
PAMP/TLR → MyD88/IRAK4/(IRAK1)/(TRAF6)/(IRF5) → IRF5, AP-1, NF-κB → 
proinflammatory cytokines, and through PAMP/TLR → 
MyD88/IRAK4/(IRAK1)/(TRAF3)/IKKα/(IRF7) → IRF3/7 → type I IFNs (Lee and Kim, 2007; 
West et al., 2006) (Fig. 1.3 and Table 1.4).          
 
TRIF-dependent signaling: The fact that stimulation of TLR3 and TLR4 in MyD88-
deficient cells results in  IRF3 activation and delayed NF-kB activation via TLR4 signaling, lead 
to the identification of TRIF and  TRIF-dependent signaling pathways. Although TLR4 uses this 
as an alternative pathway, TRIF is the only adaptor protein identified for TLR3 signaling to 
induce type I IFN production and exert antiviral responses.  After association with TIR domains 
upon TLR3 or TLR4 stimulation, TRIF mediates distinct signaling via its N- or C-terminal 
motifs.  Its N-terminal region was indicated to form a complex with two noncanonical IκB 
kinases, IKKi/IKKε and TRAF family-member-associated NF-κB activator (TANK)-binding 
kinase (TBK-1). This TRIF-kinase complex promotes appropriate phosphorylation and activation 
of associated IRF3, which is in turn translocated into nuclei to induce IFN-β production. On the 
other hand, the C-terminal domain of TRIF may associate with a receptor-interacting protein 1 
(RIP1) (Meylan et al. 2004). RIP1 is suggested to link TRIF to TRAF6 and thus to TAK1, and 
this cascade is indicated to be critical for TLR3-mediated signaling to NF-κB activation which 
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leads to cytokine production (Lee and Kim, 2007). The two other identified TLR adaptor 
proteins, TIRAP and TRAM, have been shown to mediate TLR2/4 signaling, but there is a lack 
of information about their involvement in antiviral responses (Lee and Kim, 2007; West et al., 
2006).   
 
1.4.3.  TLR-Independent Viral Recognition and Signaling Transduction 
Besides TLR-mediated viral recognition mainly in endosomal or lysomal compartments, 
animal cells also posses a set of viral recognition and signaling mechanisms in cytosol, where 
most viruses carry out their infectious cycle (Lee and Kim, 2007; Pichlmair and Reis e Sousa, 
2007). Four cytosol PRRs including retinotic acid inducible gene I (RIG-I), melanoma 
differentiation factor-5 (MDA5) and laboratory of genetics and physiology-2 (LGP2), which all 
recognize virus derived-RNA, and a cytosol dsDNA sensor named DNA-dependent activator of 
IRFs (DAI), have been identified (Lee and Kim, 2007; Pichlmair and Reis e Sousa, 2007; 
Takaoka et al., 2007). All of these cytosol receptors perceive distinct molecules of virus-derived 
nucleic acids and signal the production of IFNs including IFN-α, IFN-β and IFN-λ (Onoguchi et 
al., 2007; Takaoka et al., 2006, 2007). In addition, a cytoplasmic serine and threonine kinase 
PKR, previously identified to sense dsRNA and mediate NF-kB activation (Kumar et al., 1994; 
Williams, 2001), has not been convincingly demonstrated to have a role in induction of IRFs and 
production of type I IFNs (Honda et al., 2003; Pichlmair and Reis e Sousa, 2007; Smith et al., 
2001) (Fig. 1.4).   
 
RIG-I, MDA5 and LGP2 have been classified into the RIG-like receptor (RLR) family.  
RIG-I contains an RNA-binding helicase domain, two caspase activation and recruitment 
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domains (CARDs) and a C-terminal repression domain (RD). Likewise, MDA5 bears a helicase 
domain and two CARDs, but it lacks the C-terminal RD. In contrast, LGP2 only has a helicase 
domain but lacks CARDs (Fig. 1.4). Current evidence illustrates an interplay of these cytosol 
RLRs in signaling IRF activation and IFN production (Pichlmair and Reis e Sousa, 2007). 
Whereas the helicase domains of these RLRs bear the function of RNA detection and ligand 
specificity, the CARDs function positively, verses RD negatively, in activation of IRFs and IFN 
production. In this context, MDA5 recognizes viral dsRNA and induces the production of IFN-α 
and -β upon overexpression (Saito et al., 2007).  The function of RIG-I seems to be achieved by 
intramolecular domain interactions, showing that the C-terminal RD functions as an internal 
repressor on exposure of CARD. The agonist interaction with RIG-I helicase domain induces 
protein multimerization and conformational change which relieves the autorepression of RD on 
CARD (Saito et al., 2007). In addition, mutated RIG-I with an impaired CARD domain acted as 
dominant negative proteins to suppress wild type RIG-I in IFN-induction (Yoneyama et al., 
2004). Likely, LGP2, which lacks CARD, resembles that of the RIG-I helicase domain to 
interfere other RLRs signaling IFN induction in some cases (Rothenfusser et al., 2005; 
Venkataraman et al., 2007; Yoneyama et al., 2005).  
 
Previously, the appearance of all RLRs being capable of recognizing synthetic dsRNA (poly 
I:C) leads to an ambiguous interpretation of how RIG-I and MDA5 distinguish different virus 
infections (Lee and Kim, 2007; Pichlmair and Reis e Sousa, 2007). However, it has been found 
recently that each RLR may have remarkable ligand specificity upon different virus-derived 
RNAs. Deficiency of RIG-I greatly reduced cell responses to influenza A virus, vesicular 
stomatitis virus (VSV), Japanese encephalitis virus (JEV), and Sendai virus (SEV), whereas 
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MDA5-deficient cells lost responsiveness mainly to picornaviruses ( e.g. encephalomyocarditis 
virus (EMCV), Theiler’s encephalomyelitis virus, and mengovirus) as well as JEV and SEV 
(Diao et al., 2007; Gitlin et al., 2006; Kato et al., 2006). This suggests that RIG-I and MDA5 are 
capable of distinguishing PAMP from different RNA viruses as well as recognizing some 
common patterns shared by JEV, SEV or poly(I:C).  Recently, it was elucidated that the critical 
determinant for RIG-I stimulation is the presence of triphosphates at the 5’ end of RNA, 
independent of single or double strandedness (Hornung et al., 2006; Pichlmair et al., 2006). 
Indeed, ssRNA genomes of influenza and VSV or in vitro delivered dsRNA which bear 5’ 
triphosphates activate RIG-I (Hornung et al., 2006; Pichlmair et al., 2006). In contrast, genomes 
of picornaviruses in which no triphosphates are attached at the 5’ ends, are weak activators of 
RIG-I.  Compared to RIG-I, it is unknown if there is an extra molecular determinant for MDA5 
to sense dsRNA from picornaviruses (Pichlmair et al., 2006; Weber et al., 2006).  Besides virus-
derived RNAs, there are also dsDNA derived from DNA viruses or bacteria that also induce 
IFN-α and -β production (Ishii et al., 2006; Stetson and Medzhitov, 2006). Correspondingly, one 
cytosolic dsDNA sensor has recently been termed as DNA-dependent activator of IRFs (DAI, 
previously known as the IFN-inducible protein DLM-1 or Z-DNA binding protein 1) (Takaoka et 
al., 2007). Recent evidence shows that the binding of DAI to dsDNA potentiates signaling of 
TBK-1 to IRF3, the critical components in the RLR-signaling pathway (Fig. 1.4) (Takaoka et al., 
2007).  
 
Mainly illustrated in RIG-I- and MDA5-signaling, RLR recognition of ligands leads to 
activation of their CARD domains through ubiquitination. The activated CARD thereby interacts 
with IFN-β promoter stimulator-1 (IPS-1), which is a mitochondrion-associated adaptor protein 
 27
used by RIG-I and MDA5 but not by LGP2 and DAI (Kawai et al., 2005; Meylan et al., 2005; 
Seth et al., 2005; Xu et al., 2005). IPS-1 contains an N-terminal CARD that interacts with the 
CARDs of RIG-I and MDA5 through homotypic matching. This results in activation of the C-
terminal catalytic domain and initiation of a signaling cascade including activation of the IKK 
and TBK-1 kinase family which phosphorylate and activate IRF7 and/or IRF3 (Seth et al., 2005; 
Sun et al., 2006; Xu et al., 2005). The signaling cascades culminate in induction of type I IFN 
gene expression (Honda et al., 2005). Activated IPS-1 also regulates mitochondria-mediated 
apoptosis via the RIP-1 involved pathway; the process has been implicated in determination of 
cell death upon viral infections (Festjens et al., 2008; Takahashi et al., 2006). In contrast, current 
evidence does not support that LGP2 and DAI use IPS-1 to interplay in RLR-signaling, likely 
they adopt other mechanisms to target the components of TBK-1 and IKK in this cascade (Fig. 
1.4) (Ishii et al., 2006; Kumar et al., 2006; Pichlmair and Reis e Sousa, 2007; Stetson and 
Medzhitov, 2006; Sun et al., 2006).  
1.4.4.  Porcine TLR-Dependent and -Independent Viral Recognition 
TLRs are conserved in pigs as indicated by the gene sequences of porcine TLR1-10 
(Shinkai et al., 2006a, 2006b; Sang et al., 2008). Porcine TLR-2 and TLR-9 have been identified 
and demonstrated to be highly expressed in gut-associated lymphoid tissues (GALT) including 
ileal Peyer’s patches and mesenteric lymph nodes (MLN) (Shimosato et al., 2005; Tohno et al., 
2005, 2006).  The expression of some TLRs and their function in stimulation of IFN production 
was partially examined in monocytes and monocyte-derived dendritic cells after treatment with 
synthetic poly (I:C) and CpG oligos (Raymond and Wilkie, 2005). Along with the identification 
of porcine TLRs, MyD88 has also been studied in TLR2 signaling (Tohno et al., 2007). In 
addition, the porcine RNA helicase RIG-I has been identified and shown to be differentially 
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expressed in PRRSV present tissues (Zhang et al., 2000). Despite some evidence from TLR 
stimulation with agonists of poly (I:C) or CpG oligos, little is known about how TLR or RLR 
signaling mediates antiviral responses in pigs.         
 
1.5.  Antiviral Effectors of the Innate Immune System         
Two major groups of innate immune effectors, type I interferons (IFNs) and host defense 
peptides (HDPs), and their role in antiviral responses will be discussed in this section. Please 
also refer to a review paper for extensive discussion of porcine HDPs (Sang and Blecha, 2008).   
1.5.1. Major Innate Antiviral Cytokines --Type I Interferons  
 
Type I IFNs are a group of innate immune effectors prominent in eliciting antiviral 
responses. In contrast to type II IFN (IFN-γ alone), type I IFNs comprise multiple subtypes 
including IFN-α, IFN-β,  IFN-ε , IFN-ω, and IFN-κ (Pestka, 2007; LaFleur et al., 
2001). Humans have multiple IFN-αs, and single members of IFN-β,  IFN-ε , IFN-ω, and IFN-
κ (Takaoka and Yanai, 2006). Type I IFNs also include IFN-δ (Lefevre et al., 1998), -τ  and -ζ 
(limitin) (Oritani et al., 2000), which are only detected in pigs or cattle (IFN-δ), ruminants (IFN-
τ) and mice (IFN-ζ), respectively (Takaoka and Yanai, 2006) (Table 1.5). In pigs, type I IFNs 
consist of multiple porcine IFN-α, IFN-ω, and IFN-δ like molecules, such as porcine IFN-α 
which are encoded by as many as fifteen functional genes (Cheng et al., 2006; Sang, unpublished 
data). In addition, pigs have single gene loci encoding either IFN-β,  IFN-ε  and IFN-κ 
(Artursson et al., 1992; Sang, unpublished data).  Ιn humans and mice, ubiquitously expressed 
IFN-α/β are among the most studied subtypes in antiviral responses. Although less extensively 
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studied, the tissue/cell-specific expressed subtypes, such as IFN-ω in various leukocytes, IFN-δ/ε 
in female reproductive tissues (Demmers et al., 2001; Lefevre et al., 1998) and IFN-κ in 
epidermal keratinocytes, are potentially induced by viral infection in these cell types and further 
confer an antiviral state on uninfected cells (Pestka, 2007; Takaoka and Yanai, 2006).   
Type I IFNs, especially IFN-α/β, are central cytokines in antiviral innate immunity. First, 
almost all known viral recognition and signaling pathways, particularly TLR- and RLR-
mediated, lead to activation of genes encoding IFN-α/β in virus-infected cells. Local production 
of type I IFNs around infection sites comprises a major antiviral barrier to inactivate viruses and 
limit virus spreading. The direct antiviral activity of type I IFNs has been well documented by 
the development of various IFN-based antiviral therapies which are effective against many viral 
diseases including viral hepatitis, HIV and severe acute respiratory syndrome (SARS) (Deutsch 
and  Hadziyannis, 2007; Haagmans and Osterhaus, 2006; Loomba and Liang, 2007; Sulkowski 
and Benhamou, 2007; Yu et al., 2007). Type I IFNs, produced during the early phase of virus-
cell interaction, not only activate antiviral responses by autocrine means, but also diffuse or 
transmit systemically to induce an antiviral state in surrounding and distal cells. The induction of 
the antiviral state, which includes suppression of cellular metabolic processes such as protein 
synthesis and profound expression of genes encoding antiviral products (Haller and Weber, 
2007; Zuniga et al., 2007), is critical for developing effective immune protection against viral 
infections. Type I IFNs collectively induce antiviral responses through a common receptor 
composed of two subunits, IFNAR-1 and IFNAR-2 (Table 1.5). However, the efficacy of 
induction of antiviral responses appeares different among subtypes and even members belonging 
to the same subtype, such as human IFN-αs varying in their activity to activate human NK cells 
and IFN-β showing more potency than IFN-α2 in inhibition of  monocyte proliferation (Takaoka 
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and Yanai, 2006 García-Sastre and Biron, 2006). Functional differences among type I IFNs is 
related to their diverse affinities and kinetics in their interaction with IFNAR subunits. In 
addition, differential expression of each type I IFN and receptor subunits in regard to tissue/cell 
types also contributes to distinct regulation of antiviral responses (Uzé et al., 2007).   
The interaction of type I IFNs with their receptors leads to activation of transcription 
factors of STATs (Signal Transducers and Activators of Transcription protein) by two IFNAR-
associated kinases (Fig. 1.5). The activated STAT1, STAT2 and IRF9 thereby form an activator 
complex of IFN-activated trimeric transcription factor, ISGF3, which interact with the IFN-
stimulated response element (ISRE) in promoters of IFN-stimulated genes (ISGs) to prompt 
transcription. Hundreds of ISGs have been revealed with various functions such as direct virus 
targeting (e.g. MxA, RNase L and RNA deaminases), amplifying antiviral resistance (e.g. PKR, 
2’-5’OAS, and type I IFN themselves), and sequestration of cellular metabolic processes to 
repress virus replication (e.g. PKR-mediated arrest of protein synthesis) (Sadler and Williams, 
2007; Sen and Sarkar, 2007). Profiles of most ISGs are overlapping with the responsive genes 
stimulated by dsRNA or other viral PMAPs, which further indicates an IFN-centered antiviral 
loop jointly evoked by several antiviral signal pathways (Fig. 1.5) (Pichlmair and Reis e Sousa 
2007; Sen and Sarkar, 2007).  
 Type I IFN-centered innate immune reactions are critical for animal antiviral immunity. 
Whereas deficiency in IFN signaling results in hosts highly susceptible to viral infection, viruses 
per se must overcome IFN defensive systems to obtain successful infection. Thus, it is notable 
that most notorious viruses have evolved capabilities to evade or subvert the IFN-I system for 
their own benefit. Extensive reviews (Haller and Weber, 2007; Iannello et al., 2006; Li and Ding, 
2006; Loo and Gale, 2007) on this topic indicate that a collection of virus-derived factors may 
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interfere with major virus recognition signaling pathways leading to IFN production or IFN-
stimulated pathways resulting in antiviral gene expression. Examples of hepatitis C virus (HCV) 
and influenza A virus (IAV) are summarized here to evoke the aspects in PRRSV studies.  
Several proteins encoded by HCV genome have been implicated in interfering with IFN 
production or signaling. The non-structural protein NS3/4A of HCV has a protease activity and 
was implicated in abolishing both RIG-I and TLR3 mediated induction of type I IFNs through 
cleavage of IPS-1 and TRIF, the adaptor proteins of some RLRs and TLR3 respectively (Li et 
al., 2005). In chronic HCV infected patients, NS3/4A cleavage of IPS-1 was shown to closely 
correlate with suppression of ISG expression; conversely, targeting inhibition of NS3/4A 
protease activity restored IFN signaling (Loo and Gale, 2007). The viral core protein and NS5A 
protein of HCV have the ability to stimulate the activity of cellular protein phosphotase 2A 
(PP2A), leading to dephosphorylation of STAT1 (Thimme et al, 2006) and alteration of MAPK 
and JNK signaling (Loo and Gale, 2007; Thimme et al, 2006). In addition, HCV E2 and NS5A 
proteins were found to work as inhibitors of PKR. Collectively, HCV exploits multiple strategies 
to modulate IFN production/signaling thus enhancing the formation of a persistent infection, a 
major feature of most epidemic viral diseases (Haller and Weber, 2007; Loo and Gale, 2007).  In 
regard to IAV, the virus encodes a NS1 protein to bind dsRNA thus antagonizing dsRNA 
signaling via TLR3 and MDA5. IAV strains with mutated NS1 protein impaired in dsRNA 
binding activity, resulted in increased cellular IFN response, and had attenuated pathogenicity 
(Fernandez-Sesma, 2007). Because of its capacity for interaction with dsRNA, NS1 protein of 
IAV also blocks cellular pre-mRNA processing and impairs antiviral function of several dsRNA-
regulated ISG products such as PKR, 2’5’-OAS, and RNaseL. Therefore, NS1 protein is one 
crucial virulent factor for IAV infection (Fernandez-Sesma, 2007; Haller and Weber, 2007; Loo 
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and Gale, 2007). It is known that PRRSV also frequently causes chronic infection. Emerging 
evidence indicates that PRRSV may employ a protease activity of NSP2 to evade host innate 
immunity (Frias-Staheli et al., 2007; Rowland, 2007). In addition, PRRSV was recently shown to 
inhibit IFN induction via interfering with IPS-1 and TRIF, the adaptor proteins of RIG-I and 
TLR3-signaling pathways, respectively (Luo et al., 2008).     
Besides type I IFNs, the single type II IFN-γ, mainly produced by activated T cells and NK 
cells, is thought to be much more related to adaptive antiviral immunity (Takaoka and Yanai, 
2006 García-Sastre and Biron, 2006). Three novel IFN-λ1 to -λ3, previously known as IL-29, 
IL-28A and IL-28B respectively, have been recently classified as type III IFNs. Despite 
exploiting a distinct receptor system (Table 1.5) to exert antiviral function,  type III IFNs, 
similar to  IFN-α/β, were shown to be up-regulated through the RIG-I signaling pathway during 
viral infection (Onoguchi et al., 2007). Notably, although several signaling pathways (i.e. TLR-, 
RLR-, and IFN-signaling) lead to the production of proinflammatory cytokines and type I IFNs, 
these innate antiviral responses are finely checked. It was recently shown that interaction of 
protein phosphatase SHP-1 with kinase cascade (e.g. IRAK1) in TLR and RLR signaling 
pathways provides reciprocal regulation in balancing type I IFN production (Fig. 1.5) (An et al., 
2008; Miyake et al., 2008). This regulation is crucial, because if unchecked (e.g. by SHP-1 
mutation) or distorted (e.g. by chronic viral infection) over-production of type I IFNs or other 
cytokines results in dangerous immunopathological conditions in hosts such as autoimmune 
diseases, which is another important immunological issue of type I IFNs (Banchereau et al., 
2006; Crow et al., 2007; Tourbah et al., 2007).     
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1.5.2. Host Defense Peptides in Innate Antiviral Immunity   
 
Host defense peptides (HDPs) are another group of important innate immune effectors (Fig. 
1.1 and Fig. 1.2) (Sang et al., 2008 and references therein). Although the antiviral activity of 
HDPs has been noted for some time (Daher et al., 1986), research in this area has recently 
intensified (Klotman and Chang, 2006; Lehrer, 2007).  Using direct inactivation assays, several 
recent studies have demonstrated direct effects of LL-37, the only human cathelicidin, in 
reducing infectivity of herpes simplex virus 1 (HSV-1) and replication of lentivirus 
(Steinstraesser et al., 2005). Human α−defensins, mainly members of neutrophil α−defensin 
(HNP) 1 to 4, have been shown to inhibit entry and/or postentry events of viruses including HIV, 
HSV, IAV, adenovirus, papillomavirus and a rhabdovirus (Buck et al., 2006; Chang et al., 2005; 
Falco et al., 2007; Furci et al., 2007; Hazrati et al., 2006; Salvatore et al., 2007; Smith and 
Nemerow, 2008; Wang W et al., 2004). Inhibition HIV by HNPs was related to direct interaction 
of these peptides to viral envelope glycoprotein gp120 and cellular viral receptor CD4, as well as 
indirect inhibition of cellular protein kinase C (PKC) signaling and CD4 expression (Chang et 
al., 2005; Furci et al., 2007). Evidently, the presence of serum neutralized the direct effect of 
HNP-1 in inactivation of HIV infection suggesting a lectin-dependent property of HNPs; and the 
indirect suppression of HIV replication in cells by HNP-1 could be reproduced using the 
treatment of a PKC inhibitor and reversed by a PKC activator (Chang et al., 2005). Similarly, 
HNP-1 inhibited IAV infection mainly via indirect suppression of cellular PKC activity 
(Salvatore et al., 2007), and HNPs closely interplayed with other antiviral mechanisms such as 
SP-D at the IAV infection sites (Hartshorn et al., 2006). All six human α−defensins (HNP1-4 
and human enteric α−defensins HD5 and 6) were effective at blocking HSV infection, but differ 
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in their capacities to bind viral envelope and receptor proteins. Hazrati et al. (2006) showed that 
HNP1-3, and HD5 bound HSV glycoprotein B with high affinity, but had minimal binding to 
heparan sulfate, the receptor for HSV attachment to cells. In contrast, HNP-4 and HD6 bound 
heparan sulfate but not glycoprotein B. Through interaction with virion proteins or other 
membrane-independent mechanisms, HNPs hamper both adenovirus (Smith and Nemerow, 
2008) and papillomavirus (Buck et al., 2006) escape from endocytic vesicles thereby blocking 
virus infection. Leukotriene B4 (LTB4), a potent lipid activator for neutrophils, induced antiviral 
activity in blood leukocytes. It was shown that, HNPs and LL-37 contributed to the critical part 
of antiviral activity induced by LTB4 (Flamand et al., 2007; Gaudreault and Gosselin, 2007). In 
addition, HNPs released from activated neutrophils in turn increase neutrophil uptake of IAV and 
augment phagocytosis-accompanying oxidative burst (Tecle et al., 2007). Human β-defensins 
(hBDs), hBD-2 and -3 are increased in airway epithelial cells infected by human rhinovirus 
(HRV), showing that an increase of hBD2 mRNA correlated with viral titer and the nasal lavages 
of HRV infected patients had increased levels of hBD-2 protein (Duits et al., 2003; Proud et al., 
2004). In addition, an increase of hBD2 production in airway epithelial cells stimulated with IL-
17A, a cytokine activator for T cells, was thought to contribute to IL-17A modified anti-HRV 
response in concert with other cytokines (Wiehler and Proud, 2007).  Exposure of primary oral 
epithelial cells to HIV-1 increased expression of hBD-2 and -3 mRNA 4- to 78-fold, 
respectively. No hBD-1 upregulation in the epithelial cells by HIV-1 exposure was observed. 
Consistently, recombinant peptides of hBD-2 and hBD-3 showed dose-dependent in vitro 
inhibition of HIV-1 replication and in vivo suppression of HIV intracellular replication 
(Quiñones-Mateu et al., 2003; Sun et al., 2005). Furthermore, hBD3 was shown to block HIV 
replication via direct interaction with virions and through internalization of cellular receptor 
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CXCR4 to dampen HIV binding (Feng et al., 2006). In addition, crosslinking of hBD3 with IAV 
membrane glycoprotein impaired the viral infection by blocking the virus fusion with the cell 
membrane (Leikina et al., 2005). Most recently, circular θ-defensins, such as retrocyclin (RC)-1 
and -2, showed potential anti-HIV activity via interaction with the viral envelope protein gp41 
(Cole and Cole, 2008; Gallo et al., 2006; Wang W et al., 2003, 2004). RC-1 and its D-amino acid 
derivative, RC-112, protected human cells from infection by 30 primary HIV-1 isolates (Owen et 
al., 2004). RC-112 was several times more potent than RC-1, likely because of the resistance to 
degradation of the D-amino acid-backbone (Owen et al., 2004). In addition, RC-2 has been 
shown to suppress the infection of several viruses including HSV, IAV, Sindbis virus and 
baculovirus (Yasin et al., 2004; Leikina et al., 2005). Besides the antiviral activity, cytotoxicity 
to host cells is also a critical factor influencing the therapeutic potential of HDPs (Hancock and 
Sahl, 2006). Most of above studies indicate that human cathelicidin LL-37, hBD-2 and -3, and 
retrocyclins, have no or tolerable cytotoxicity to host cells (Leikina et al., 2005; Sun et al., 2005). 
However, most α-defensins are toxic to host cells as well as viruses. One porcine cathelicidin, 
protegrin-1, has shown antiviral activity comparable to LL-37, however, it is cytotoxic to host 
cells as well (Steinstraesser et al., 2005). To our knowledge, protegrin-1 is the only porcine HDP 
that has been reported to have antiviral activity, albeit to viruses of no importance to the swine 
industry.  In summary, animal HDPs have the potential to distort virion glycoproteins and lipid 
membrane in enveloped viruses, and to impede viral fusion with and entry into host cells. Other 
mechanisms for HDP antiviral activity have also been proposed, including downregulation of 
viral receptors (eg. hBD3 for CXCR4 of receptor to HIV-1) (Feng et al., 2006), modulation of 
cellular antiviral signaling (eg. HNP-1 for PKC signaling) (Chang et al., 2005; Salvatore et al., 
2007), and potentiation of adaptive immunity (Yang et al. 2004).       
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 1.5.3. Multifunction Property of Host Defense Peptides (HDPs) and Relationship to 
IFN Signaling   
Besides direct inactivation of virions, HDPs have been shown to exert profound 
immunoregulatory functions that may link to IFN-signaling and production of cytokines 
including TNF-α, IL-8 and IL-18 (Braff et al., 2005; Yang et al., 2007). For example, human 
LL-37 mediates IL-8 and IL-18 production in keratinocytes, airway epithelial cells and 
monocytic cells (Bowdish et al., 2004; Braff et al., 2005; Mookherjee et al. 2006; Niyonsaba et 
al., 2005; Tjabringa et al., 2003). The process is mediated by p38 and other MAPK cascade 
possibly involving some Toll-like receptors (TLRs) (Bowdish et al., 2004; Mookherjee et al. 
2006). On the one hand, HDPs such as murine β-defensin 14 (mBD14), an ortholog of hBD3, 
could be induced by dsRNA in dendritic cells (Röhrl et al., 2008); other β-defensins such as 
hBD2 and hBD3 have been reported to modulate TLR7 expression (Stroinigg and Srivastava, 
2005) and to activate dendritic cells via TLR1/2 (Funderburg et al. 2007). Prominently, HNP-1 
was recently reported to impede a rhabdovirus infection through inactivation of virus particles 
and induction of a type I IFN response (Falco et al., 2007). Therefore, interplay of HDPs with 
IFN-signaling is emerging via expression of some antiviral HDPs being regulated by TLR 
signaling and some HDPs at infection sites will directly inactivate viruses and augment IFN 
production (Fig. 1.5). It is noteworthy that both unchecked production IFNs and deviant 
induction of HDPs may lead to detrimental effects to the host (e.g autoimmune diseases) (Crow 
et al., 2007; Tourbah et al., 2007; Lande et al. 2007).  For instance,  abnormally high expressed 
LL-37 at skin lesions of psoriatic patients acts as a key factor to trigger autoimmune reaction in 
psoriasis by converting self-DNA into a potent agonist for TLR9 (Lande et al. 2007). Likewise, 
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higher risk of psoriasis in a subgroup of people was shown to have significant association with 
aberrantly multiplied genomic copy numbers of β-defensin genes (Hollox et al. 2008). Although 
it is not known how β-defensin is involved in psoriasis, potential links to IFN-signaling may be 
logical. Clearly, the beneficial immune reaction of both IFNs and HDPs requires appropriate 
control of expression.  
 
1.6.  Determining Adaptive Immune Responses     
Despite arbitrary separation in mammals, innate and adaptive immunity comprise a virtual 
continuum to interactively protect hosts. Whereas most invading microorganisms are halted at 
the level of innate immunity, pathogen-specific adaptive immunity is developed in mammals to 
eliminate the most dangerous pathogens and to mount immune memory to effectively prevent 
infection in the future (Hoebe et al., 2004; Kabelitz and Medzhitov, 2007). Activation of 
adaptive immunity in antiviral responses is manifested mainly by elevation of humoral 
neutralizing antibodies and cytotoxic T cells to target viruses or virus-infected cells. Although 
still largely unknown, accumulated evidence implicates the importance of innate immune 
components in shaping adaptive immunity. First, adjuvant and potentiation effects are served by 
innate immune molecules. The action of innate immune cells (plus humoral innate immune 
cascades esp. complement cascade (Fig. 1.1)) leads to processing of pathogenic molecules and 
secretion of a multitude of immune regulators including cytokines, chemokines, HDPs and other 
molecules conveying “activator signaling” (Table 1.1) (Hoebe et al., 2004; Kabelitz and 
Medzhitov, 2007). For antiviral responses, prominent examples are pDCs, which are 
characterized as natural IFN-α producers (Szabo and Dolganiuc, 2008), and pulmonary alveolar 
macrophages, which are implicated as primary IFN-α producers in murine models upon 
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respiratory viral infections (Kumagai et al., 2007). The in situ formation of a chemical gradient 
of chemokines recruits leukocytes to infection sites collectively during the inflammatory process, 
and elevated IFNs in the peripheral system may signal immune cells in distant lymphoid tissues. 
Second, engagement and activation of antigen-presenting cells (APCs) are the major players 
directing adaptive immune cells. Innate immune cells include both professional (i.e. DCs) and 
non-professional (e.g. macrophages) antigen-presenting cells (APCs). One critical part during an 
innate immune reaction is engagement of MHC II class moluceles with antigenic peptides and 
upregulation of co-stimulatory molecules on APCs. The process is associated with directly 
sensing viral PMAPs by APCs via TLRs and stimulated by IFNs produced from other innate 
immune cells. The activated APCs will migrate to the cortex of lymphoid tissues to educate the 
differentiation and maturation of T/B cells (Hoebe et al., 2004; Kabelitz and Medzhitov, 2007). 
Third, B cells and T cells themselves also express innate immune receptors such as TLR 
receptors. Collectively, human naïve B cells express a low amount of most TLRs; however, 
abundant TLR9 along with TLR10 is significantly upregulated on activated B cells and 
expressed at constitutively high levels in memory B cells. TLR9 activation promotes 
proliferation and differentiation of both naïve and memory B cells (Gerondakis et al., 2007). In T 
cells, stimulation of TLR2, 3, and 9 was indicated to act as co-stimulatory receptors subsidiary to 
T-cell receptor (TCR) to enhance proliferation and/or cytokine production of T lymphocytes 
(McGettrick and O'Neill, 2007). In addition, TLR2, TLR5 and TLR8 may modulate the 
suppressive activity of a special group T regulatory (Treg) cells (Kabelitz, 2007; McGettrick and 
O'Neill, 2007).  
 
1.7.  PRRSV: An Immunnological Challenge  
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Porcine reproductive and respiratory syndrome virus (PRRSV), belonging to newly defined 
arteriviridae in the order of nidovirales, causes an economically significant pandemic viral 
disease in pigs (Neumann et al., 2005). PRRSV is an enveloped virus, which has a positive-
sense, single-stranded RNA molecule that is 14.5 kb containing nine open reading frames (ORF) 
encoding as many as nine viral proteins including a membrane-spanning (M) protein, 
nucleocapsid (N) protein, glycoprotein (GP)-5 and non-structural protein (NSP)-2. The primary 
infection of PRRSV is through alveolar macrophages or other tissue macrophages, followed by 
spread from the lungs to the rest of the body via peripheral circulation (viremia). A second route 
of PRRSV infection initiates from the reproductive tract by insemination with infected sperm 
further spreading from sows to newborns. Immunity to PRRSV begins with the interaction 
between the virus and porcine cells, predominately pulmonary alveolar macrophages (PAMs) 
and intravascular macrophages of the placenta and umbilical cord (Oleksiewicz and Nielsen, 
1999; Riber et al., 2004; Thanawongnuwech et al., 2000).  PRRSV frequently causes persistent 
or repeated infection in susceptible pigs and herds. Pigs vaccinated with one serotype are 
generally not protected against infection by heterogonous strains indicating high genomic 
diversity among PRRSV isolates (Labarque et al., 2004).  PRRSV infection stimulated much less 
IFN-α production than did porcine coronavirus or swine influenza virus in the lungs (van Reeth 
et al., 1999). Different isolates of PRRSV are diverse in their ability to induce IFN-α, IL-10 and 
IL-12 in lung or PAMs; and a weakened IFN response plus an IL-10 increase may contribute to 
immune modulation by some viral isolates (Lee et al., 2004; Diaz et al., 2006). Down-regulation 
of type I IFNs and other early inflammatory cytokines represents one of early consequences from 
the initial PRRSV-host cell interaction, which probably leads to inappropriate stimulation of 
antiviral immune responses and results in persistent viral infection. Recent evidence indicates 
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that PRRSV uses NSP2-derived protease activity to alter host innate immunity (Frias-Staheli et 
al., 2007; Rowland, 2007), and the virus was also shown to intervene in dsRNA-stimulated 
signaling leading to weaker IFN induction (Luo et al., 2008).  PRRSV infection of monocyte-
derived DCs decreases the expression of MHC molecules thus compromising antigen presenting 
activity of DCs to activate T cells (Loving et al., 2007; Wang et al., 2007).  Considering adaptive 
immunity to PRRSV, paradoxical responses include (1) circulating antibodies to PRRSV are 
detectable in 1-2 weeks post infection but the antibodies are not efficient at neutralizing the virus 
(Yoon et al., 1994; Mateu and Diaz, 2007); (2) although early upregulation of IFN-γ production 
was detected, an increase of IFN-γ-secreting cells (mainly CD4+CD8+-T cells) was much weaker 
and delayed (Meier et al, 2003; Mateu and Diaz, 2007). In summary, optimal immune protection 
was not achieved to eradiate the virus from infected pigs (Wang et al., 2007; Xiao et al., 2004). 
Despite significant efforts to identify immunogenic viral epitopes (de Lima et al., 2006; 
Plagemann, 2006; Zhou et al., 2006) and to develop and optimize vaccines with various 
adjuvants, effective means to control this disease have not been achieved (Charerntantanakul et 
al., 2006; Royaee et al., 2004).  Therefore, direct investigation and manipulation of IFN-centered 
antiviral signaling of porcine innate immunity may provide novel strategies to prevent this 
economically significant swine disease.          
 
1.8.  Concluding Remarks 
Innate immune mechanisms, comprising receptors, effectors and intervening signaling 
cascades, protect most species from virus infection. The functional conservation and expansion 
of innate immune components in higher vertebrates, further indicates the integral role of animal 
innate immunity in both early protection and overall orchestration of systemic antiviral 
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responses. The discoveries of type I IFNs and signaling connections to upstream PRRs and 
downstream IFNARs have opened our understanding about cellular innate immune networks to 
combat viral infection. Whereas increasing insights in mice and humans will reveal more 
information about innate immune mechanisms in antiviral responses, it is imperative to extend 
these findings to other mammalian species. Studies in domestic animals will not only expand our 
understanding about the repertoire of innate immune receptors and effectors such as IFNs and 
HDPs, which serve as paratypes for developing novel antimicrobials, but may also directly 
suggest therapeutic approaches to prevent epidemic viral diseases in animals and zoonotic viral 
diseases important for both animals and humans. In addition, pigs are increasingly used as 
animal models for human diseases and for xenotransplantation (Cooper et al., 2007; Lunney, 
2007). Thus, direct information about the porcine innate immune system, i.e. the receptors and 
effectors and regulation over integral immune responses, will be beneficial for developing novel 
antimicrobial therapies and controlling immune rejection during xenotransplantation.     
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Fig. 1.1. The afferent and efferent arms of the innate antiviral immune response. Lists of 
potential cellular and humoral components of each arm are illustrated. *Natural antibodies 
belong to the “innate” part of specific immunity. (Abbreviations: CDS, cytosolic DNA sensor; 
DAI, DNA-dependent activator of IFN-regulatory factors; GCN2, general control 
nonderepressible-2; LGP-2, laboratory of genetics and physiology 2; Mda-5, melanoma 
differentiation-associated antigen 5; 2’5’OAS, 2’,5’-oligoadenylate synthetase; PKR, protein 
kinase R; RIG-I, retinoic acid-inducible gene I; TLR, toll-like receptor; TRIM5α, tripartite motif 
protein)  
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Fig. 1.2. Diagram of innate immune cells and their functional systems in antiviral immune 
responses. Innate immune cells are arbitrarily distributed by their preference in immune 
surveillance (yellow circle) or killing (blue circle). The afferent and efferent components 
interplay to direct innate immune responses and bridge adaptive immunity in antiviral responses. 
RLR, retinoic acid-inducible gene I-related receptors; TLR, Toll-like receptors.  
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Fig. 1.3.  TLR-dependent antiviral signaling. Viral responsive TLRs, mainly TLR3, TLR7-9 are 
illustrated from agonist recognition, adaptor recruitment, main kinase cascade to induction of 
transcription factors and gene expression. Please refer the abbreviations from legend of Fig. 1.1 
and Table 1.4.    
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Fig. 1.4.  RLR-dependent antiviral signaling. Viral responsive RLRs and their main domains are 
illustrated with major events of agonist recognition, adaptor recruitment, kinase cascade to 
induction of transcription factors and gene expression. Please refer the abbreviations from legend 
of Fig. 1.1 and Table 1.4.      
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Fig. 1.5.  Interplay of IFN-centered innate antiviral signaling. Viral infection is sensed by cell-
based receptors such as TLRs and RLRs. Antiviral effectors including IFNs, HDPs and 
proinflammatory cytokines are shown. The antiviral effectors interact to inactivate viruses and 
re-modulate signaling leading to IFN expression/signaling loop. The production of IFNs in turn 
induces the expression of hundreds of ISGs (including IFNs themselves) to establish an antiviral 
state. Please refer the abbreviations from legend of Fig. 1.1 and Table 1.4.       
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Table 1.1.  Antiviral effectors and receptors in innate immune cells.  
 
Cell types 
 
Viral PRRs Antiviral effectors References 
Epithelial cells TLRs*: TLR-2, -3, -
4, -7/-8, and -9 
RLRs:  DAI, RIG-I, 
Mda-5, PKR  
AMPs, type I IFNs, proinflammatory 
cytokines (such as IL-1α/β, IL-6, IL-11, IL-
16, TNF-α, and GM-CSF), chemokines (such 
as IL-8, RANTES, and MIP-1α), collectins, 
nitric oxide,  IFN-inducible proteins 
Behera et al., 2002 
Fu et al., 1999 
Message et al., 2004 
Schleimer et al., 
2007 
Takaoka et al., 2006 
    
Endothelial 
cells 
TLRs: TLR-2, -3, -
4, and -9(?) 
RLRs: RIG-I(?), 
Mda-5(?)  
AMPs (?), type I IFNs, IL-8,  TNF-α,  
proinflammatory cytokines, IFN-iducible 
proteins, nitric oxide 
Chaudhuri et al., 
2007 
Frantz et al., 2005  
Opitz et al., 2007 
Warke et al., 2003 
    
Dendritic cells 
(Conventional 
DC (cDC) and 
plasmacytoid 
DC (pDC))  
 
TLRs: TLR-2, -3, -
4, -7/-8, -9 
RLRs:  RIG-I**, 
Mda-5**  
Autophagocytic activity related (cDC),   type I 
IFNs (pDC), IL-12 (pDC), defensins 
(immature DC)   
Barchet et al., 2005 
Kato et al., 2006 
Rodríguez-García et 
al., 2007 
Takeuchi et al., 
2007 
Zilliox et al., 2006 
    
Macrophages TLRs: TLR-2, -3, -
4, -7/-8, -9 
 RLRs: DAI, RIG-I, 
PKR, Mda-5 
Oxidative related:  reactive oxygen or nitrogen 
intermediates  
Nonoxidative related: Phagocytic and 
endocytic related (esp. pH gradient, lysosomal 
enzymes), AMPs and overall macrophage 
antiviral factors (MAFs) (incomplete list 
including type I IFNs, IL-10, TNF-α, and 
chemokines  of  RANTES, MCP-1, MIP-1α 
and MIP-1β). 
Beisswenger et al., 
2005 
Daffis et al., 2007 
Fantuzzi et al., 2003 
Kumagai et al., 2007 
 
    
Natural killer 
cells 
TLRs: TLR-2, -3, -
4, -8 
Two-receptor model promoted granule 
exocytosis to kill target cells, production of 
INF-γ, TNF-α, and GM-CSF. 
Alter et al., 2007 
Saikh et al., 2003 
    
Neutrophils TLRs: TLR-2, -4, 
TLR-7/-8, -9 
Activated killing system including a variety of 
granule microbicidal proteins,  and  hypertonic 
and alkaline condition made by oxidative burst   
Borregaard et al., 
2007 
Hattermann et al., 
2007 
Lee et al., 2006 
Segal, 2005 
    
* Primarily exemplified with features of cells in human or mouse respiratory tracts.  TLR, Toll-like receptors; RLR, 
RIG-I-like receptors including retinoic-acid-inducible protein I (RIG-I), melanoma differentiation-associated protein 
5 (Mda-5), DNA-dependent activator of interferon-regulatory factors (DAI), and protein kinase R (PKR).  
** Mainly in cDCs not in pDCs.  
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Table 1.2.  Examples of viruses that infect alveolar macrophages. 
 
Hosts/Viruses  
(Genome, family) 
PRRs possibly 
related* 
Mechanism and 
effect on type I IFN 
production* 
Evading 
innate 
immunity? 
References 
Human respiratory syncytial 
virus  
((-)ssRNA, Paramyxoviridae) 
 
TLR3, TLR4, 
TLR7, TLR9, 
RIG-I, PKR 
NS1, esp. NS2 gene 
products inhibit IFN 
activity 
Yes Groskreutz et al., 2006 
Kotelkin  et al., 2006 
Liu et al., 2007 
Schlender et al., 2005, 
2006  
Tulic et al., 2007 
 
Human (pig) Influenza 
(Segmented (-) RNA, 
Orthomyxoviridae) 
Multiple TLRs 
and RLRs in 
respect to cell 
types 
NS1 gene product 
inhibit IFN secretion 
and activity 
Yes Koyama et al., 2007 
Seo et al., 2004 
Tyner et al., 2005 
van Riel et al., 2006 
 
Human severe acute 
respiratory syndrome 
((+)ssRNA, Coronaviridae) 
 
? A papain-like 
protease inhibits IFN 
secretion via 
interfering IRF3 
 
Yes Devaraj et al., 2007 
Shieh et al., 2005 
 
Human immuno-deficiency 
virus-1 
((+)ssRNA, Retroviridae) 
 
TLR2, TLR3,  
TLR4, TLR7, 
TLR8, TLR9 
Suppression via 
undermining immune 
function of 
macrophages 
Yes Ieong et al., 2000 
Martinelli et al., 2007 
Sanders et al., 2008 
Thibault et al., 2007 
 
Parainfluenza/mouse  
(ssRNA, Paramyxoviridae) 
 
Multiple TLRs 
and RLRs in 
respect to cell 
types 
Sendai virus C 
protein blocks signal 
trans-duction of IFN 
Yes Bousse et al., 2006 
Carey et al., 2007 
Kato et al., 2005 
Melchjorsen et al., 
2005, 
 
Adenovirus/mouse 
(dsDNA, Adenoviridae) 
 
Some TLRs and 
RLRs in respect 
to cell types 
 
Induction ? Nociari et al., 2007 
Tyner et al., 2005 
Zhu et al., 2007 
Porcine pseudorabies virus 
(dsDNA, Herpesviridae) 
 
? Suppressed in PAM, 
and induction in pDC  
 
? Iglesias et al., 1992 
Vincent et al., 2006 
Porcine African swine fever 
virus, ((+)ssRNA, 
Flaviviridae)  
? Strain-dependent  
suppression 
Yes Afonso et al., 2004 
Zhang et al., 2006 
 
Porcine circovirus-2 
(ssDNA, Circoviridae) 
 
Possible TLR7 
and TLR9 
 
Suppression Yes Chang et al., 2006 
Vincent et al., 2006 
Porcine foot-and-mouth 
disease virus 
((+)ssRNA, Picornaviridae) 
 
? Suppression Yes de Los Santos et al., 
2006, 2007 
Rigden et al., 2002 
 
Porcine arterivirus (PRRSV)  
((+)ssRNA, Arteriviridae) 
TLR3 and 
RLRs** 
Delayed and 
weakened  
Yes Luo et al., 2008 
Mateu et al., 2007  
* Based on information from AMs and other cells; ** Based on studies mainly in this dissertation. 
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Table 1.3.  Viral or synthetic ligands for Toll-like receptors (TLRs) and non-TLR receptors 
 
Receptors Ligands Origin of ligands Reference 
TLRs    
TLR2 Hemagglutinin Measles virus Bieback et al., 2002 
TLR3 Poly (I:C)*  
dsRNA 
Synthetic compounds  
Virus 
Alexopoulou et al., 2001 
TLR4 Fusion protein  Respiratory syncytial virus  Kurt-Jones et al., 2000 
 Envelope proteins  Mouse mammary tumor virus Rassa et al., 2002 
TLR7 GU-rich ssRNA Virus Heil  et al. 2004 
Lund et al. 2004 
 Imiquimod (R-848) Synthetic compounds Hemmi et al., 2002 
TLR8 GU-rich ssRNA Virus Heil  et al. 2004 
 R-848 Synthetic compounds Jurk et al., 2002 
TLR9 Unmethylated CpG DNA Bacteria, virus, yeast, insects  Gay and Gangloff, 2007 
Non-TLRs    
RIG-I  5’-PPP-ssRNA/dsRNA  Virus Yoneyama et al., 2004 
Mda5 dsRNA Virus Yoneyama et al., 2005 
LGP2 dsRNA Virus Yoneyama et al., 2005 
DAI dsDNA DNA viruses Takaoka et al., 2007 
*Abbreviation:  DAI, DNA-dependent activator of IRFs; LGP2, laboratory of genetics and physiology-2; Mda5,  
melanoma differentiation factor-5; Poly (I:C), polyriboinosinic:polyribocytidylic acid; RIG-I, retinoic acid inducible 
gene I. Modified mainly from the references of Gay and Gangloff, 2007;  Pichlmair and Reis e Sousa, 2007. 
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Table 1.4.  Key components in TLR-mediated antiviral signaling cascades 
 
 TLR2/4 TLR3 TLR7/8/9 
Agonists  Viral proteins Viral/synthetic 
dsRNAs 
Viral ssRNAs or um-CpG 
DNA 
Co-receptors ?TLR2:  homo-/heterodimers, 
CD14 *or CD36  
?TLR4: homo-/heterodimers, 
MD2, or CD14  
 
Homodimer and CD14 Homodimer 
Adaptors TLR2: MyD88, TIRAP 
TLR4: MyD88, TIRAP, TRIF, 
TRAM 
TRIF MyD88 
Protein 
kinases and  
associated 
proteins  
MyD88-dependent (TLR 2 or 4): 
IRAK4, TRAF6, IRAK1, TAK1,  
IKKγ, JNK, p38, ERK 
MyD88-independent (TLR4): 
RIP1, TRAF6, TRAF3, 
TBK1/IKKi, TAK1,  
TRIF-dependent: 
RIP1, PI3K, 
TBK1/IKKi 
MyD88-dependent: 
IRAK4, IRAK1, TRAF3, 
TRAF6, TAK1,  
MAPK/IKKα,  
 
Transcription 
factors  
MyD88-dependent (TLR 2 or 4): 
NF-κB, AP-1, IRF5 
MyD88-independent (TLR4): 
AP-1, IRF3, NF-κB 
IRF3, IRF7, NF-κB NF-κB, AP-1, IRF7 
Responsive 
genes 
Proinflammatory cytokines, NO, 
HDPs, IFNβ  
IFNβ, IFN-inducible 
genes and 
proinflammatory 
cytokines 
IFNα, IFN-inducible 
genes  and 
proinflammatory 
cytokines,  
*Abbreviation: AP-1, activator protein 1; CD14 and CD36, cluster of differentiation cell marker protein14 and 
36, co-receptor of some TLRs; ERK, extracellular signal-regulated kinase; HDP, host defense peptide; IFN, 
interferon; IRF, interferon regulatory factor; IKK, IκB kinase;  IRAK, IL-1R associated kinase; JNK, c-Jun-N-
terminal kinase; MAPK, mitogen-activated protein kinase; MD2, also lymphocyte antigen 96, a co-receptor of 
TLR4; MyD88, myeloid differentiation primary response gene 88; NF-κB, nuclear factor-kappa B; NO, nitric oxide; 
p38, p38 MAP kinase; RIP1, receptor-interacting protein1; TAK, TGFβ-activated kinase; TBK, TRAF-family-
member-associated NF-κB activator-binding kinase; TIRAP/MAL, TIR domain-containing adaptor or MYD88 
adaptor-like protein; TRAF, TNF receptor associated factor; TRAM, TIR-domain-containing adapter molecule; 
TRIF, TIR-domain-containing adapter-inducing interferon-β. Major references are Gay and Gangloff, 2007; Lee and 
Kim, 2007; West et al., 2006. 
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Table1.5. The interferon family members and porcine gene candidates*  
 
Types  Subtypes  Gene locus/ 
(numbers)a 
Receptors Amino 
acids 
Expression pattern 
I IFN-α 
IFN-β 
IFN-δ b 
IFN-ε 
IFN-ω 
IFN-κ 
IFN-τ c 
IFN-ζ d 
1q22-q27 (15 & 2ψ) 
1q23-q27(1) 
SSA1 (9) 
SSA1 (1) 
SSA1 (5 & 2ψ) 
SSA10 (1) 
N/A 
N/A 
IFNAR1/IF
NAR2 
 
181-189 
186 
170 
193 
179-190 
207 
Ubiquitous expression 
Ubiquitous expression 
Trophoblasts 
Uterus, ovary 
Leukocytes 
Epidermal keratinocytes (?) 
Trophoblasts 
Lymphoid tissues  
      
II IFN-γ 5p1.2-q1.1 / (1) IFNGR1/IF
NGR2 
166 Activated T cells, NK-cells 
      
III IFN-λ1 (IL-29) 
IFN-λ2 (IL-28A) 
IFN-λ3 (IL-28B) 
? IL-28Rα/ 
IL-10R2 
 
? 
? 
      
*Modified from Cheng et al., 2006; Takaoka and Yanai, 2006; and other unpublished data defined from NCBI 
website: http://www.ncbi.nlm.nih.gov/ 
a.  Pig 
b.  Found in pigs and cattle only 
c.  Found in ruminants only 
d.  Found in mice only 
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CHAPTER 2 - Bioinformatic and Molecular Analysis of Novel 
Porcine β-defensins: Emerging Repertoire and Functions 
ABSTRACT. β-defensins are a major group of mammalian antimicrobial peptides.  Although 
more than 30 β-defensins have been identified in humans, only one porcine β-defensin has been 
reported.  Here we report the identification and initial characterization of 11 novel porcine β-
defensins (pBD).  Using bioinformatic approaches, we screened 287,821 porcine expressed 
sequence tags for similarity of their predicted peptides to known human β-defensins and 
identified full-length or partial sequences for 11 novel pBDs. Similar to the previously identified 
pBD1, all of these peptides have a consensus β-defensin motif.  A differential expression pattern 
for these newly identified genes was found.  For example, unlike most β-defensins, pBD2 and 
pBD3 were expressed in bone marrow and in other lymphoid tissues including thymus, spleen, 
lymph nodes, duodenum and liver.  Including pBD2 and pBD3, six porcine β-defensins were 
expressed in lung and skin. Several newly identified porcine β-defensins, including pBD123, 
pBD125, and pBD129 were expressed in male reproductive tissues, including lobuli testis and 
some segments of the epididymis. Phylogenetic analysis indicates that in most cases the 
evolutionary relationship between individual porcine β-defensins and their human orthologs is 
closer than the relationship among β-defensins in the same species. Structural modulation and 
antimicrobial analysis also indicates that they conserve tertiary structure and antibacterial 
activity. Genomic sequences of pBD2, pBD3, and pBD4 show highly diverse in intron regions 
and conserved exon regions. These findings establish the existence of multiple porcine β-
defensins and suggest that the pig may be an ideal model for the characterization of β-defensin 
diversity and function.    
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2.1 Introduction 
Antimicrobial peptides are small cationic polypeptides that function as one of the earliest 
mediators of host defense in many species of insects, plants, and animals (Boman 1995; Boman 
2003). In humans and other mammals, defensins are a major family of antimicrobial peptides 
whose two main subfamilies, α and β, are characterized by β-sheet folds and a framework of six 
disulphide-linked cysteines (Ganz 2003; Lehrer and Ganz 2002; Schutte and McCray 2002).  The 
α-and β-defensins differ in their cysteine disulphide parings and in the number of amino acids 
between the six cysteines.  For β-defensins, the six cysteines are linked at positions 1-5, 2-4, and 
3-6. The canonical sequence represented by human β-defensins usually is X2-10-C-X6-C-X3-4-C-
X9-13-C-X4-7-C-CXn, where X represents any amino acid residue (Ganz 2003; Patil et al. 2005; 
Selsted and Ouellette 2005; Yeaman and Yount 2007).  The third defensin subfamily, θ-
defensins, is structurally unlike α and β-defensins and is expressed in Old World monkeys and 
orangutans (Nguyen et al. 2003; Selsted and Ouellette 2005).  
At least one and usually several defensins have been identified in all mammals that have 
been studied (Boman 2003; Ganz 2003).  However, tissue distribution profiles and existence of 
subfamily defensins vary greatly even between closely related species. For example, humans 
have α-defensins in leukocytes and intestinal Paneth cells, and β-defensins are found in many 
epithelial cells.  Mice and rats have Paneth cell α-defensins and epithelial cell β-defensins; 
however, although mice lack leukocyte α-defensins, rats possess neutrophil α-defensins (Boman 
2003; Ganz 2003; Patil et al. 2004; Patil et al. 2005; Yang et al. 2004). Bovine neutrophils have 
several β-defensins and epithelial β-defensins are expressed in bovine trachea, tongue, and 
intestine (Diamond et al. 1991; Ganz 2003; Selsted et al. 1993).  To date, only one epithelial β-
defensin (pBD1) has been identified in pigs and defensins have not been detected in porcine 
leukocytes (Ganz 2003; Zhang et al. 1998; Zhang et al. 1999).  Moreover, there is no evidence 
 89
that α-defensins are present in pigs (Ganz 2003).     
Although considerable progress has been made in identifying complete defensin repertoires 
in several species including humans, chimpanzees, mice, rats, dogs, and chickens, (Kao et al. 
2003; Patil et al. 2004; Patil et al. 2005; Rodriguez-Jimenez et al. 2003; Schutte et al. 2002; Xiao 
et al. 2004), information on the complete repertoire of porcine β-defensins is lacking. Because 
pigs are often used for comparative physiological and immunological studies and because 
porcine tissues and organs are often used for xenotransplantation, we sought to identify the 
complete β-defensin profile in pigs.  Here we report the identification and initial characterization 
of 11 novel porcine β-defensins; information that is fundamental to the comparative investigation 
of β-defensins in innate immunity.  
 
2.2. Materials and Methods 
BLAST-based searches.  The porcine expressed sequence tag (EST) database was searched 
with BLASTP and TBLASTN programs (Altschul 1990), using the National Center for 
Biotechnology Information (NCBI) website tools (http://www.ncbi.nlm.nih.gov/blast/) against 
the EST collection other than human or mouse (EST_others). Initial queries for the search used 
amino acid sequences for known human defensins (DEFB1-31) (Schutte et al. 2002) and three 
HE2/EP2 sequences (Frohlich et al. 2000, 2001) as well as some identified bovine β-defensins 
(Diamond et al. 1991; Selsted et al. 1993). NCBI default parameters were used in the searches 
and any potential hits were curated manually.  
 
EST annotation and defining coding regions. Most porcine EST clones represent 
information defining full-length β-defensin cDNA and thus do not need additional annotation. 
However, in some cases the ESTs were annotated using the stack-PACK version 2.2 program 
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(http://www.sanbi.ac.za) as described (Lynn et al. 2003, 2004). Briefly, input ESTs were masked 
to remove repeat sequences and clustered if they shared more than 100 bp at greater than 96% 
identity. Representative EST sequences or processed consensus sequences were used to define 
the coding region with ESTScan (http://www.ch.embnet.org/software/ESTScan.html) and 
predicted peptides were translated using the Translate program 
(http://www.us.expasy.org/tools/).  
 
Alignment and phylogenetic analysis. Multiple sequence alignment was performed using 
the PILEUP program from the Wisconsin Package Software (Accelrys, San Diego, CA). Amino 
acid sequences selected for alignment were three residues before and several residues after the 
six-cysteine motif (Schutte et al. 2002). The comparison matrix was set at Blosum 62 with a gap 
creation penalty of 8 and a gap extension penalty of 2. Phylogenetic and molecular evolutionary 
analyses were conducted on the most complete peptide sequences using MEGA version 2.1 
(Kumar et al. 2001).  
 
Expression analysis by semiquantitative RT-PCR and real-time RT-PCR. Tissues 
obtained from healthy 5-week-old male crossbred pigs, as previously described (Zhang et al. 
1998), were chosen to represent organs of the digestive, pulmonary, and immune systems and 
included bone marrow, intestine, liver, lung, spleen, thymus, testes, and epididymis. All 
collection procedures were approved by the Kansas State University Institutional Animal Care 
and Use Committee. Tissue samples were collected, placed immediately in liquid nitrogen, and 
stored at −135°C until use. Total RNA was extracted with TRI Reagent (Sigma-Aldrich, St. 
Louis, MO) after grinding frozen tissues in liquid nitrogen. A one-step RT-PCR was used to 
detect expression of target transcripts. Briefly, total RNA was treated with RQ1 RNase-free 
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DNAse I (Promega, Madison, WI) to remove possible genomic DNA contamination. RNA 
samples (250 ng) were run in a 25-μl RT-PCR reaction mixture with a 0.1 μM concentration of 
each sense and antisense primer derived from cDNA sequences (Table 2.1). Semiquantitative 
RT-PCR was performed using a one-step RT-PCR kit (Qiagen, Valencia, CA). cDNA synthesis 
and predenaturation were performed at 50°C for 30 min and 95°C for 15 min to activate the 
antibody-protected DNA polymerase, and amplification was carried out at 95°C for 30 sec, 55°C 
for 30 sec, and 72°C for 40 sec; final extension was at 72°C for 10 min. For most genes, 32, 35, 
and 40 PCR cycles were used in different replicates to ensure linear amplification and optimal 
estimation of relative expression levels. After amplification, 10 μl of each reaction mixture were 
analyzed by 2% agarose gel electrophoresis, bands were then visualized by ethidium bromide 
staining in a FluorChemTM digital imaging system (Alpha Innotech Corp., San Leandro, CA), 
and integrated density values were measured using the digital imaging system. Integrated density 
values were standardized with values of the housekeeping gene, glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH), and presented as a ratio relative to the expression of GAPDH.  
For genes reported to show expression patterns similar to their human orthologs, we 
confirmed their expression profiles in tissues using a SYBR-Green-based real-time RT-PCR 
system (Qiagen). In brief, real-time quantitative RT-PCR was performed on a SmartCycler 
(Cepheid, Sunnyvale, CA) as previously described (Sang et al. 2005) with gene-specific primers 
as described. DNase-treated total RNA (200 ng) was used in each 25-μl RT-PCR reaction. The 
RT-PCR cycling conditions were 30 min at 50°C, 95°C for 15 min, followed by 45 cycles of 15 
sec at 95°C, 30 sec at 56°C, and 30 sec at 72°C with the optic on to perform fluorescence data 
collection. Amplicon authenticity was confirmed by sequencing before performing real-time RT-
PCR. Threshold cycle (Ct) was determined by exponential product amplification and subsequent 
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increased fluorescence intensity above background. Relative gene-expression data were 
normalized against the Ct values of the housekeeping gene (GAPDH) and the relative index 
(2−ΔΔCt) was determined in comparison to the average expression levels of control samples with 
the index defined as 1.000 (Livak and Schmittgen 2001). 
 
Tertiary structure simulation and alignment. Structural models were generated via 
homology modeling for the various β-defensin peptides with structures from the database 
(http://www.ncbi.nlm.nih.gov/sites/entrez?db=structure). Initial sequence alignment for each 
target with its set of templates was effected via the Clustal-W program (Thompson  et al., 1994), 
using the Blosum 30 substitution matrix, a gap-opening penalty of 10 and a gap-extension 
penalty of 0.1.  The resulting alignment and the corresponding three-dimensional peptide 
structures were then processed via the Modeller program (Sanchez and Sali, 2000) to yield 
structural predictions for the β−defensin targets. Modeller's default simulated annealing cycles 
were used for structural refinement.  Analysis of the peptide secondary structure and surface 
characteristics was carried out on the resulting structures via SYBYL 6.9.2 (The Tripos 
Associates, St. Louis, MO), and secondary structure prediction was validated via the PSIPRED 
program (McGuffin et al., 2000).   
 
Genomic sequences of pBD2, pBD3 and pBD4.  Gene sequences of pBD2, pBD3 and 
pBD4, including exon and intron regions and ~1-2 kb putative promoter regions before the first 
exon, were amplified with a PCR-based GenomeWalker™ kit (Clontech, Mountain View, CA). 
Briefly, porcine genomic DNA (Novagen, Madison, WI) of high quality was digested separately 
with four different restriction enzymes and ligated to the specially designed adaptors in the kit to 
make premade libraries. Serial gene-specific primers were designed based on identified cDNA 
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sequences. Amplicons generated using PCR amplification of target sequences from some 
libraries were cloned into a TA vector (New England Biolabs, Ipswich, MA) or directly 
sequenced to obtain a 2-3X coverage, which were used to fuse final gene sequences with a  
SeqBuilder program in Lasergene (DNASTAR, Inc. Madison, WI). 
 
Antibacterial assays. Two 34- and 36- amino acid peptides, spanning the pBD cysteine-
motif of pBD2 and pBD3 respectively, were chemically synthesized (Abgent, San Diego, CA). 
Peptide preparation and quality control were conducted as described (Sang et al., 2005). For 
antibacterial assays, a broth microdilution method was used to determine susceptibilities of 
tested bacteria to peptides of pBDs and canine cBD as positive control (Sang et al., 2005). The 
bacterial strains used, Escherichia coli ATCC 25922, Listeria monocytogenes ATCC 19115, and 
Staphylococcus aureus ATCC 10832, were cultured in trypticase soy broth (TSB). Working 
solutions of peptides (0, 0.25, 0.5, 1, 2, 5, 10, 20, 50, 100, and 200 μg/ml), were obtained by 
dilution of 50 μl stocks (in 0.1% HAS plus 0.01% acetic acid) in 96-well plates, in which 25 μl 
of 30 mM sodium PB (pH 7.4, [Na+] = 53.49 mM) and 25 μl H2O and 100 μl of the microbial 
suspension (103 CFU), were previously added. The final sodium concentration for the assays was 
15 mM in a total volume of 200 μl/well. Microtiter plates were incubated at 37 oC for 2 h in a 
shaking incubator (100 rpm).  To determine minimal inhibitory concentrations (MIC), 100 μl 
double strength broth was added to each assay well. MICs were defined as the lowest 
concentration in which the microorganism growth was prevented, as determined by no colony 
development  on TSB agar plates after 24 h of incubation at 37 oC in 5 % CO2. 
 
2.3. Results and Discussion 
 94
The first porcine β-defensin, pBD1, was identified based on PCR amplification of tissue 
RNA with primers generated from bovine lingual β-defensin (Zhang et al. 1998, 1999). We now 
know that identification of pBD1 was quite fortuitous, because of the 287,821 EST entries 
generated from various sources today, no pBD1 EST was identified. In contrast, using a 
bioinformatic approach, we have identified 11 novel porcine β-defensins. Each novel porcine 
defensin is related to at least one EST clone whose sequence range covers the six-cysteine 
defensin motif. Porcine β-defensin-2 (pBD2) is highly expressed in many tissues and, has the 
most (19) EST clones identified, with 12 of these covering the entire open reading frame in their 
registered cDNA sequences. Similarly, pBD3, pBD4, and pBD129 have abundant EST entries in 
the database; all are represented by five almost identical ESTs. The other eight pBD candidates 
are represented by one to three EST clones and cover all or most of the coding regions of 
putative porcine β-defensins. We did not identify any porcine EST with an α-defensin signature 
in their translated frames using a similar strategy.  
Alignment of the pBD predicted peptides clearly shows that they possess typical β-defensin 
characteristics, such as the six-cysteine β-defensin motif, spacing patterns of the six cysteines, 
and representative content of positive-charged residues (Fig. 2.1 and Table 2.2). In addition, the 
canonical sequence of porcine β-defensins is almost identical to that of human β-defensins. After 
identifying the novel porcine defensins, we used them to query the Swiss-Prot database using 
BLASTP and assigned a tentative name for each porcine defensin as suggested by the HUGO 
Gene Nomenclature Committee, University College, London, UK 
(http://www.gene.ucl.ac.uk/nomenclature/). For example, pBD125 is most homologous to human 
DEFB125 and so on. Exceptions to this naming convention are pBD2, pBD3, and pBD4, which 
we previously identified experimentally, confirmed by bioinformatics searching, and thus were 
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named serially following pBD1 (Zhang et al. 1998). Most porcine β-defensins show significant 
similarities to their human counterparts in both sequence length and identity.  
Generally, β-defensin precursors consist of less than 80 amino acid residues, which are 
encoded by two exons (Ganz 2003; Yang et al. 2004). This characteristic is found in pBD1, 
pBD2, pBD3, pBD4, and pBD114. Exceptions to this characteristic are two groups of defensin-
like molecules, including some EP2/HP2 gene products (EP2C/D/E) and DEFB25-29. These 
defensins are longer because of the addition of as many as 20-100 amino acids after the N-
terminal leader sequence or at the C-terminus adjacent to the C5 and C6 residues (Schutte and 
McCray 2002). Candidates representing these two groups of β-defensins also have been 
identified in the pig and are represented by pBD125, pBD129, pEP2C, and pEP2E (Table 2.2). 
Two other features we compared are related to the six-cysteine motif. As shown in Table 2, 
almost all porcine β-defensins conserve the number of amino acids between the six cysteine 
residues and the ratio of positive residues, which contributes to the positive charge of the cationic 
peptides and relates to antimicrobial activity (Schutte et al. 2002; Yang et al. 2004).  
Phylogenetic analysis of representative human and porcine β-defensins indicated that they 
were derived from a common ancestor. This analysis showed that individual porcine β-defensins 
are in the same sub-branch as their human homolog, except pBD1, which is a more diverse 
isoform than human β-defensins and has no close human homolog. Furthermore, similarity 
among each subclass of β-defensins from different species is higher than that between different 
subclasses from the same species. The phylogenetic relationship between human and porcine β-
defensins is supported by the high bootstrap values on the branches, which are based on multiple 
resampling of the original data. Bootstrap analysis is the most common method for estimating 
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the degree of confidence in the topology of phylogenetic trees (Fig. 2.2) (Kumar et al. 2001; 
Lynn et al. 2004).  
To evaluate tissue expression profiles of pBDs and verify the accuracy of the EST 
sequences, we designed gene-specific primers based on representative EST sequences 
(Table 2.1). Each set of primers was designed from diverse regions on different exons to 
facilitate specific amplification of target genes and to ensure that PCR products were amplified 
from cDNA and not genomic DNA. Fig. 2.3 shows the quantitative data and represents the 
expression profile of all newly found pBDs, except the EP2E molecule. In general, pBD2, pBD3, 
pBD114, pBD125, and pBD129 were expressed in multiple tissues, including intestine, spleen, 
lung, and male reproductive tissues. pBD2 and pBD3 are expressed in bone marrow, which 
suggests that they may represent porcine myeloid β-defensins. pBD3 is detected primarily in 
lymphoid tissues including thymus, spleen, and lymph nodes, and there is high-level expression 
in duodenum, liver, skin, testis, and proximal epididymis. Similar to the β-defensin expression 
profile in species like rats and humans, all pBDs were detected, to some extent, in male 
reproductive tissues including lobuli testis and various segments of the epididymis. In particular, 
pBD114, pBD123, pBD125, and pBD129, similar to human DEFB 125-129, were differentially 
expressed in various segments of the epididymis. Real-time RT-PCR data emphasize that the 
highest expression of pBD2 and six pBDs, including pBD3, pBD4, pBD114, pBD123, pBD125, 
and pBD129, were expressed in lung; and at least seven pBDs, including pBD2, pBD3, and 
pBD4, were expressed in skin (Fig. 2.4). Conversely, pBD104 and pBD108 were lower-
expressed isoforms. pBD104 was weakly detected in spleen, liver, and testis, and pBD108 was 
weakly expressed in liver and somewhat strongly expressed in the proximal epididymis. All of 
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our findings relate to constitutive gene expression; however, it is possible that under different 
conditions such as infection porcine β-defensins may exhibit inducible expression. 
The detection of pBD2 and pBD3 in bone marrow and the prevalent expression of several 
pBDs in porcine lung and skin likely relates to their involvement in innate immune responses. 
Similarly, because adaptive immunity is largely absent in the male reproductive system, the 
preferential expression of β-defensins in the testis and different regions of the epididymis likely 
provides an innate immune mechanism for defense of this system. In support of this hypothesis, 
many testis- and epididymis-specific β-defensins have been found to be antimicrobial and 
capable of protecting sperm from infections (Frohlich et al. 2000, 2001; Patil et al., 2005; 
Rodriguez-Jimenez et al. 2003). It is noteworthy that pBD3 is abundantly detected in lymphoid 
tissues. The preferential expression of multiple pBDs in thymus suggests the potential for β-
defensins linking innate immunity to adaptive immune reactions in lymphoid tissues.  
The gene sequences of pBD2, pBD3 and pBD4 were obtained by a PCR-based genome-
walking technique (Clonetech). Elucidated gene structures show that each of the three pBD 
genes has two exons, encoding a signal peptide and most of mature peptide respectively, and one 
very diverse intron (Schutte and McCray 2002). Fig. 2.5 shows the proportional diagrams of 
gene structures of the three pBDs. Whereas pBD3 and pBD4 genes are 2.8 and 5.6 kb long with 
introns of 0.9 and 4.2 kb respectively, the pBD2 gene is about 10 kb long with an intron of 8 kb. 
Preliminary prediction shows conserved binding sites for transcription factors such as AP1, NF-
κB, and IRFs existing in the putative promoter regions for pBD3 and pBD4 genes (Zhang et al., 
1999; Sang unpublished data). We already know that the pBD-1 gene is located on 15q14-q15.1, 
and the progress of porcine genome project will allow rapid discovery of the chromosomal 
location of these pBDs. Current information indicates that porcine pBDs genes may resemble to 
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human orthologs regarding to their genomic cluster numbers and distribution among 
chromosomes. We know that human β-defensins are clustered in five chromosomal loci (Schutte 
and McCray 2002; Patil et al., 2005), and the identified 12 pBDs mirror very well in the 
chromosomal distributions. The top six (pBD-1 to pBD108L) and bottom two (pEP2CL and 
pEP2EL) in Fig 1, reflect the human’s on 8p23-p22 locus, pBD125L and pBD129L are similar 
to DEFB25 and 29, which cluster on 20p13, and the other two, pBD114L and pBD123L reflect 
two human’s defensins on 6p12 and 20q11.1 respectively. No porcine EST was identified to 
encode a peptide similar to DEFB30 and DEFB31, which were indicated in an ambiguous locus 
of human chromosome (Schutte et al., 2002;  Schutte and McCray 2002; Patil et al., 2005).  
Although β-defensins from different species show substantial difference in their primary 
sequences, they generally are conserved in tertiary structure, which may underlie a common 
theme of the comparable functions of these molecules (Selsted and Ouellette 2005; Yeaman and 
Yount 2007). To investigate the tertiary structural information of porcine β-defensins, we have 
predicted their three-dimensional structures (Molecular Graphics/Modeling Lab, The University 
of Kansas, Lawrence, KS) (McGuffin et al., 2000). As show in Fig. 2.6, pBD1 and pBD2 both 
exhibit strong homology with a number of other mammalian (human and bovine) β-defensins for 
which x-ray crystal structures exist. As general properties of mammalian β-defensins, predicted 
3D structures of pBD peptides contain a short N-terminal amphipathic alfa-helix and three-
stranded twisted antiparallel beta-sheets stabilized by  three disulfide bonds (Ganz, 2003; Selsted 
and Ouellette 2005; Yeaman and Yount 2007). The surface charge modules show that pBD1 has 
a hydrophobic core and pBD3 has a cationic (positive charged) core (Fig. 2.6), which are 
consistent with their residual composition and likely related to their antimicrobial activity. In 
contrast, pBD2 has relatively less and an even distribution of hydrophobic/cationic residues, 
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which may indicate its weak interaction with microbial membranes (Ganz, 2003; Selsted and 
Ouellette 2005; Yeaman and Yount 2007). The peptides deduced from the 34 and 36 C-terminal 
residues of pBD2 and pBD3 were synthesized and tested against E. coli, L. monocytogenes, and 
S.  aureus.  pBD3 showed similar activity to the positive control (a canine β-defensin) (Sang et 
al., 2005), and pBD2 is weaker (Table 2.3). However, a 37-residue peptide of pBD2 appeared to 
have increased antimicrobial activity compared to the 34-residue peptide used here (Veldhuizen 
et al., 2008).   
In summary, 11 novel porcine β-defensins have been identified using bioinformatic 
exploration of the available EST database and confirmed by experimental detection. Tissue 
expression profiles of these genes indicate some special patterns in comparison with species in 
which α-defensins have evolved, such as humans and mice. Extended studies with pBD2, pBD3 
and pBD4 demonstrate the properties of pBDs in gene structure, tertiary structure and 
antimicrobial activity. Our findings also support the notion that β-defensins represent the most 
conserved group of antimicrobial peptides in mammals and suggest that the pig may be an ideal 
animal model to investigate defensin-related diseases and other physiologic functions of these 
innate immune molecules.  
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              1       2    3         4      56  
pBD1       SVSCLRNK-GVCMPGKCAPKMKQIGTCGMPQVKCCKRK--------- 
GTCNFSPCPLFNRIEGTCYSGKAKCCIR-----------   
GRCAVLGCLPKEEQIGSCSVSGRKCCRKRK---------
GRCKLE-CREGEIRIAYCMRPATYCCLQK---------
GRCPHT-YPCCLKKWRDSSLNP-- 
GSCRKK-CRTEEVELHYCVNG-KKCCMKSY--STIIPNV 
GQCRTR-CYKIEKQIDICYSPSKICCIQRAFEEDLS--- 
GRCRTT-CQESEVFHILC-RDATMCCVHPKYIPIKT--- 
GHCRRR-CLHLERYKHLCMN-KRACC-----IPLSSDDP 
GRCKDH-CAVNEKEIDKC-K-
pBD2       HYICAKKG-
pBD3       RYYCKIRR-
pBD4       RRECRRGN-     
pBD104     DRICGYGT-SRCRRY-CKRQEIRI
pBD108     GNICEKDQ-
pBD114     PERCSKMY-
pBD123     AMKCWSAL-
pBD125     VERCWRYNI
pBD126 
pBD129     LGRCVMGL-
   
KKKCCIGPKGIQLIKSYL    
pEP2C      VINCKRSE-GRCQNF-CNYMEMQIGYCSKNKDPCCLPQN--------- pEP2E      VI-CLMQH- Consensus  x++Cx+xx-
PEKCWNLH-
GTCRLFFCHSGEKKSEICSDPWNRCCVPNTEEEKRS---   
G+C+xx-C+xxE+xIGxCxxxx++CC 
GSCRDK-CSKNEKVYVFCVSG-KLCCVKPKFQPNLFPKVN 
 
 
 
 
 
 
 
 
 
 
Fig. 2.1. Multiple sequence alignment of porcine β-defensin proteins. Amino acid sequences 
were predicted from cDNA sequences and aligned with minor manipulations to maximize 
sequence alignment. The Gly residues of GXC motif(s) are labeled in red. Conserved residues 
are shaded and the six cysteines are also boxed. The consensus sequence shows cysteines (C), 
positively charged amino acids (+), and other amino acids if they are represented in more than 
50% of all predicted β-defensin proteins. 
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Fig. 2.2.  Phylogenetic tree of human and porcine β-defensins. Human β-defensins are DEFBs 
and porcine β-defensins are pBDs. For branches supported by bootstrap analysis with the 
percentage of 1000 replications, the percentage is indicated on the branches. The bar indicates 
the p-distance. GenBank accession numbers are the same as in Table 2.2. 
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Fig. 2.3. Tissue expression profile of novel porcine β-defensins. (A) Tissues were obtained from 
healthy 5-week-old pigs and RT-PCR was performed using 250 ng total RNA as template in 
each reaction. The PCR products were measured and calibrated with glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) as described in the Material and methods section. Data are means ± 
SD, n = 3, L.N. = lymph nodes; ep. = epididymis. (B) Representative (pBD2, pBD3, and 
pBD129) RT-PCR products (10 μl/lane) of porcine β-defensins. Amplicons were resolved and 
stained with ethidium bromide in 1.5% agarose gel. M.L.N. = mesenteric lymph nodes; ep. = 
epididymis. 
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Fig. 2.4. Lung and skin expression of porcine β-defensin mRNA. Real-time RT-PCR was 
conducted with gene-specific primers using total RNA (200 ng in 25-μl PCR reaction). Relative 
gene-expression data were normalized against Ct values of the housekeeping gene, GAPDH, and 
the relative index (2−ΔΔCt) was determined in comparison to the average expression levels of all 
β-defensins with the index defined as 1.000 (indicated by the horizontal line). 
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I. Predicted 
promoter
region  
III. Intron 1  IV. Exon 2II. Exon 1
~1.0 kb  ~8.0 kb  
60 bp 147 bp
GINLLTGLGQRSDHYICAKK
GGTCNFSPCPLFNRIEGTCY
SGKAKCCIR 
MRALCLLLLTV
CLLSSQLAA 
~1.4 kb  
58 bp 143 bp
0.93 kb  
MRIHYLLFAL
LFLFLMPLPG
NGRIINTLQRYYC
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~1.0 kb  
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Fig. 2.5. Gene structure schematic of porcine β-defensin (pBD)2, pBD3 and pBD4. Putative 
promoter regions (solid bars before Exon 1), exons (dashed bars) and introns (solid bars) are 
proportional to the length of DNA fragments with the exception of the intron in pBD2. The 
length of each region is labeled above. The translated peptide sequences of each exon is included 
under the exon.  
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bBD12 (1BNB) hBD3 (1KJ
  
6)A hBD2 (1FD4)
pBD1 pBD2 pBD3
pBD-1 (front) pBD-2 (front) pBD-3 (front)
pBD-1 (back) pBD-2 (back) pBD-3 (back)
B
 
Fig. 2.6.  Tertiary structures for porcine β-defensin (pBD) 1-3. (A) Ribbon models of pBD1, 
pBD2, and pBD3 tertiary structures were generated via homology modeling from various β-
defensin templates. The coloring scheme using for the diagrams is purple = helix, yellow = 
strand/sheet and cyan= coil. (B) Surface charge models of pBD1, pBD2, and pBD3. The upper is 
the front view and the bottom, back view. The color scheme is, red = acidic or mostly negative; 
blue = basic or mostly positive; yellow = hydrophobic; and white = neutral or nonpolar.  
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Table 2.1.  Primer sequences for RT-PCR and real-time RT-PCR analysis   
 
pBDs 
 
Primer sequence (5’ to 3’) 
GenBank 
accession number 
Location 
in cDNA (nt) 
pBD2 
  sense 
  antisense 
 
ATGAGGGCCCTCTGCTTGCT 
ATACTTCACTTGGCCTGTGTGTCC 
AY506573 
(AW785442) 
 
53-72 
312-289 
pBD3 
  sense 
  antisense 
 
CTTCCTATCCAGTCTCAGTGTTCTGC 
GGCTTCTGTAGACTTCAAGGAGACAT 
AY460575 
(CF789126) 
 
200-225 
508-483 
pBD4  
  sense 
  antisense 
 
GTGGCTTGGATTTGAGGAGAGAGT  
AGTGATACACAGGCCTGGAAGGAT  
AY460576 
(BX672669) 
 
107-130 
339-316 
pBD104 
  sense (1) 
  antisense( 1) 
  sense (2) 
  antisense (2) 
 
 
TCCTTCCACGTATGGAGGCTTGTT  
TTACAATACCTCCGGCAGCGAGAA    
AAGACTCCTGTTAGCACCCAGCAT     
TTACAATACCTCCGGCAGCGAGAA    
DQ274056 
 (BX918848) 
 
300-323 
632-608 
449-472 
632-608 
pBD108 
  sense (1) 
  antisense( 1) 
  sense (2) 
  antisense (2) 
 
 
GACGATTGTCATTCTTCTGATCCTGG  
TAGGTTGACTTGTGGTGCCCGAAA 
GTGAGAAAGACCAAGGATCATGCAG  
TAGGTTGACTTGTGGTGCCCGAAA  
DQ274057 
 (BX917425) 
 
33-58 
291-268 
124-148 
291-268 
pBD114 
  sense (1) 
  antisense( 1) 
  sense (2) 
  antisense (2) 
 
 
TGTACCTTGGTGGATCCTGAACGA 
CGCCCTCTGAATGCAGCATATCTT 
TGTACCTTGGTGGATCCTGAACGA 
ATTCCTACACCTCTCTGTACTGGTGC 
BK005518 
 (BX923414) 
 
95-118 
221-196 
95-118 
304-279 
pBD123 
  sense (1) 
  antisense( 1) 
  sense (2) 
  antisense (2) 
 
 
AGCCATGAAGTGTTGGAGTGCGTT  
GTACACAGCACATAGTTGCATCCC 
GTGCGTTGGGAAGATGCAGAACAA  
AACAGGGTAGGGCCAAGAATGAGT 
BK005519 
(BX915917) 
 
76-100 
177-153 
93-116 
322-298 
pBD125 
  sense (1) 
  antisense( 1) 
  sense (2) 
  antisense (2) 
 
 
AGCCATGAATCTCCTGCTGACCTT  
TGCAGCATGCTCGCTTGTTCATAC 
GTGACCAAAGCTGGCTGGAATGTT  
TCCTGCTCAGTTCCTGTGCTTTCT 
BK005520 
(BX926653) 
 
32-55 
201-178 
81-104 
370-347 
pBD129 
  sense 
  antisense 
 
CAAAGACCACTGTGCCGTGAATGA 
TTGATGCTGGCGAAAGGGTTGGTA 
BK005521 
(BX918362) 
 
118-141 
357-334 
pEP2C 
  sense 
  antisense 
 
CCCTTTCCAGGAACCTGAACCAAA 
TGGCTTGTAGGCTCTGGAGAACAA 
BK005522 
(BX925543) 
 
184-208 
388-365 
pEP2E 
  sense (1) 
  antisense( 1) 
  sense (2) 
  antisense (2) 
 
 
TGCCTTATGCAACATGGAACCTGC  
AGGTGCTAGAACCACCATTCATCG 
TCCAGACACTTCCCTATGGCCTTT  
GCCTGCAGGTTCCATGTTGCATAA 
BK005523 
(BX919973) 
 
295-318 
445-422 
12-35 
322-299 
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Table 2.2. Properties of porcine β-defensins (pBDs) 
pBDs GenBank 
accession 
number 
Amino 
acids 
ORF 
verified a 
Six-cysteine 
spacing 
pattern b 
 
H+R+K 
c 
 
Main expression features in 
healthy tissues 
pBD1 AF031666 64 Y 6 4 9 6 9 Airway and oral mucosa 
pBD2 AY506573 69 Y 6 4 9 6 8 Liver, intestined, lung and bone 
marrow  
pBD3 AY460575 67 Y 6 4 9 6 12 Bone marrow, liver, lung and 
lymphoid tissues 
pBD4 AY460576 67 Y 6 3 9 6 9 Lung and proximal epididymis 
pBD104 DQ274056 - - 6 3 9 5 11 Spleen, liver and testis 
pBD108 DQ274057 73 Y 6 3 9 5 10 Liver and  proximal epididymis 
pBD114 BK005518 69 Y 6 3 9 6 8 Ileum, spleen, liver, lung, and 
male reproductive tissues 
pBD123 BK005519 - Y 6 3 9 5 8 Ileum, spleen, lung, and male 
reproductive tissues  
pBD125 BK005520 147 Y 7 3 9 5 13 Lung, thymus, and epididymis 
pBD129 BK005521 >173 Y 6 3 9 4 11 Epididymis, intestine, spleen, lung 
, skin  
pEP2C BK005522 >108 Y 6 3 9 6 6 Thymus, skin, testis, and some 
sections of epididymis 
pEP2E BK005523 85 Y 6 4 9 6 9 Not evident in all tested tissues 
 
 
a. Open reading frames (ORF) in EST sequence were verified either by computational predication or sequencing 
after PCR amplification. 
b. Numbers of amino acids that  separate the cysteine residues (C1-C2, C2-C3, C3-C4 and C4-C5) in the six-
cysteine β-defensin motif. 
c. Numbers of positively charged residues (H, histidine; R, arginine; K, lysine) in the putative mature β-defensin 
peptides.  Calculations count positive residues between seven amino acids before the first cysteine (C1) and, at 
most, seven amino acids beyond the last cysteine (C6). 
d. Indicates the gene expressed in all three tested sections (duodenum, jejunum and ileum) of intestine. 
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Table 2.3. Antimicrobial activity of porcine β-defensin (pBD)-2 and pBD-3. 
MIC (µg/ml)c Microorganism ATCC number 
cBD pBD2 pBD3 
Escherichia coli (generic)a 25922  20  80 30 
Staphylococcus aureus  
 
10832  100  150 100 
Listeria monocytogenesb 
 
19115  10  150 100 
a Enterobacteriaceae.  b Non Enterobacteriaceae 
c The MIC was determined with a broth microdilution method adapted from NCCLS and the 
canine BD (cBD) was taken as a control  (Sang Y. et al. 2005) . 
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CHAPTER 3 - Porcine Antimicrobial Peptides in Arteriviral 
Infection: Differential Expression and Inactivation of PRRSV 
ABSTRACT. In this report, we evaluated the potential antiviral activity of porcine host defense 
peptides (HDPs) against porcine reproductive and respiratory syndrome virus (PRRSV); a virus 
that causes an economically significant pandemic disease in pigs. Porcine alveolar macrophages 
(PAMs) are primary cells of PRRSV infection. Among twenty-four identified porcine HDPs, 
most are highly expressed in lungs. However, only β-defensins (pBDs) not cathelicidins were 
detected in PAMs. In PRRSV-positive lungs of fetal and 2-week-old congentinally infected pigs, 
gene expression of most HDPs showed no significant upregulation. Expression of pBD-1 and 
protegrins was down-regulated in PRRSV-infected fetal lungs. In vitro incubation of PRRSV 
with synthetic pBD-3 or protegrin (PG)-4 at >20 µg/ml significantly inhibited viral infectivity. 
Using nine protegrin-derived peptides, we determined that cyclization of PG-4 increased anti-
PRRSV activity and that substitution of Phe14 with Val in PG-4 diminished most of the activity. 
Consistently, the presence of pBD-3 and PG-4 at 5-40 µg/ml in culture medium suppressed 
PRRSV titer in PAM cultures. Collectively, these findings suggest a potential role for some 
porcine HDPs as innate antiviral effectors in PRRSV pathogenesis. Manipulation of porcine 
innate immune mechanisms with HDPs may be one tactic for preventing this costly pandemic 
viral disease.  
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3.1. Introduction 
One defense mechanism of an animal’s innate immune system is constitutive or inducible 
production of host defense peptides (HDPs). Many HDPs have broad-spectrum antimicrobial 
activity with potency against bacteria, fungi, protozoa or/and viruses. Antiviral activity of HDPs 
was noted in early studies and research in this area has recently intensified (Daher et al., 1986; 
Klotman and Chang, 2006). Using direct inactivation assays, several studies have demonstrated 
that LL-37, the only cathelicidin in humans, significantly reduces the infectivity of herpes 
simplex virus (HSV)-1, adenovirus, Vaccinia virus and human immunodeficiency virus (HIV) in 
some tissues and cells (Bergman et al., 2007; Gordon et al., 2005; Howell et al., 2004, 2006). 
Constitutive expression of β-defensins and combinations of other HDPs in oral epithelia and 
vaginal fluids has been shown to form an effective innate immune barrier against HIV infection 
(Quiñones-Mateu et al., 2003; Sun et al., 2005). Human β-defensin 3 (hBD-3) inhibited influenza 
virus infection through direct interaction with viron surface glycoprotein preventing virus fusion 
to the cell membrane, and suppressed HIV entrance into cells by competition for viral co-
receptors on immunocompetent cells (Feng et al., 2006; Leikina et al., 2005).  Retrocyclins, 
circular θ-defensins based on human pseudogene sequences, have been characterized for their 
antiviral activity. Retrocyclin (RC)-1 protected human cells from infection by 30 primary HIV-1 
isolates and RC-2 effectively suppressed  infection by several viruses including influenza, 
Sindbis virus and baculovirus (Cole and Cole, 2008; Gallo et al., 2006; Wang et al., 2003, 2004). 
In addition to antiviral activity,  cytotoxicity of a HDP to host cells is a critical aspect for 
potential therapeutic use (Hancock and Sahl, 2006). Studies have shown that LL-37, hBD-2 and -
3, and RCs have limited and tolerable cytotoxicity. However, most α-defensins exert cytotoxicity 
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to mammalian cells at a concentration that kills virus (Leikina et al., 2005; Sun et al., 2005). A 
porcine cathelicidin, protegrin (PG)-1, exerted anti-lentiviral activity comparable to LL-37, but 
had cytotoxicity to host cells as well (Steinstraesser et al., 2005). To our knowledge, protegrin-1 
is the only porcine HDP that has been reported to have antiviral activity. To date, about thirty 
porcine HDPs including 13 β-defensins (pBDs) and 12 cathelicidins have been identified. There 
are no α-defensins identified in pigs, and it has been suggested that some porcine cathelicidins 
shch as PG-1 substitute for the functions of  α-defensins as in other species (Ganz, 2003).   
Few studies have been involved in antiviral activity of porcine HDPs. Porcine reproductive 
and respiratory syndrome virus (PRRSV) is an enveloped, (+)-ssRNA virus that has been an 
immunological challenge and a devastating pathogen for the swine industry (Mateu and Diaz, 
2007; Neumann et al., 2005). We reasoned that some porcine HDPs may be potential antiviral 
effectors during PRRSV infection. Accordingly, we examined the expression profile of all 
identified porcine HDPs in lungs from PRRSV-negative and -positive pigs, and evaluated the 
direct inactivation activity of a group of synthetic porcine HDPs. Here we report that PRRSV 
infection displays little upregulation of HDP expression, and that pBD-3 and PG-4 show direct 
suppression of PRRSV infectivity.     
 
3. 2. Materials and Methods 
 
Virus strains and titration in cell cultures. The North American macrophage-tropic 
PRRSV strain, SDSU-23983-P6 (P6), was used to infect pigs as previously described (Kim et al., 
2002; Rowland et al., 2001, 2003). All animal and virus procedures were approved by the 
Kansas State University Institutional Animal Care and Use, and Biosafety Committees. MARC-
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145 cells, an African green monkey kidney cell line sensitive to PRRSV infection, was used to 
test PRRSV infectivity and for virus titration.  Virus stocks [SDSU-23983-P7 (P7)] collected 
from supernatant of P6-infected MARC-145 cells were used to infect cell cultures. In addition, a 
full-length cDNA infectious clone with expression of green fluorescent protein (GFP) in the 
region of nonstructural protein 2 (Nsp2) of PRRSV (GFP-PRRSV) was used to infect MARC-
145 cells to facilitate examination with fluorescent microscopy. The GFP-PRRSV was generated 
from North American type 1 PRRSV isolate, SD01-08, and maintained growth properties similar 
to those of the parental virus in cell cultures (Fang et al., 2006). The tissue culture 50% 
infectious dose (TCID50) of P7 and GFP-PRRSV stocks was 107.25 and 107.14 PFU/ml, 
respectively. Cells were infected at a multiplicity of infection (MOI) of 0.1 TCID50/cell 
(Rowland et al., 2001, 2003).  For titration, MARC-145 cells were cultured in Eagle’s minimum 
essential medium (MEM, ATCC) supplemented with 8% heat-inactivated fetal bovine serum 
(FBS) and antibiotics (100 IU penicillin and 100 μg/ml streptomycin, CHEMICON International, 
Inc., Temecula, CA) in a humidified 5% CO2, 95% air atmosphere at 37 °C.  P7-virus-infected 
monolayers of MARC-145 cells in 96-well tissue culture plates were fixed with 80% cold 
acetone and incubated with fluorescent-labeled monoclonal antibodies to PRRSV nucleocapsid 
protein N (SDOW17, Rural Technologies, Inc., Brookings, SD).  PRRSV-positive cells were 
identified by fluorescent microscopy, or duplicate cell monolayers were fixed with buffered 4% 
formaldehyde and stained with crystal violet to identify viral plaques (Rowland et al., 2001, 
2003).        
 
In vivo infection and tissue collection. Fetal and young pig lung samples from an earlier 
study were used in which seronegative pregnant females were infected at 85-90 days of gestation 
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with wild type P6 as described (44, 46). Some animals were allowed to give birth and live-born 
pigs were euthanized at 14 days of age or fetuses were obtained at 107 and 112 days of gestation. 
Tissue samples were immediately placed in RNAlater (Ambion, Inc. Austin, TX) and stored at -
20 °C until used (Rowland et al., 2001, 2003).  
 
PAM collection, treatment and infection. Porcine pulmonary alveolar macrophages 
(PAM) were obtained by bronchoalveolar lavage from healthy 5-wk-old pigs and cultured as 
previously described (Chitko-McKown et al., 1991; Xiao et al., 2004). Two days before 
treatments or infection with PRRSV, PAMs were thawed from stocks and plated in 24-well 
tissue culture plates (7×104 cells/well) in  supplemented RPMI 1640 medium and cultured in a 
humidified 5% CO2, 95% air atmosphere at 37 °C. After one-change of fresh medium 2 h later to 
remove non-adherent cells, PAMs were cultured with replenished medium containing synthetic  
peptides of pBD-2, pBD-3 and PR-39 at 0, 5, 10, 20 or 40 μg/ml for indicate time  (0, 4, 10 or 24 
h). PAMs used for viral infection were infected with PRRSV-P7 at the indicated MOI for 18 h. 
Supernatants were collected for viral titration on MARC-145 cells, and cell RNA was extracted 
with TRI reagent (Sigma-Aldrich, St. Louis, MO). 
   
RT-PCR and real-time RT-PCR. Analysis of gene expression by RT-PCR and real-time 
RT-PCR was conducted as previsously described (Chapter 2, Section 2.2, Page 91-92). 
 
Peptide synthesis and preparation. The C-terminal peptides of pBD-2 (34 aa), pBD-3 (36 
aa), pBD-3 analogue (36 aa) and PR-39 (39 aa) were chemically synthesized by solid-phase 
peptide synthesis (Abgent, San Diego, CA). The linear analogue of pBD3 was designed and 
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synthesized using alanines to replace six cysteine residues in pBD3 peptides. The material was 
eluted as a single peak by reverse-phase HPLC and the peptide identity was confirmed by mass 
spectroscopy. The final purity of the peptide is >95%. The eight protegrin-related peptides and 
RC-100B were prepared at the University of California, Los Angeles, by solid-phase peptide 
synthesis, using fluorenylmethoxycarbonyl (FMOC) chemistry. The peptides were purified by 
HPLC, and concentration was determined by measuring absorbance at 280 nm. PG-1, PG-4 and 
PG-5 were derived from the C-terminal 18 aa (without the last glycine residue) of the 
endogenous protegrins. The cyclic versions of PG-4 and PG-5 bear end-to-end peptide bonds 
linking two arginine residues at both ends of the corresponding linear forms. The peptides were 
oxidized to form two inter-strand disulfide bonds. The other two analogs of PG-4 include PG-4/ 
F14-V, in which phenylalanine at position 14 is replaced with valine, and cyclic PG-
4/1Nal/Chg/PheF5, which contains 1-naphthy-alanine (1Nal), cyclohexylglycine (Chg), and 
pentafluorophenylalanine (Phe F5) instead of residues of GWI. These substitutions were designed 
to make the analog much more hydrophobic than endogenous PG-4. The three other protegrin-
like peptides are PG-307, cyclic PG-307 and PG-303, which were designed based on backbones 
of PG-1 and PG-5 to improve their antiviral activity and reduce their cytotoxicity. The peptides 
were lyophilized and dissolved in 0.01% acetic acid at 1 mg/ml (~0.5 mM) as a stock solution 
and stored at –135 ºC until further use.  
 
Viral inactivation and cytotoxicity assays of HDPs. To evaluate antiviral activity of 
HDPs, peptides were diluted in 50 μl of FBS-free MEM containing PRRSV (P7) or GFP-PRRSV 
at 10 X of viral titers used for inoculation (MOI of 1 TCID50/cell). Final concentrations of tested 
HDPs were at 0, 5, 10, 20, and 40 μg/ml, and some peptides were used up to 240 μg/ml. After 
 119
incubation at 37 °C for 2 h, 10 μl of the mixture of virus and peptide was added to 90 μl medium 
of MARC-145 cells cultured in wells of 96-well plates. Most times, HDPs were directly diluted 
in culture medium containing the virus at MOI of 0.1 TCID50/cell and applied to the cells in 96-
well plates (Salvatore et al., 2007). The plates were washed with fresh medium after infection for 
2 h, and replenished with HDP-containing medium. The infectivity of virus was examined at 24 
or 48 h by immunostaining of PRRSV nucleocapsid protein N or detection of fused GFP 
fluorescence in GFP-PRRSV infected cells. The virus positive cells were photographed using an 
inverted fluorescent microcopy and fluorescent intensity was quantified with digital image 
software (AlphaEase FC, FluorChemTM, Alpha Innotech Corp., San Leandro, CA). For 
evaluation of HDP effects on viral infection in PAMs, viral supernatants were collected from 
PAMs infected with PRRSV for 18 h in presence of HDPs. The supernatants were diluted 10-
fold serially into MARC-145 cell monolayers in 96–well plates. MARC-145 monolayers were 
fixed with buffered 4% formaldehyde after 48-72 h post infection and stained with crystal violet 
to identify viral plaques for calculation of TCID50/ml (Rowland et al., 2001, 2003). 
 Cytotoxicity of each HDP was microscopically evaluated or quantified by determining the 
number of viable cells using a tetrazolium-based colorimetric (MTT) assay (Maher and 
McClean, 2006).  
 
3.3. Results and Discussion  
Differential expression of HDPs in PRRSV-infected lungs and PAMs. To determine if 
PRRSV influences the expression of HDPs, we evaluated the expression of porcine defensins 
and cathelicidins in lungs and PAMs exposed to the virus. Lung samples were collected from 
either 14-d-old piglets or fetuses (107 and 112 days of gestation), which were farrowed by sows 
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infected by PRRSV at 85-90 days of gestation (Rowland et al., 2001, 2003). PAMs were 
obtained by bronchoalveolar lavage from healty pigs, and infected with PRRSV in vitro (Xiao et 
al., 2004). Tissue/cell RNA was extracted and a one-step standard RT-RNA (Qiagen) was run 
using gene-specific primers (Table. 3.1). As shown in Fig. 3.1, multiple β-defensins are 
expressed in lungs of 14-d old pigs and fetuses. pBD-2 and pBD-3 displayed the highest 
expression levels, following by pBD-1 and pBD-114. No significant stimulation or suppression 
was found in lungs of 14-d-old pigs; however, lungs from PRRSV-infected fetus showed a 
decrease in pBD-1 expression. pBD-2 and -3 were also the main defensins detected in isolated 
PAMs, and slightly downregulated by exposure of cells to PRRSV for 5 hours. Conversely, 
pBD-114 (along with pBD123 and pBD125, data not shown) was slightly stimulated, but not 
significantly, in lungs of fetuses from PRRSV-infected sows, and a similar stimulation was also 
observed in the macrophages exposed to the virus in vitro.  Weak regulation of innate immune 
genes appears to be prominent feature in PRRSV infections, such as expression of IFN-α, IL-1 
and IL-6 genes (Petry et al., 2007). This was also found for porcine defensin expression in pig 
lungs. However, pBD expression in fetal lungs was more responsive such as in the case of pBD-
1 and pBD-114, indicating that pBD expression in lungs may be differentially responsive to 
PRRSV infection and dependent on pig development.          
Most porcine cathelicidins were expressed in lungs. PR-39, prophenin-2 (PF-2), and  
protegrin-1-5 (PGs) were expressed at levels two- to fourfold higher than defensins. PR-39 was 
not influenced by PRRSV infection; however, PF-2 was suppressed in lungs of 14-d-old pigs and 
stimulated in lungs of fetuses from PRRSV-infected sows. Lungs of fetuses from sows infected 
with PRRSV had lower expression of protegrins; other cathelicidins, PMAP-23 and PMAP-37 
were detected in lungs at low levels; however, PAMP-36 was only detected in fetal lungs (Fig 
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3.1). No porcine cathelicidins were detected in PAMs (data not shown). The high expression of 
cathelicidins in lungs but not in PAMs is consistent with the literature showing that porcine 
cathelicidins are not present in macrophages (Zanetti, 2004). The source of cathelicidin 
expression in lungs probably relates to pulmonary presence of granulocytes. Again, weak, even 
negative responses of cathelicidin expression may be probably due to suboptimal induction of 
inflammatory responses during PRRSV infection (Petry et al., 2007; Thanawongnuwech et al., 
2004).      
  
Suppression of PRRSV infectivity in MARK-145 cells.  Porcine HDPs, including pBD-
1, pBD-2, pBD-3, PR-39, PG-1, PG-4, and PG-5, were selected to evaluate anti-PRRSV activity. 
Two primate HDPs, hBD-3 and RC-100B, which have been shown to be active in suppression of 
multiple viruses, were also evaluated. As shown in Fig. 3.2 and Fig. 3.3, pBD-3 and PG-4  
suppressed PRRSV infectivity in MARC-145 cells. Incubation with either pBD-3 or PG-4 at 
higher than 20 μg/ml suppressed about 50-80% of viral infectivity when estimated by 
immunofluoresce intensity using an antibody to PRRSV nucleocapsid protein N.  The effects of 
peptides at the concentrations lower than 10 μg/ml were not significant, and complete 
elimination of PRRSV positive cells could not be attained even at 240 μg/ml of the peptides 
(Fig. 3.3). Other porcine HDPs, including pBD-1, pBD-2, PR-39, PG-1 and PG-5, showed no 
significant effects repeatedly at concentrations lower than 40 μg/ml. Of the primate HDPs used, 
hBD-3 showed activity similar to pBD3 (data not shown), and RC-100B was not active against 
PRRSV. For most peptides assayed, higher than 80 μg/ml inhibited virus infectivity to some 
extent; however, these concentrations were not considered to be physiological or due to 
cytotoxicity to cells (Fig. 3.4). In most cases, the two procedures, either peptide pre-incubation 
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for 2 h with virus in FBS-free medium prior to addition to cells or simultaneous addition to cells 
in cell culture medium, had similar results in respect to inactivation of viral infectivity (Salvatore 
et al., 2007). However, slightly better activity of pBD-3 and PG-4 was noted sometimes with the 
pre-incubation procedure. In addition to above activity assays, which used a wild-type PRRSV 
isolate (P7), a cell-culture-adapted PRRSV (P136) and a DNA infectious clone GFP-PRRSV 
(Fang et al., 2006) have also been tested for sensitivity to the listed HDPs. The efficacy of these 
HDPs in suppression of PRRSV infectivity was consistent among these three PRRSV strains; 
however, the GFP-PRRSV infectious clone provided a real-time means to examine the HDP 
effect by GFP fused to viral Nsp2 protein.  As summarized in Table 3.2, pBD-3 and PG-4 were 
active in tests against all three PRRSV strains. Incubation cells with PR-39 or RC-100B at 
>40 μg/ml, inhibited PRRSV and GFP-PRRSV clone infectivity for 20-40% without obvious 
cytotoxicity. In contrast, PG-1 and PG-5, at concentrations higher than 40 μg/ml, decreased the 
viral infectivity probably via cytotoxicity to cells thus limited virus replication (Fig. 3.4). 
  
Anti-PRRSV activity of protegrin-derived peptides. The nature of pBD-3 and PG-4 in 
inactivation of PRRSV promoted us to study this activity further. We were especially interested 
in the characteristics of PG-4. Alignment of the five isoforms of porcine protegrin mature 
peptides indicates that only four of eighteen residues of PG-4 differ from the other PGs (Fig 3.5). 
Whereas PG-4 has a hydrophobic beta turn at residue 10 to 12 (GWI) and other PGs have 
arginine-rich polar turns with residues of (R)RRF or (R)PRF. In addition, PG-4 has a Phe (F) at 
residue 14 and other PGs have Val (V) or Ile (I) at this position. Considering that cyclic PGs may 
exert more antimicrobial activity, we synthesized cyclic forms of PG-4 and two analogs of PG-4 
including PG-4/ F14-V (PG4FV), which  Phe14 is replaced with Val, and cyclic PG-
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4/1Nal/Chg/PheF5 (PG-4NCP), which contains 1-naphthy-alanine (1Nal), cyclohexylglycine 
(Chg), and pentafluorophenylalanine (Phe F5) instead of the residues GWI. These substitutions 
were designed to make the analog more hydrophobic than ordinary PG-4 (Fig. 3.5).   
 
We thus evaluated antiviral activity of these protegrin-derived peptides against both wild-
type PRRSV and GFP-PRRSV. Examined at 48 or 72 h post infection, the presence of linear PG-
4, cyclic PG-4 (PG-4CY) and cyclic PG-4NCP had similar anti-PRRSV activity at 5-20 μg/ml 
(Fig. 3.6). The cyclization of PG-4 (PG-4CY and PG-4NCP) showed some improvement in anti-
PRRSV activity comparing to PG-4 at 20 and 40 μg/ml. However, PG-4NCP was no better than 
PG-4CY. Clearly, cyclic PG-4 with substitution of Phe14 with Val14 (PG-4FV) has less anti-
PRRSV activity than PG-4 and PG-4CY at all test concentrations. We also tested the activity of 
cyclic PG-5 and three other protegrin-like peptides, PG-303, PG-307, and cyclic PG-307, which 
were designed based on backbones of PG-1 and PG-5 but modified in position 2 with Trp. Both 
PG-303 and PG-307 have been shown to be more active against HIV-1 than PG-1 (personal 
communication, Dr. Lehrer, UCLA). In respect to suppression of PRRSV infectivity, PG-5 had 
little anti-PRRSV activity at <40 μg/ml; but cyclic PG-5 showed increased anti-PRRSV activity 
at earlier time of viral infection when tested with GFP-PRRSV (Data not shown). In general, PG-
303 and PG307 showed no obvious activity in suppression of PRRSV infectivity. In conclusion, 
anti-PRRSV activity was shown in PG-4 and its derived peptides, PG-4CY and PG-4NCP in 
which cyclization and residue-substitution were conducted to improve its viral accessibility and 
molecular hydrophobicity. Whereas cyclization increased some of viral-suppression activity, 
changing GWI to NCP did not improve anti-PRRSV activity. In contrast, PG-4F-V (substitution 
of Phe14 with Val) diminished most of the anti-PRRSV activity. This may indicate that the 
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aromatic side-chain of Phe14 defines a stereo-specific interaction with a viral target on the surface 
of PRRSV virions. Still the hydrophobic beta turn (GWI) in PG-4 may coordinate with Phe14 to 
determine the potential peptide-PRRSV interaction therefore to suppress viral infectivity. The 
ability of a simple tripeptide motif (GWI) to have marked functional consequences is reminiscent 
of the RGD motif in integrin studies (Garrigues et al., 2008).    
 
Suppression of PRRSV infection/replication in PAMs.  We also evaluated antiviral 
activity of selected HDPs directly on PAMs. The peptides were co-incubated with PAMs during  
virus infection for 18 h, and released viruses in the PAM supernatants were titrated on MARC-
145 cells. As shown in Table 3.3, at concentrations of 5 and 10 μg/ml, pBD3 and PG-4 were 
most active peptides suppressing PRRSV TCID50 comparing to the control. PG-1 and PG-5 also 
decreased PRRSV TCID50 at 10 μg/ml. At the concentrations of 20 and 40 μg/ml, all tested 
HDPs showed some effects on suppression of PRRSV infectivity for ~1-3 TCID50 unit or 10-
30% suppression to the control. We interpreted these results arose from the combination effects 
of direct PRRSV-inactivation activity, such as by pBD3 and PG-4, and indirect induction effects, 
such as by PR-39, and cytotoxicity such as in the cases of PG-1 and PG-5.  In addition, 
substitution of six cysteine residues of pBD3 did not decrease the antiviral activity in comparison 
to original pBD3 peptide (Taylor et al., 2008).  
In summary, we have evaluated differential expression patterns of porcine HDPs in lungs 
of PRRSV-infected pigs that indicate a potential weak induction mechanism adopted by PRRSV 
infection. Selected porcine HDPs were used to suppress PRRSV infectivity in cell culture 
systems. Although no peptide eliminated PRRSV completely, the porcine defensin pBD-3 and 
the cathelicidin PG-4 showed promising activity in suppression of PRRSV infectivity. A panel of 
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peptides derived from pBD3 and protegins were used to determine the critical motifs of the 
peptides interacting with PRRSV and to improve anti-PRRSV activity. Whereas the cysteine 
residues were found to not be essential for the antiviral activity of pBD3, the stereo-structure 
formed by GWI and Phe14 residues appears critical for PG-4/PRRSV interaction and provokes 
further investigation.    
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Fig. 3.1. Expression of porcine HDPs in PRRSV-infected lungs and pulmonary alveolar 
macrophages (PAMs).  Fetal and 14-d-old pig lungs from sows infected with PRRSV, and PAMs 
infected in vitro with PRRSV were evaluated for mRNA expression of porcine defensins (A) and 
cathelicidins (B). RT-PCR was conducted with gene-specific primers using total RNA of 200 ng 
in 25 μl volume. The gene-specific amplicons were resolved and ethidium bromide-stained on 
1.5% agarose gels and band intensities were quantified using a digital imaging system.  * 
Differential from control p<0.05, n=3.  
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Fig. 3.2. pBD-3 inhibits PRRSV infectivity. PRRSV was incubated with pBD-3 before infection 
of MARC-145 cells for 2 h and infected cells were cultured in the presence of pBD-3 for 48 h. 
Top four panels are immunofluorescence of cells detected with a mAb to PRRSV. Bottom two 
panels are brightfield micrographs. Immunofluorescence intensity of 3-5 randomly photographed 
areas was measured and standardized relative to the controls using a digital imaging system.  * 
Differential from control p<0.05, n=3.  
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Fig. 3.3. PG-4 inhibits PRRSV infectivity. PRRSV was incubated with PG-4 before infection of 
MARC-145 cells for 2 h and infected cells were cultured in the presence of PG-4 for 48 h. Top 
four panels are immunofluorescence of cells detected with a mAb to PRRSV. Bottom two panels 
are brightfield micrographs. Immunofluorescence intensity of 3-5 randomly photographed areas 
was measured and standardized relative to the controls using a digital imaging system.  * 
Differential from control p<0.05, n=3. 
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Fig. 3.4. Effects of other HDPs inhibiting PRRSV infectivity. PRRSV was incubated with 
individual HDP before infection of MARC-145 cells for 2 h and infected cells were cultured in 
the presence the same HDP for 48 h. PRRSV was then detected using immunofluorescence and 
quantified as indicated. Immunofluorescence intensity of 3-5 randomly photographed areas was 
measured and standardized relative to the controls using a digital imaging system. * Differential 
from control p<0.05, n=3.  
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Fig. 3.5. Peptide sequences of porcine protegrins (PGs) and PG-4 derived peptides. Different 
residues of PG-4 including the aromatic beta turn (GWI) and Phe14 (F) are shaded.  The designed 
cyclic forms of PG-4 (PG-4CY) and derived peptides (PG-4NCP and PG-4F-V) with indicated 
residue changes (residues defined by three letter codes replacing the original residues indicated 
by one letter codes in original sequence) are shown. The cyclization was catalyzed at the 
positions mimicking Arg1/Gly2 and Gly10/Trp11 and synthetic peptides were oxidized to form 
intramolecular disulfide bonds (black bars). 1Nal, 1-naphthy-alanine, Chg, cyclohexylglycine, 
PheF5, and pentafluorophenylalanine. 
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Fig. 3.6. Effects of other PG-4 derived peptides inhibiting PRRSV infectivity. PRRSV was 
incubated with individual HDP before infection of MARC-145 cells for 2 h and infected cells 
were cultured in the presence the same HDP for 48 h. PRRSV was then detected using 
immunofluorescence and quantified as indicated. Immunofluorescence intensity of 3-5 randomly 
photographed areas was measured and standardized relative to the controls using a digital 
imaging system.  * Differential from control p<0.05, n=3.  
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Table 3.1. Primer sequences for RT-PCR analysis*. 
 
               
Cathelicidin Primer sequence (5’ to 3’) 
GenBank 
accession number 
Location
 in cDNA (nt) 
PR-39 
  sense 
  antisense 
 
CGGAGCTGTGTGACTTCAAGGAGAA 
ATGGGTATGTTATCAGCCACTCCAT 
 
L23825 
 
295-319 
560-534 
PF-1/2 
  sense 
  antisense 
 
CGGAGCTGTGTGACTTCAAGGAGAA 
AAAGGTGGAGGCGGAGGGAACCA 
 
X75438 
 
280-304 
643-621 
PMAP-23  
  sense 
  antisense 
 
CGGAGCTGTGTGACTTCAAGGAGAA 
AAATTTGGGTTTCTGTGGCCGACG  
  
L26053 
 
291-315 
454-431 
PMAP-36  
  sense 
  antisense    
 
CGGAGCTGTGTGACTTCAAGGAGAA 
ACCCAAGGGTATTGAGCCGACAAT 
 
L29125 
 
291-315 
505-482 
PMAP-37  
  sense 
  antisense    
 
CGGAGCTGTGTGACTTCAAGGAGAA 
TCCGACCACGATCACTGAGGAAAT 
 
L39641 
 
291-315 
449-426 
PG-1-5 
  sense 
  antisense    
 
CGGAGCTGTGTGACTTCAAGGAGAA 
TGCCGTCGCAACCGTCATCCT 
 
X79868 
 
 
278-302 
464-444 
* Please refer to Table 2.1 for the primers for porcine defensins.  
 138
 
 
 
 
             Table 3.2.  Summary of anti-PRRSV activity of tested HDPs* 
 
               
Tested HDPs Direct inhibitory effects Cytotoxicity at 40 μg/ml 
Porcine HDPs 
pBD-1 - - 
pBD-2 - - 
pBD-3 + - 
PR-39 +/- - 
PG-1 - + 
PG-4 + - 
PG-5 +/- + 
Primate HDPs 
hBD-3 + - 
RC-100B +/- - 
 
 
 
 
 
 
 
 
*Based on inactivation of infectivity of three PRRSV strains on MARC-145 
cells at the HDP concentration ≤ 40 μg/ml  
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Table 3.3.  Suppression of PRRSV infectivity by HDPs in PAMs. 
 
               TCID50 
Peptides 
5 μg/ml         10 μg/ml        20 μg/ml         40 μg/ml 
Control 7.4 7.4 7.8 7.4 
pBD-2 7.4 7.4 6.6 6.8 
pBD-3 6.8 6.6 6.5 4.8a 
pBD-3ΔC 7.3 6.7  6.8 5.3a 
PR-39 7.2 7.5 7.4 5.8a 
PG-1 7.4 6.6 5.8 4.7a 
PG-4 6.8 6.4 6.3 4.7a 
PG-5 7.2 7  7  5.3a 
RC-100B 7  8 7.2 7  
 
 
 
 
 
 
a. p<0.05 in comparison to controls. 
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CHAPTER 4 - Molecular Identification and Functional Expression 
of Porcine Toll-Like Receptor (TLR) 3 and TLR7  
 
ABSTRACT   To investigate porcine Toll-like receptors (TLR) responding to viral pathogen 
associated molecular patterns, the full-length cDNA of porcine TLR3 andTLR7 were identified 
and characterized. Porcine TLR3 and TLR7 cDNA encode 904- and 1050-amnio-acid 
polypeptides, respectively. Both porcine TLR3 and TLR7 contain typical functional TLR 
domains and share about 80% sequence identity to other mammalian orthologues. Tissue 
expression profiles showed that TLR3 was highly expressed in kidney, duodenum, spleen and 
liver, and moderately expressed in bone marrow, lung, and skin. Conversely, TLR7 was 
moderately and constitutively expressed in all tissues evaluated. Stimulation of mammalian cells 
transfected with porcine TLR3 and TLR7 constructs elicited activation of interferon regulatory 
factors (IRFs). These data provide molecular and functional information for porcine TLR3 and 
TLR7, and implicate their role in mediating immune protection against porcine viral diseases. 
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4.1. Introduction 
Toll-like receptors (TLRs) are pathogen recognition receptors that are primary components 
of the afferent arm of innate immunity (Pichlmair and Reis e Sousa, 2007; Takeuchi and Akira, 
2007). Among the more than ten TLRs that have been identified in mammals, four receptors, 
TLR3, TLR7, TLR8 and TLR9, are involved notably in virus recognition. For example, TLR3 
detects double-stranded RNA (dsRNA) formed during viral genome replication or transcription; 
TLR7 and TLR8 recognize elements of single stranded RNA (ssRNA) found in genomes of 
RNA viruses; and TLR9 senses unmethylated cytosine-phosphate-guanine (CpG) motifs 
common to both bacterial and viral DNA (Barton, 2007; Pichlmair and Reis e Sousa, 2007; 
Takeuchi and Akira, 2007). Unlike TLRs located on the cell surface such as TLR1 to TLR6 and 
TLR10 to TLR13, virus-sensing TLRs are located mainly in endosomes, which is where viruses 
undergo decoating during infection (Pichlmair and Reis e Sousa, 2007). Structurally, all 
identified TLRs contain a ligand-binding, leucine-rich extracellular domain, a transmembrane 
region, and a conserved Toll/IL-1 receptor (TIR) domain, which transduces perceived signals 
and induces expression of immune responsive genes (Barton, 2007; Gay and Gangloff, 2007). 
Prominently in antiviral responses, TLR-mediated signaling pathways activate core transcription 
factors including nuclear factor (NF)-κB and interferon regulatory factors (IRFs), such as IRF-3 
and IRF-7, which subsequently induce the production of type I IFN, a hallmark of antiviral 
immune responses (Barton, 2007; Kawai and Akira, 2006; Pichlmair and Reis e Sousa, 2007; 
Severa and Fitzgerald, 2007). 
Although several porcine TLRs have been identified (Meier, et al., 2004; Shimosato et al., 
2005; Shinkai et al., 2006a; Shinkai et al., 2006b; Tohno et al., 2005; Tohno et al., 2006), 
identification and studies on porcine TLRs responding to viral pathogen associated molecular 
patterns are limited. Porcine TLR9 has been identified and shown to be expressed in intestinal 
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Peyer’s patches and expression was stimulated in monocytes and monocyte-derived dendritic 
cells after treatment with synthetic poly (I:C) and CpG oligonucleotides (Tohno et al., 2006). In 
addition, a complete cDNA for TLR8 has been identified and deposited in GenBankTM, 
accession number NM 214187. Here, we report the identification and initial characterization of 
porcine TLR3 and TLR7. Both TLRs were expressed in immune tissues, show 76 to 90% 
identity to other mammalian orthologues, and conserve the typical TLR domains. Furthermore, 
gain-of-function experiments showed that both TLRs augment the activation of IRFs. 
Collectively, these findings provide a molecular foundation to examine the role of porcine TLR3 
and TLR7 in mediating immune responses against porcine viral diseases. 
4.2. Identification and Phylogenic Analysis of Porcine TLR3 and TLR7  
To begin investigating porcine TLR3 and TLR7, full-length cDNAs were obtained using RT-
PCR based on a SMART™ RACE cDNA (Clontech, Mountain View, CA) amplification 
technique (Sang et al., 2005; Sang et al., 2007). Briefly, ‘Smart Oligo’ was incorporated into the 
5'-end of reverse-transcribed cDNA for 5'-RACE analysis. For 3'-RACE analysis, the Smart 
Oligo was attached to an oligo (dT) primer to yield cDNA that had a complete 3'-UTR, a poly-A 
tail, and a Smart Oligo sequence extension. The 5'- and 3'-ends of the cDNA fragments were 
amplified using an Advantage 2 PCR kit (Clontech). Serial gene-specific RACE primers shown 
in Table 4.1 were retrieved from the identified cDNA fragments and the consensus sequences 
derived from alignment of other mammalian orthologues (listed in Fig. 4.1). Amplified 5'- and 
3'-RACE fragments were cloned and sequenced. The full sequences were generated using the 
sequence editor program in Lasergene 6 (DNASTAR, Inc. Madison, WI) to fuse the identified 
cDNA fragments and to remove the overlapped regions. Both porcine TLR3 and TLR7 genes 
have been registered in GenBankTM, accession numbers DQ647698 and DQ647699, respectively. 
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Porcine TLR3 cDNA has an open reading frame (ORF) of 2712 nt encoding a polypeptide of 904 
aa, an approximate 400 bp 5'- UTR, and an approximate 500 bp 3'-UTR. Porcine TLR7 cDNA 
has an ORF of 3150 nt encoding a polypeptide of 1050 aa, an approximate 120 bp 5'-UTR, and 
an approximate 400 bp 3'-UTR. Both porcine TLR3 and TLR7 show high similarity to 
orthologues from other mammalian species with approximately 80% identity in their peptide 
sequences. Porcine TLR3 or TLR7 cluster most closely to bovine orthologues with identity near 
or at 90%. TLR functional domains, including the N-terminal extracellular domain, the 
transmembrane domain, and the TIR domain, were clearly detected in the primary structure of 
porcine TLR3 and TLR7 (Fig. 4.1). 
4.3. Expression Analysis of Porcine TLR3 and TLR7  
To evaluate tissue expression profiles of porcine TLR3 and TLR7, mRNA expression in 
tissues from 5-week-old healthy pigs were examined using semi-quantitative RT-PCR (Sang et 
al., 2005). Total RNA was extracted with TRI Regent (Sigma-Aldrich) directly from cells or 
from frozen tissues ground in liquid nitrogen. A one-step RT-PCR (Qiagen) was used to detect 
expression of mRNA transcripts as previously described (Sang et al., 2005; Sang et al., 2007). 
Briefly, total RNA was treated with RQ1 RNAse-free DNase I (Promega) to remove possible 
genomic DNA contamination. RNA samples (100-250 ng) were run in a 25-μl RT-PCR mixture 
with 0.1 μM of each sense and antisense primer derived from cDNA sequences (Table 4.1). 
Semi-quantitative RT-PCR was performed at 1 32, 35, 38, and 40 cycles. After amplification, 10 
μl of each reaction mixture was analyzed by 1.5% agarose gel electrophoresis and bands were 
visualized by ethidium bromide staining using a FluorChemTM digital imaging system 
(AlphaInnotech Corp., San Leandro, CA). Integrated density values were measured and 
standardized to values of a housekeeping gene, glyceraldehyde 3-phosphate dehydrogenase 
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(GAPDH), and presented as a ratio relative to the expression of GAPDH in the same samples 
(Sang et al., 2005; Sang et al., 2007). Porcine TLR3 was highly expressed in kidney, duodenum, 
spleen and liver, and moderately expressed in bone marrow, lung, and skin (Fig. 4.2). 
Conversely, porcine TLR7, was moderately expressed in all tissues evaluated, which included 
bone marrow, segments of the intestine, spleen, liver, lung, mesenteric lymph nodes, trachea, 
thymus, kidney and skin. 
4. 4. Overexpression of Porcine TLR3 and TLR7 in Mammalian Cells  
To examine functional aspects of TLR3 and TLR7, ORFs were amplified from enriched 
mRNA from porcine macrophages using a high fidelity RT-PCR system (Invitrogen). To 
facilitate cloning, linkers containing Hind III and BamH I restriction sites were introduced at 
their 5' and 3' termini, respectively, by PCR. The inserts were cloned into the expression vector 
pEGFP-N1 (Clontech). E. coli (Topo 10, Invitrogen) transformed with the constructs were 
selected with kanamycin (30 μg/ml; Sigma), and positive clones were identified and confirmed 
by sequencing (Sang et al., 2005). Purified plasmids from the positive clones were used to 
transfect HEK293A cells for expression of enhanced green fluorescent protein (EGFP)-tagged 
proteins using FuGENE HD transfection reagent (Roche Diagnostics) as previously described 
(Sang et al., 2005; Sang et al., 2007). Transformation efficiency was determined by EGFP 
expression using fluorescence microscopy. Expression of EGFP-tagged proteins was confirmed 
using both RT-PCR and immunoblotting with monoclonal anti-EGFP antibodies (1:8,000; 
Clontech). In addition, partial ORFs of porcine TLR3 and TLR7 fused to EGFP at their carboxyl 
terminus were generated. The partial ORFs were designed to express N-terminal extracellular 
and transmembrane domains (termed TLR3N and TLR7N) after truncation of 3'-cDNA regions 
encoding C-terminal TIR domains. Thus, these truncated mutants were used as functional 
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controls that would not induce signal transduction upon perceiving ligands (Kawai and Akira, 
2006; Werts et al., 2006). The expression of fused proteins was achieved by transfection of a 
HEK293A cell line (Invitrogen). Complete and truncated ORFs of TLR3 and TLR7 were 
expressed into appropriate proteins as predicted. Estimated molecular weights of porcine TLR3 
and TLR7 were 103.5 and 120.8 kDa, respectively, and the TLR3N and TLR7N proteins were 
24.3 and 28.9 KDa less, respectively, than their intact forms (Fig 4.3). 
4.5. Functional Induction of Interferon-Related Gene Expression 
Two reporter systems were used to characterize the function of porcine TLR3 and TLR7 in 
activating type I IFN-related gene expression. Two transcription factor genes, IFR-3 and IRF-7, 
which have been implicated in TLR3 (both) and TLR7 (primarily IRF-7) signaling pathways, 
were evaluated (Barton, 2007; Kawai and Akira, 2006; Pichlmair and Reis e Sousa, 2007; Severa 
and Fitzgerald, 2007). Briefly, promoter regions corresponding to human IRF-3 (-779/+1) 
(Lowther et al., 1999) and IRF-7 (-1123/+575) (Lu et al., 2001) were retrieved from human 
genomic DNA (Invitrogen) using a high-fidelity PCR kit (Invitrogen). The promoter regions 
were cloned into a luciferase reporter vector pGL4.14 [luc2/Hygro] (Promega, Madison, WI) 
through its Kpn I and Hind III multi-cloning sites. Cloning and plasmid purification procedures 
were conducted as described above (Sang et al., 2005). HEK293 cells were chosen because they 
have been shown to express low levels of endogenous TLRs and have been widely used for 
functional expression of TLR constructs (Invivogen) (Kariko et al., 2004). HEK-293A cells were 
cultured to 80% confluence and co-transfected with a pair of TLR and IFN related reporter 
constructs in 6-well culture plates (FuGENE HD, Roche Diagnostics). Twenty-four hours after 
transfection, the efficiency of transfection, estimated with green fluorescent proteins, was 50-
70% in different construct combinations. Cells were then trypsinized at 37˚C for 5 min and 
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collected by centrifugation at 500 × g for 10 min. After fresh medium was added (2 ml), single-
cell suspensions from each well of the 6-well plates were dispersed into wells of 96-well plates at 
a density of 5000 cells/well. Cells were cultured for 5 h to ensure adherence, and replenished 
with fresh medium plus agonists for TLR3 (poly I:C at 5 μg/ml, Invivogen), TLR7 (R837 at 5 
μg/ml, Invivogen), or vector-type adenovirus (pAd/CMV/V5-DEST-EGFP, Invitrogen) at a MOI 
of 1. Control wells contained fresh medium plus equal volumes of endotoxin-free water, which 
was used as the agonist vehicle. Sixteen hours later, cells were lysed and luciferase was detected 
simultaneously by addition of a Steady-Glo® luciferase assay reagent at 100 μl/well (Promega). 
After incubation for 10 min at 22˚C, luminescence was measured in a luminometer (Fluoroskan 
Ascent FL). TLR3 agonist stimulation of HEK293A cells that were co-transfected with TLR3 
and reporter constructs for IRF-3 or IRF-7 augmented induction of IRF-3 and IRF-7 promoter 
activity (Fig. 4.4A). TLR7 agonist stimulation in TLR7 co-transfected cells increased IRF-7, but 
not IRF-3 promoter activity (Fig. 4.4B). Adenoviral infection stimulated IRF reporter activity in 
all TLR3 and TLR7 transfected cells, except in cells transfected with TLR7 plus IRF-3 (Fig. 4.4 
C). 
Collectively, these data provide comparative molecular information for porcine TLR3 and 
TLR7. Importantly, functional overexpression of porcine TLR3 and TLR7 and subsequent 
agonist-induced stimulation of IFN-inducible genes in mammalian cells authenticates the 
molecular information. These findings may be useful in examining the role of porcine TLR3 and 
TLR7 in mediating immune responses against porcine viral diseases. 
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Fig. 4. 1A. Identification and phylogenic analysis of porcine TLR3. Schematic diagrams of 
cDNA and predicted conserved domains in peptide sequences are aligned (LRR_RI or 
COG4886, leucine-rich repeats (LRRs) domains; TIR, Toll/interleukin-1 receptor homology 
domain). Gene and protein sequence analyses were conducted with the CDD program at the 
NCBI website and ClustalW was used for phylogenic analysis. GenBankTM accession numbers of 
TLR3 homologues are: Bos taurus, AJ812026; Canis lupus, XM_540020; Homo sapiens, 
BC017954; Mus musculus, NM_126166; Bubalus bubalis, ABF59103; Macaca mulatta, 
AY864735; Rat norvegicus, NP_942086; Sus scrofa, DQ647698 and Oncorhynchus mykiss, 
AAX68425 
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 B Porcine TLR7
cDNA (3686 bp)  
Polypeptide (1050 aa)
Start codon Stop codon
120 nt 3270 nt
Phylogenic tree
100%
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Fig. 4. 1B. Identification and phylogenic analysis of porcine TLR7. Schematic diagrams of 
cDNA and predicted conserved domains in peptide sequences are aligned (LRR_RI or 
COG4886, leucine-rich repeats (LRRs) domains; TIR, Toll/interleukin-1 receptor homology 
domain). Gene and protein sequence analyses were conducted with the CDD program at the 
NCBI website and ClustalW was used for phylogenic analysis. GenBankTM accession numbers 
of TLR7 homologues are: Bos taurus, NP_001028933; Canis lupus, NP_001041589; Homo 
sapiens, NP_057646; Mus musculus, NP_573474; Macaca mulatta, XP_001095269; Rat 
norvegicus, XP_228909 and Sus scrofa, DQ647699. 
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Fig. 4.2. Tissue expression profiles of porcine TLR3 and TLR7. Total RNA (250 ng in 25 μl) 
was used to conduct one step RT-PCR. (A) Gels presented were run with 10 μl of amplicons at 
35 cycles for TLRs and 32 cycles for GAPDH. (B) Integrated density values of DNA bands were 
measured and standardized to the housekeeping gene, GAPDH, and presented as a ratio relative 
to the expression of GAPDH in the same samples. Data are means ± SD, n=3. 
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Fig. 4.3. Overexpression of porcine TLR3, TLR7 and corresponding TIR-domain truncated 
mutants (TLR3N and TLR7N respectively) in HEK293A cells. The overexpressed proteins are 
fused with EGFP at C-termini. Overexpression of EGFP-tagged proteins was detected using 
immunoblotting (upper) with monoclonal anti-EGFP antibodies (1:8,000; Clontech) and RT-
PCR (bottom) at both protein and RNA levels. The primers used for RT-PCR are listed in Table. 
4.1. 
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Fig. 4.4.  Induction of interferon regulatory factor promoter activity in HEK293A cells 
transfected with porcine TLR3 and TLR7. Promoter regions of IRF-3 and IRF-7 were amplified 
and cloned into a luciferase reporter vector pGL4.14 [luc2/Hygro]. Cells were co-transfected 
with a pair of TLR and reporter constructs as indicated in the X-axis legend. TIR-domain 
truncated null mutants, TLR3N and TLR7N were used as null tunction controls. Induction of 
reporter luciferase activity by agonists of (A) TLR3 (poly (I:C), at 5 μg/ml) (B) TLR7 (R837, at 
5 μg/ml) or (C) adenovirus was measured and standardized to controls; pGL4 = the empty 
reporter vector. Data are means ± SD, n=3, 9 *p<0.05 in comparison to the controls. 
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Table 4.1.  Primers used for PCR and RT-PCR 
 
Primers 
 
 
Primer sequences (5’ to 3’) 
 
accession 
numbers 
 
 
Location in 
cDNA (nt) 
TLR3 RACE  DQ647698  
5’ RACE-inner    TTGCCGGGAGGTCATCGGATATTT   555-531 
5’ RACE-outer    AGCTGAGAGAGCTCATTGTGTTGG  741-718 
3’ RACE-inner    GCACCATGCAGTTCAGCAAGCTAT  2893-2916 
3’ RACE-outer    CAGGTGCCCTTGAACTTGAAGCAA  2781-2804 
TLR3 RT-PCR    
    Sense 1 AAGAACTCACAGGCCAGGARTGGA  1731-1754 
    Antisense 1 AGCCGTGCTAAGTTGTTATGCTGM  2032-2009 
TLR3 clone    
    Sense ggaagcttATGTCTACCTACTTATGTACTGTTAGA 
CAT (underlined part, introduced for cloning) 
 470-496 
    Antisense 1 ccggatcccgATGTACTGAATTTCTTGAACCAAG  3132-3109 
    Antisense 2 ccggatccGCACTGTCTTTGCAGGGTGATGT  2520-2498 
    
TLR7 RACE  DQ647699  
5’ RACE-inner    AGTAACAGTTCTGGCCCAGGTAGA  672-649 
5’ RACE-outer    AGGGCAATTTCCACTTAGGTCCAG  902-879 
3’ RACE-inner    AAATCCACAGGCTCACCCGTACTT  3173-3196 
3’ RACE-outer    TCACCCAATTCCTGCTACGATGCT  2778-2801 
TLR7 RT-PCR    
    Sense ACAATGATATCGCCACCTCCACCA  1936-1959 
    Antisense TGGCCAAGGAGAGAGTCTTCAGAT  2172-2149 
TLR7 clone    
    Sense ggaagcttATGGCTAGATGGTTTCCTAAAACTCTG  197-220 
    Antisense 1 gaccgcggTGTCTCTTTGAACACCTGACT  3266-3246 
    Antisense 2 gaccgcggATGGTTAACCCACCAGACAAG  2522-2502 
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CHAPTER 5 - Toll-Like Receptor 3 (TLR3) Activation Decreases 
Porcine Arterivirus Infection 
ABSTRACT. Porcine reproductive and respiratory syndrome virus (PRRSV) is an RNA virus 
that initiates infection in pulmonary alveolar macrophages (PAMs), elicits weak immune 
responses, and establishes a persistent infection. To understand the role of dsRNA intermediates 
in eliciting host immunity, we sought to determine if Toll-like receptor-3 (TLR3), a well-known 
dsRNA sensor, is involved in the regulation of PRRSV infection.  TLR3 gene expression was 
increased in PAMs of congenitally infected 2-wk-old pigs. Stimulation of PAMs with dsRNA 
increased gene expression for TLR3 and interferon-β, and suppressed PRRSV infectivity.  To 
investigate activation and signaling parameters, expression constructs of wild-type and 
functional-domain-truncated porcine TLR3 were used in cell transfection studies. When cells 
that overexpressed porcine TLR3 were stimulated with dsRNA a rapid and robust calcium influx 
was induced. Moreover, ligand activation of porcine TLR3 expressed in MARC-145 cells 
elicited an antiviral response to PRRSV. Conversely, transfection of PAMs with small-
interfering RNA targeting porcine TLR3 resulted in up to 80% suppression of TLR3 mRNA 
expression and an increase in PRRSV infectivity.  These data provide fundamental genetic and 
molecular information for porcine TLR3, and implicate its involvement in PRRSV infection; 
findings that may suggest new strategies to limit this costly pandemic disease. 
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5.1. Introduction 
 
Although pigs are increasingly used as animal models for human diseases and for 
xenotransplantation (Cooper et al., 2007; Lunney, 2007), information about porcine receptors that 
recognize disease agents, particularly viruses, is limited.  The porcine arterivirus, porcine 
reproductive and respiratory syndrome virus (PRRSV), causes an economically significant 
pandemic viral disease in pigs (Holck et al., 2003; Neumann et al., 2005). This virus is one of the 
primary pathogens involved in the porcine respiratory disease complex, which causes severe 
respiratory disease in young pigs (Rossow et al., 2006; Stevenson, 2003; van Reeth, 1997). During 
late gestation, PRRSV infection results in reproductive failure including aborted, stillborn and 
weak-born pigs followed by decreases in conception and fertilization rates (Neumann et al., 2005; 
Rossow et al., 2006; Stevenson, 2003; van Reeth, 1997; Yoon, 2003). Although much has been 
learned about PRRSV since its initial appearance as “mystery swine disease” in the late 1980s, 
several aspects of the interaction of PRRSV with the host immune system remain unresolved 
(Murtaugh et al., 2002, 2003;  Neumann et al., 2005; Thacker, 2001).   
Immunity to PRRSV begins with the interaction between the virus and porcine cells, 
predominately pulmonary alveolar macrophages (PAMs), and intravascular macrophages of the 
placenta and umbilical cord (Oleksiewicz and Nielsen, 1999; Riber et al., 2004; 
Thanawongnuwech et al., 2000).  Recent studies have made progress in identifying a receptor for 
PRRSV (Calvert et al., 2007; Delputte et al., 2007; Kim et al., 2006; Shanmukhappa et al., 
2007); however, how porcine cells interact with PRRSV at early stages of innate immunity is 
largely unknown.  PRRSV is an enveloped, positive-sense, single-stranded RNA virus (Yoon, 
2003).  During replication, genomic and subgenomic RNAs participate in the formation of 
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several double-stranded intermediate structures (Yoon, 2003).  Interaction between PRRSV and 
macrophages likely alters the production of cytokines, including interferon (IFN)-α, IFN-β, IFN-
γ, and interleukin (IL)-10 (Carter and Curiel, 2005; Charerntanttanakul et al., 2006; Royaee et al., 
2004; Thanawongnuwech et al., 2000). Replication of PRRSV in monocyte-derived dendritic 
cells also leads to suboptimal induction of adaptive immunity (Wang et al., 2007). Although 
early upregulation of IFN-γ production, activation of NK cells and γδ T cells, and stimulation of 
protective antibody were found in PRRSV-infected pigs (Olin et al., 2005; Wesley et al., 2006), 
optimal immune protection was not achieved (Wang et al., 2007; Xiao et al., 2004). Despite 
significant efforts to identify immunogenic viral epitopes (de Lima et al., 2006; Plagemann, 
2006; Zhou et al., 2006) and to develop and optimize vaccines with various adjuvants, effective 
means to control this disease have not been achieved (Rompato et al., 2006; Charerntanttanakul 
et al., 2006; Royaee et al., 2004).  
Host cells use various receptors to perceive viral infections by recognizing pathogen-
associated molecular patterns (PAMPs) and subsequently induce an antiviral response (Kawai 
and Akira, 2006; Werts et al., 2006). Prominent among these are Toll-like receptors (TLRs). 
Currently, more than ten TLRs have been identified in humans and mice (Kawai and Akira, 
2006; Meylan and Tschopp et al., 2006; Werts et al., 2006).  Several TLRs perceive viral 
PAMPs, including: TLR3, which detects double-stranded RNA (dsRNA) derived from viral 
replication; TLR7 and TLR8, which recognize single-stranded RNA (ssRNA) fragments derived 
from viral genomes; and TLR9, which senses unmethylated cytosine-phosphate-guanine (CpG) 
motifs common to both bacterial and viral DNA.  A non-TLR cytosolic receptor, retinoic acid 
inducible gene I (RIG-I) that was originally thought to recognize dsRNA, binds to 5' triphosphate 
ssRNA (Hornung et al., 2006). TLR7, TLR8 and TLR9, likely form a functional subgroup within 
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the TLR family that recognizes viral PAMPs in endosomal or lysosomal compartments (Kawai 
and Akira, 2006; Meylan and Tschopp et al., 2006).  In contrast, the location of TLR3 varies 
depending on the viral infection and cell type, being expressed intracellularly or on the cell 
surface (Groskreutz et al., 2006; Meier et al., 2004; Schroder and Bowie, 2005).  After 
perceiving the presence of viral nucleic acids, these TLRs, such as TLR3, mediate the induction 
of type I IFNs through a signaling pathway involving adaptor proteins, myeloid differentiation 
factor 88 (MyD88) or Toll/IL-1R domain-containing adapter-inducing IFN-β protein (TRIF), 
elicit a rapid increase of intracellular calcium influx, activate the intermediate protein kinase 
cascade, and activate transcription factors including NF-κB and interferon regulatory factor 
(IRF)-3 and IRF-7.  Although several porcine TLRs have been identified (Meier et al., 2004; 
Shimosato et al., 2005; Shinkai et al., 2006; Tohno et al., 2005, 2006), identification and detailed 
studies on porcine TLRs responding to viral PAMPs are limited. We have recently reported the 
molecular identification and functional expression of porcine TLR3 (Sang et al. 2008).  Here we 
report the involvement of porcine TLR3 in PRRSV infection. Our findings show that activation 
of porcine TLR3 signaling is important in stimulating effective responses to PRRSV infection, a 
property that may be exploited by the virus to avoid eliciting effective immune responses and 
may suggest new strategies to limit this costly pandemic disease.      
 
5.2. Materials and Methods 
 
Virus strains and titration. The North American macrophage-tropic PRRSV strain, 
SDSU-23983-P6 (P6), was used to infect pigs as previously described (Kim et al., 2004; 
Rowland et al., 2001, 2003). All animal and virus procedures were approved by the Kansas State 
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University Institutional Animal Care and Use, and Biosafety Committees. MARC-145 cells, an 
African green monkey kidney cell line sensitive to PRRSV infection, was used to test PRRSV 
infectivity and for virus titration.  Virus stocks [SDSU-23983-P7 (P7)] collected from 
supernatant of P6-infected MARC-145 cells were used to infect cell cultures. The tissue culture 
50% infectious dose (TCID50) of P7 stocks was 107.25/ml. Cells were infected at a standard 
multiplicity of infection (MOI) of 0.1 TCID50/cell.  This MOI was chosen because quantities of 
the SDSU-23983 virus greater than 0.1 MOI do not enhance infectivity of MARC-145 cells 
(Rowland et al., 2001).  For titration, MARC-145 cells were cultured in MEM supplemented 
with 8% heat-inactivated fetal bovine serum (FBS) and antibiotics (100 IU penicillin and 100 
μg/ml streptomycin, Chemicon International, Inc., Temecula, CA) in a humidified 5% CO2, 95% 
air atmosphere at 37 °C.  Monolayers of MARC-145 cells in 96-well tissue culture plates were 
fixed with 80% cold acetone and incubated with fluorescent-labeled monoclonal antibodies to 
PRRSV nucleocapsid (N) protein (SDOW17; Rural Technologies, Inc., Brookings, SD).  
PRRSV-positive cells were identified by fluorescent microscopy.  
 
PRRSV infection and tissue sample collection. Fetal and young pig lung samples from an 
earlier study were used in which seronegative pregnant females were infected at 85-90 days of 
gestation with wild type P6 as described (Rowland et al., 2001, 2003). Infection of late gestation 
females is a standard model for the study of fetal and congenital PRRSV infection.  For the pigs 
that survive birth, the outcome is productively infected pigs with more severe disease (Rowland 
et al., 2001).  Animals were allowed to give birth and live-born pigs were euthanized at 14 days 
of age or fetuses were obtained at 107 and 112 days of gestation. Tissue samples were 
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immediately placed in RNAlater (Ambion, Inc. Austin, TX) and stored at -20 °C until used 
(Rowland et al., 2001).  
 
PAM collection and culture.  Porcine pulmonary alveolar macrophages (PAMs) were 
obtained by bronchoalveolar lavage from healthy 5-wk-old pigs (Chitko-McKown et al., 1991; 
Xiao et al., 2004). Lungs were lavaged with PBS and recovered lavage fluid was centrifuged at 
400 × g for 15 min. After washing with PBS, cells were resuspended in culture medium (RPMI 
1640, 10% fetal bovine sera, 5 mM HEPES, 1 mM glutamine, antibiotic-antimycotic, and 50 
mg/ml gentamicin; Invitrogen Life Technologies).  Cells were cultured in T75 flasks for 2 h in a 
humidified 5% CO2, 95% air atmosphere at 37 °C.  Adherent PAMs were collected by washing 
with cold (4 °C) PBS, counted and cryopreserved until used.  
             
Cell cultures and treatments. Two days before treatments or infection with PRRSV, 
PAMs were thawed from stocks and plated in 24- or 48-well tissue culture plates (7×104 or 
4×104 cells/well) in  supplemented RPMI 1640 medium and cultured in a humidified 5% CO2, 
95% air atmosphere at 37 °C.  After one-change of fresh medium 2 h later to remove non-
adherent cells, PAMs were cultured for 16 h with replenished medium containing the TLR3 
ligand, synthetic dsRNA (polyinosinic-polycytidilic acid; Invivogen, San Diego, CA) at 5 μg/ml. 
This concentration was chosen after dose-response tests using ranges of 1-25 μg/ml. 
Supernatants were collected for interferon assays and RNA was extracted with TRI reagent 
(Sigma-Aldrich, St. Louis, MO). Cells in duplicate wells were infected with PRRSV-P7 and 
replenished with fresh medium containing the indicated stimulators for 18 h. PAMs were directly 
stained for PRRSV N protein with a monoclonal antibody (SDOW17) and visualized with 
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TRITC-conjugated goat anti-mouse IgG. The PRRSV-positive cells were examined and counted 
using fluorescent microscopy.  
 
RT-PCR analysis. Total RNA was extracted with TRI reagent (Sigma-Aldrich) from cells 
or from frozen tissues ground in liquid nitrogen. Real-time and one-step RT-PCR assays 
(Qiagen) were used to detect expression of mRNA transcripts. Briefly, total RNA was treated 
with RQ1 RNase-free DNAse I (Promega) to remove possible genomic DNA contamination. For 
real-time RT-PCR a SYBR-Green-based assay (Qiagen) was performed on a SmartCycler 
(Cepheid, Sunnyvale, CA) as previously described (Sang et al., 2005, 2006).  Relative gene-
expression data were normalized against Ct values of the housekeeping gene glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) and the relative index (2-ΔΔCt) was determined in 
comparison to the average expression levels of control samples with the index defined as 1.000 
(Livak and Schmittgen, 2001). Semi-quantitative RT-PCR was performed using one-step RT-
PCR (Qiagen) at 32, 35, 38, or 40 cycles.  RNA samples (50-250 ng) were run in a 15 or 25-μl 
RT-PCR reaction mixture with 0.1 μM of each sense and antisense primer derived from cDNA 
sequences (Sang et al., 2008).  Generation of PCR primers, PCR data acquisition and 
standardization were conducted as described (Sang et al., 2005, 2006, 2008). 
 
Interferon bioassay.  Concentrations of type I IFN were measured using a bovine kidney 
cell line (MDBK) stably expressing a human MxA-promoter (Fray et al., 2001) in a luciferase 
reporter vector pGL4.14 [luc2/Hygro] (Promega, Madison, WI). Luminescence from the 
activated luciferase in IFN-treated cells was measured with a Steady-Glo® luciferase assay 
system (Promega) according to the manufacturer’s instructions. Standard curves were calculated 
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using recombinant human IFN-β (R&D Systems) at a concentration range of 0-1000 U/ml, and 
regression analysis between luminescence intensity and IFN concentration was conducted with 
an exponential growth model (SigmaPlot 9.0, Systat Software, Inc.).  
 
Construction and expression of porcine TLR3 and TLR3N cDNAs. Full-length cDNA of 
porcine TLR3 was obtained using RT-PCR and rapid amplification of cDNA ends as described 
(Sang et al., 2006, 2008).  In addition, the 3'-terminal region of TLR3 at 612 nt long, which is 
predicted to encode the cytoplasmic TIR/IL-1 domain, was truncated using PCR to create 
mutated TLR3, i.e., TLR3N. Purified plasmids were used to transfect HEK293A cells for 
expression of EGFP-tagged proteins using Fugene 6 transfection reagent (Roche Diagnostics) as 
described (Sang et al., 2008). Transformation efficiency was determined by enhanced green 
fluorescent protein (EGFP) expression using inverted fluorescence microscopy. After 
transformation (24 h), cells were collected and transformants were sorted by fluorescence-
activated flow cytometry (FACSVantage SE; Becton Dickenson). Overexpression of control 
EGFP and EGFP-fused TLR proteins was confirmed by both RT-PCR and immunoblotting. For 
immunoblotting, proteins were extracted with a mammalian protein extraction reagent (Pierce), 
separated on 4-20% precast sodium dodecyl sulfate (SDS)-polyacrylamide gels (Pierce) and 
transferred onto polyvinylidene difluoride blots. EGFP and EGFP-fused proteins were then 
detected with monoclonal anti-EGFP antibodies (1:8,000; Clontech) and visualized using a color 
development reaction catalyzed by alkaline phosphatase-conjugated secondary antibodies (Sang 
et al., 2005). 
 MARC-145 cells were transfected with pEGFP-TLR3 or pEGFP-TLR3N constructs using 
FuGENE® HD transfection reagent (Roche Diagnostics).  Cells were cultured in 24-well plates or 
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8-well chamber slides (Electron Microscopy Sciences, Hatfield, PA), and transfection was 
performed according to the manufacturer’s instructions. After transfection (24 h), cells (>20 % of 
EGFP positive cells) in different wells were treated with dsRNA (poly (I:C), 5 μg/ml), or 
incubated with monoclonal antibodies to EGFP (Clontech, Jl-8, 10 μg/ml) for 30 min then 
crosslinked with goat anti-mouse IgG (5 μg/ml, Sigma). Cells were then infected with PRRSV 
(P7) for 48 h (Kim et al., 2002; Rowland et al., 2003), and collected for RNA extraction and 
detection of viral RNA replication using RT-PCR.  Cells in chamber slides were fixed and 
permeablized with Fix/Perm solution (BD Biosciences).  Slides were then treated with a 
monoclonal antibody (SDOW17) to PRRSV N protein and treated with TRITC-conjugated goat 
anti-mouse IgG. After counterstaining nuclei with Hoechst 33342, the slides were examined 
using fluorescent microscopy for EGFP (transformed TLR3 or TLR3N) and TRITC (PRRSV).  
The influence of porcine TLR3 overexpression in mediating PRRSV infectivity was evaluated by 
comparison with TLR3N transfected and normal MARC-145 cells.  
 
Intracellular calcium measurement. TLR3-mediated calcium flux in transfected 
HEK293A cells was measured (1) using the calcium dyes Fluo-3-AM and Fura Red-AM 
(Molecular Probes).  HEK293A cells transfected with pEGFP-C3 constructs were sorted (45) 
and suspended at 5×106/ml in 1X Hanks’ balanced salt solution (HBSS) with Fluo-3 and Fura 
Red (2.6 μM Fluo-3 and 5.5 μM Fura Red). Cells were incubated at 37 °C for 30–45 min, 
washed once with 1X HBSS and resuspended at 1×106/ml. Aliquots (250 μl) were warmed to 37 
°C prior to measurement on a FACSCalibur flow cytometer (Becton Dickenson) equipped with 
argon and Red diode lasers.  Fluo-3 was detected at 530/30 nm and Fura Red at 610/20 nm. Cells 
were analyzed at a rate of ~1,000 events/s. After establishment of the baseline for about 20 s, 
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dsRNA was added to achieve a final concentration of 10 μg/ml. Recording commenced after 
replacing the tubes with the stimulator and continued for up to 204 s. Fluorescence signals of 
Fluo-3 and Fura Red were collected and the data were processed using flow cytometry analysis 
software (WinList 5.0, Verity Software House, Inc. Topsham, ME) to obtain the geometric mean 
fluorescence intensity every 2 s. The ratio of fluorescence intensity of Fluo-3 to Fura Red was 
plotted against time using SigmaPlot 9.0 (Systat Software, Inc. San Jose, CA).  
 
Confocal microscopy. Confocal laser microscopy was used to determine the cellular 
localization of the EGFP-tagged TLR3. Briefly, slides with >20% EGFP-positive cells were 
fixed and examined 24 h after transfection.  Media were removed and cells were washed once 
with Dulbecco’s phosphate buffered saline (DPBS; pH 7.4) and 1 ml of 4% 
paraformaldehyde/DPBS was added to each well. Cells were fixed for 30 min at 22 °C, nuclei 
were counterstained with Hoechst 33342 (0.12 μg/ml), and cells were rinsed twice with DPBS.  
Slides were mounted with ProLong® Antifade solution (Molecular Probes), and examined with a 
confocal laser scanning microscope (LSM 510, Zeiss). 
 
siRNA. Gene-specific siRNA for porcine TLR3 was designed (siRNA Target Finder 
http://www.ambion.com/techlib/misc/siRNA_finder.html) and matched to position 1088-1108 in 
the TLR3 cDNA sequence (5'-UGUCAAACUGAGCCCCAGUtt-3', GenBankTM accession 
number, DQ647698).  Sense and antisense sequences of the siRNA were synthesized (Qiagen). 
To facilitate the selection of efficient transfection reagents, an Alexa Fluor-488 (AF 488)-labeled 
scrambled siRNA (Qiagen), which was designed to not suppress any mammalian gene, also was 
used.  PAMs were seeded in a 24-well plate at 7×104 cells/well/0.5 ml, and transfected with 
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different reagents after 24 h according to the manufacturer’s instruction. Transfection efficiency 
was estimated using the AF 488-labeled scrambled siRNA and evaluated by inverted 
fluorescence microscopy after 24 h. The transfection reagent, HiPerfect™ (Qiagen) was used for 
transfection of TLR3 siRNA into PAMs. Twenty-four hours after siRNA transfection, cells were 
infected with PRRSV for an additional 24 h. Cells in different wells were collected for RNA 
extraction at 24 and 48 h, or fixed for PRRSV immunostaining as described.  Infection (%) was 
obtained by calculation of PRRSV-positive cells in ~500 randomly examined cells in each 
treatment.  
 
Statistical analysis. Data are presented as means ± SD.  Experimental data were analyzed by 
Student’s t- test and statistical significance was denoted at p < 0.05.     
   
5.3. Results 
Expression of porcine TLR3 in PRRSV-infected lungs and PAMs. Our initial approach in 
studying porcine TLR3 aimed to determine if it was expressed and regulated in PRRSV-infected 
animals and cells.  Indeed, porcine TLR3 was expressed in porcine lungs, and PAMs.  Upon 
PRRSV infection, expression of TLR3 mRNA was increased up to threefold in lungs of infected 
2-wk-old pigs from pregnant females that had been exposed to PRRSV in late gestation; 
however, TLR3 mRNA expression was not altered in fetuses from PRRSV-infected sows or in 
PAMs infected with PRRSV in vitro (Fig. 5. 1).  The absence of upregulated TLR3 in PAMs and 
fetuses does not reflect a lack of infection as PRRSV replication was clearly evident (Fig. 5.1).     
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TLR activation induces anti-PRRSV activity in PAMs and MARC-145 cells. 
Engagement of TLR3 with dsRNA caused a clear decrease in PRRSV infectivity in PAMs, 
indicated by almost no PRRSV-positive cells in the dsRNA-treated PAMs (Fig. 5.2).  In 
addition, the influence of TLR3 activation in MARC-145 cells on PRRSV infectivity also was 
evaluated. Consistent with the PAM data, dsRNA treatment suppressed PRRSV-infectivity in 
MARC-145 cells.  The effective concentration range of dsRNA tested on MARC-145 to suppress 
PRRSV infectivity was 0.5 to 25 μg/ml. More than 60% infectivity of PRRSV was inhibited by 
dsRNA at concentrations higher than 2.5 μg/ml, with the optimal suppressive dose at 5-10 μg/ml 
(data not shown).             
 
PRRSV infection and dsRNA treatment increases TLR3 and IFN-β gene expression and 
IFN-β activity. Treatment of PAMs with dsRNA for 6 h significantly increased expression of 
TLR3 mRNA three- to fourfold (Fig. 5.3A).  The increase in TLR3 mRNA expression was 
accompanied with a similar increase in IFN-β gene expression; however, IFN-α was not altered 
(Fig. 5.3A).  Similar to the gene expression data, dsRNA increased the production of type I IFNs 
in  PAMs as early as 5 h after treatment and the activity was equivalent to 40- and 158-fold 
increases in IFN-β at 5 and 10 h, respectively (Fig. 5.3B).  PRRSV-infected PAMs exhibited 
delayed and lower IFN-β activity compared to cells treated with dsRNA.  Supernatants from 
PRRSV-treated PAMs, had 30- and 60-fold increases in IFN-β activity at 10 and 24 h, 
respectively, compared to controls.   
 
Overexpression of porcine TLR3 and its truncated mutant. We recently reported the 
molecular identification and functional expression of porcine TLR3 (Sang et al., 2008).  Using 
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those findings to facilitate gain-of-function studies, we expressed whole or partial ORFs of 
porcine TLR3 fused to EGFP at their amino termini. The partial ORFs were designed to express 
N-terminal extracellular and transmembrane domains after truncation of the 3'-cDNA regions 
encoding the C-terminal TIR domains (named TLR3N). Thus, this truncated mutant was 
designed as a functional control that lacks the ability to induce signal transduction upon 
perceiving ligands (Kawai and Airka, 2006; Werts et al., 2006). Expression of fused proteins was 
first achieved by introducing TLR3 plasmid constructs into HEK293A cells. Shown in Fig. 5.4A 
are the expressed whole and truncated proteins encoded by the whole and truncated ORFs of 
TLR3.  Estimated molecular weight of porcine TLR3 is 103.5 kDa and TLR3N is 24.3 kDa less 
than its intact forms.  
 
Location and expression of functional porcine TLR3 in HEK293A cells. Before 
examining potential antiviral responses mediated by cells overexpressing porcine TLR3, we first 
identified its location and functional properties in HEK293A cells.  The transfection efficiency of 
HEK293A cells was consistently >50% with lipid-formulated reagents (Fugene 6 or HD, Roche).  
Cells treated with dsRNA displayed a small but authentic proportion of porcine TLR3 that 
localized on the cell surface (Fig. 5.4B). Importantly, porcine TLR3 expressed in HEK293A 
cells was biologically relevant as cells stimulated with dsRNA (10 μg/ml) exhibited a rapid and 
robust calcium influx (Fig. 5.4C). Before stimulation, cells transformed to express EGFP, EGFP-
TLR3N and EGFP-TLR3 all had similar basal levels of calcium influx.  
 
Activation of porcine TLR3 suppresses PRRSV infectivity.  To evaluate the role of TLR3 
in mediating anti-PRRSV activity, MARC-145 cells, an established cell line sensitive to PRRSV 
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infection, were transfected with EGFP-TLR3, or EGFP-TLR3N constructs; control cells were 
mock transfected. Treatment of cells with dsRNA suppressed PRRSV infectivity in transformed 
and non-transformed cells (Fig 5.5A); a finding that likely resulted from activation of 
endogenous TLR3.  To address this issue, anti-EGFP antibody plus secondary antibody was used 
to aggregate surface-expressed N-terminal EGFP fused to TLR3 in transformed cells (de 
Bouteiller et al., 2005).  Similar to dsRNA, aggregation of surface-expressed porcine TLR3 with 
anti-EGFP antibody also significantly decreased PRRSV infectivity.  This response was specific 
as antibody aggregation of TLR3 was only able to induce an antiviral response in EGFP-TLR3 
transformed cells, not in mock- or EGFP-TLR3N-transformed cells (Fig. 5.5A).  When PRRSV 
replication was evaluated by fluorescent microscopy, similar results were obtained, i.e., cross-
linking TLR3 with the anti-EGFP significantly decreased PRRSV infectivity (Fig. 5.5B).  TLR3 
in transfected cells colocalized with PRRSV N protein in cytoplasmic areas with some PRRSV 
detected with EGFP-TLR3 near the cell surface (Fig. 5.5C).   
 
Silencing porcine TLR3 decreases IFN-β mRNA expression and increases PRRSV 
infectivity in PAMs. To further investigate TLR3 involvement in PRRSV infection in PAMs, 
siRNA was used to silence endogenous TLR3. Optimal transfection conditions were established 
with an AF-488-labeled control siRNA (Qiagen) (Zhang et al., 2005). At 50 h after transfection, 
approximately 80% of cultured PAMs loaded with siRNA were successfully transfected as 
estimated with the control AF-488 siRNA. Transfection with siRNA for TLR3 decreased 
endogenous TLR3 mRNA expression 50-70% at 24 h, and 80% at 48 h (Fig. 5.6A). When 
compared to mock and scrambled siRNA-transfected cells, suppression of TLR3 in PAMs by 
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gene-specific siRNA caused six to eightfold increases in PRRSV-positive cells at 20 h after 
infection (Fig. 5.6B).   
 
5.4. Discussion 
 
 This study provides experimental support for three new findings concerning the involvement 
of TLR3 in porcine viral infections.  First, it provides the first molecular and functional 
characterization of porcine TLR3; data that are critical for comparative studies using porcine 
models for infection and immunity.  Second, it shows that activation of TLR3 produced 
significant antiviral responses to PRRSV and decreased replication of this economically 
significant porcine virus.  Third, it shows that cells with mutated or diminished TLR3 function 
exhibit increased PRRSV infection. These findings suggest that TLR3 is important for effective 
innate immunity to PRRSV.   
Similar to other mammals, pigs have an extensive repertoire of TLRs and, at the amino acid 
sequence level, generally show about 80% similarity to TLR orthologs from other mammalian 
species (Meier et al., 2004; Sang et al., 2008; Shimosato et al., 2005; Shinkai et al., 2006; Tohno 
et al., 2005, 2006).  Here we provide the first functional characterization of porcine TLR3, an 
innate immune receptor well characterized for its function in perceiving viral molecules. TLR3 
recognizes dsRNA originating from viruses or host cells. Other viral sensing TLRs, TLR7, TLR8 
and TLR9 recognize viral ssRNA and unmethylated CpG DNA in viral genomes (Kawai and 
Akira, 2006; Meylan and Tschopp, 2006; Schroder and Bowie, 2005). When we examined viral 
TLR gene expression in response to PRRSV infection in porcine lungs and PAMs, we found that 
TLR3 mRNA expression was increased in lungs of young pigs but not in lungs of fetal pigs or 
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PAMs.  The absence of upregulation of TLR3 in the fetal pig may reflect downregulation of in 
utero TH1 responses or the immaturity of the fetal immune system.  Expression of other TLR 
mRNA was not significantly influenced by PRRSV infection (data not shown). Several 
possibilities might explain the finding that PRRSV infection selectively influenced the 
expression of these viral TLRs. First, these innate immune receptors may be constitutively 
expressed in various tissues, and thus are not susceptible to significant upregulation.  Second, an 
increase in TLRs elicited by PRRSV infection may have occurred at an earlier time than when 
the samples were collected.  Third, it is possible that PRRSV has a mechanism to mitigate 
upregulation of TLRs.  
Because PAMs are a primary cell type for PRRSV infection, we examined expression of 
porcine TLR3 in PAMs and evaluated the influence of activating TLR3 on innate viral 
protection. Poly (I:C), a synthetic dsRNA TLR3 ligand, induced significant effects in PAMs 
yielding  protective responses against PRRSV infection. Porcine TLR3 and IFN-β were 
significantly increased by poly (I:C) treatment, which suggests that TLR3 was involved in the 
stimulation of IFN-β expression and the subsequent suppression of PRRSV infection.  After 
extensively comparing poly (I:C)-induced cytokine profiles in porcine PAMs and peritoneal 
macrophages, Loving et al. (2006) concluded that dsRNA induced cytokine expression in PAMs 
mainly via mediation of TLR3 and in peritoneal macrophages via PKR.  Similar to our findings 
in PAMs, treating MARC-145 cells with poly (I:C) also suppressed PRRSV infection, suggesting 
that poly (I:C) stimulated similar antiviral responses at least partially via TLR3 in MARC-145 
cells (Luo et al., 2008).          
To evaluate the contribution of the TLR3 pathway in anti-PRRSV responses, we conducted 
gain-of-function and loss-of-function studies. In gain-of-function experiments, EGFP-tagged 
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porcine TLR3 was functionally expressed in both HEK293A cells and MARC-145 cells.  Porcine 
TLR3, when overexpressed in MARC-145 cells, colocalized intracellularly with the virus 
nucleocapsid (N) protein (Fig. 5C). During virus replication and after transfection with PRRSV 
N gene constructs the N protein traffics through the nucleoplasm and accumulates in the 
nucleolus, where it forms an association with nucleolar proteins, such as fibrillarin (Dongwan et 
al., 2003; Rowland et al., 2003). Translocation of N protein across the nuclear pore complex is 
via a classic nuclear localization signal sequence (NLS). A second, nucleolar localization signal 
(NoLS) domain is involved in accumulating the protein in the nucleolus.  The localization of 
expressed EGFP-TLR3 is intriguing.  Analysis of the porcine TLR3 peptide sequence by the 
web-based program PSORT (Nakai and Kanehisa, 1992) identifies a NLS domain, PLCKRFK, 
beginning at amino acid 825. Another possibility for the accumulation of TLR3 in the 
nucleus/nucleolus is the co-translocation of TLR3 with N protein. The formation of a non-
covalent interaction with N and subsequent sequestration in the cytoplasm could represent a 
novel strategy for the prevention of newly synthesized TLR3 from reaching the cell surface. This 
property of TLR3 during virus infection deserves further investigation (Pei et al., 2008).   
Selective activation of transfected EGFP-TLR3 using antibody aggregation resulted in 
protective activity against PRRSV infection. Because only about 10% of the cells had EGFP-
TLR3 located on the surface and thus available for cross-linking by antibodies, the cells may 
exploit a communication pathway to transmit and enhance the signal from stimulated cells that 
have activated TLR3, perhaps analogous to the cross-priming function of TLR3 in dendritic cells 
to cytotoxic T cells (Schulz et al., 2005).  Overexpression of the null mutant, TLR3N, only 
slightly enhanced PRRSV infectivity in MARC-145 cells.  We reason that this finding likely 
resulted because PRRSV attains nearly saturated infectivity in MARC-145 cells.  The loss-of-
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function study using siRNA to TLR3 confirmed that TLR3 plays an irreplaceable role in 
perceiving dsRNA in PAMs and probably in inducing expression of IFN-β. Importantly, 
silencing endogenous TLR3 caused a clear increase of PRRSV infectivity; further implicating 
the importance of TLR3 in antiviral responses to PRRSV.  In addition to TLR3, PKR, RIG-I and 
melanoma differentiation-associated gene-5 (Mda-5) also have been implicated as dsRNA 
sensors (Gowen et al., 2007).  During preparation of this paper, a study reported that PRRSV 
suppresses IFN-β production primarily by interfering with the RIG-I signaling pathway and 
partially by suppression of TLR3 signaling in MARC-145 cells (Luo et al., 2008).   It is 
unknown whether PRRSV adopts a similar mechanism to escape innate immunity in porcine 
cells such as PAMs.  Our data, generated mostly in PAMs, show that TLR3 signaling is 
important for PAM antiviral responses to PRRSV.  It is possible that the TLR3-signaling 
pathway could be augmented in response to RIG-I signaling attenuation by PRRSV. Further 
investigation of the signaling pathways mediated by TLR3, RIG-I-like receptors, and Mda-5 in 
innate immune responses to PRRSV is needed.   
   Taken together, these findings suggest that activation of porcine TLR3 stimulates 
significant protective activity against PRRSV infection. The TLR3-mediated responses include 
production of type I IFNs.  Because production of type I IFNs has been reported to be 
compromised during PRRSV infection (Oleksiewicz and Nielson, 1999; Riber et al., 2004; 
Royaee et al., 2004), it is tempting to speculate that this virus may possess mechanisms to evade 
TLR3 activation in host immune cells.  This possibility warrants further investigation.  
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FIG. 5.1.  Expression of porcine TLR3 in PRRSV-infected lungs and alveolar macrophages.  
Lungs from fetal and 14-d-old pigs from pregnant females infected with PRRSV, and alveolar 
macrophages infected in vitro with PRRSV for 16 h were evaluated for mRNA expression of 
TLR3. Real time RT-PCR was conducted with gene-specific primers using total RNA (200 ng in 
25-μl PCR reaction). Relative gene-expression data were normalized against Ct values of the 
housekeeping gene, GAPDH, and the relative index (2-ΔΔCt) was determined in comparison to the 
average expression levels of control samples with the index defined as 1.000 (indicated by the 
horizontal line). Data are means ± SD, n=3. *Different from control, p < 0.05.  
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FIG. 5.2.  TLR3 ligand, dsRNA, decreases PRRSV-infection in porcine alveolar macrophages 
(PAMs).  PAMs were cultured in 48-well plates, treated with dsRNA and infected with PRRSV. 
Eighteen hours after infection, PAMs were stained for PRRSV N protein with a monoclonal 
antibody and visualized with TRITC-conjugated goat anti-mouse IgG. The PRRSV-positive cells 
were examined using fluorescent microscopy. Data are means ± SD, n=3 of 500 cell counted fore 
each repeat.*Different from control, p <0.001. 
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FIG. 5.3.  Stimulation of TLR3 and type I IFN expression by synthetic dsRNA, poly (I:C). (A) 
PAMs were cultured in 48-well plates and treated with dsRNA for 6 h and cells were collected 
for RNA detection with RT-PCR.   (B) Bioassay of porcine type I IFNs in PAM supernatants 
after stimulation with the TLR3 ligand, dsRNA and infection with PRRSV.  Data are activity 
equivalent to IFN-β. Data are means ± SD, n=3. *Different from control, p < 0.05. 
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FIG. 5.4.  Expression of functional porcine TLR3 in HEK293A cells. (A) Immunoblot of EGFP-
fused TLR3 and TIR-domain truncated TLR3 (TLR3N) in lysates of cells transfected with 
pEGFP-C3 constructs.  Cell lysates (50 µg) were resolved on a SDS-PAGE and immunoblotted. 
MW, prestained molecular mass markers. (B) Cell surface translocation of EGFP-tagged porcine 
TLR3 was stimulated by dsRNA (poly (I:C), 10 μg/ml) in transformed cells. Surface located 
EGFP-TLR3 was labeled with anti-EGFP mAb and detected with phycoerythrin (R-PE)-
conjugated goat anti-mouse IgG. The ratio of R-PE positive cells (FL2) in EGFP-positive cells 
(FL1) was quantified by flow cytometric analysis. (C) Stimulation of calcium influx in TLR3-
transformed HEK293A cells. Cells were loaded with calcium dyes Fluo-3 and Fura Red, 
stimulated with dsRNA (poly (I:C); fluorescence was detected with FL1 and FL2 detectors of a 
flow cytometer in the EGFP-positive cells, and the fluorescence ratio of Fluo-3/Fura red was 
analyzed with WinList 5.0.  
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FIG. 5.5.  Activation of porcine TLR3 suppresses PRRSV infectivity in MARC-145 cells. (A) 
MARC-145 cells were transformed with pEGFP-TLR3 or -TLR3N constructs in 24-well plates. 
Control and transformed cells were infected with PRRSV and stimulated with dsRNA (poly 
(I:C), 5 μg/ml) or anti-EGFP mAb (10 μg/ml) plus goat anti-mouse IgG (5 μg/ml) from 24 h 
after transfection.  Total RNA was extracted from cells collected from individual wells and 
TLR3, TLR3N, and PRRSV mRNA expression was detected using RT-PCR. (B) Cells were 
treated as in (A) but cultured in 8-well chamber slides. Cells were fixed with 4% 
paraformaldehyde in PBS at 48 h (24 h after PRRSV infection) and examined after 
immunostaining of PRRSV with a mAb (SDOW17) to viral nucleocapsid protein and detected 
with TRITC-conjugated goat anti-mouse IgG.   Representative images from the group treated 
with anti-EGFP antibodies are shown. PRRSV fluorescence data for all treatments are shown 
below the images. (C) Colocalization of EGFP-tagged porcine TLR3 with PRRSV in MARC-
145 cells. Samples were prepared as in (A) and examined by confocal microscopy.  The left 
image is EGFP-TLR3, the middle image is TRITC-labeled PRRSV, and the right image is a 
merged image of green (TLR3) and red (PRRSV) fluorescence.  Nuclei were stained with 
Hoechst 33342 as shown in the middle image.  Data in panels A and B are means ± SD, n=3. 
*Different from control, p < 0.05.  
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FIG. 5.6.  Silencing TLR3 increases PRRSV infectivity in porcine alveolar macrophages 
(PAMs).  (A) PAMs were cultured in 24-well plates and transfected with, siRNA dissolving 
buffer (Mock), Alexa Fluor 488 (AF 488)-labeled scrambled (sc) siRNA or gene-specific siRNA 
to porcine TLR3 (TLR3 siRNA) for 48 h. Cells in individual wells were collected for RNA 
extraction at 24 h and 48 h. Gene expression of TLR3 and GAPDH was assayed using RT-PCR 
and quantified as described in Fig. 5.  Data are means ± SD, n=3; different from mock-
transfected cells, **p < 0.01.  (B) Silencing TLR3 increases PRRSV infection. PAMs were 
transfected with siRNA and infected with PRRSV at 30 h after transfection.  Twenty hours after 
infection, PAMs were fixed and immunostained for PRRSV as in Fig. 5.   Infection (%) was 
obtained by calculation of PRRSV-positive cells in ~500 randomly examined cells in each 
treatment. 
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 CHAPTER 6 - OVERVIEW AND FUTURE PROSPECTS 
 
The general background and idea for this dissertation on innate antiviral immunity was 
reviewed in Chapter 1. This short chapter is written to summarize the studies in this dissertation 
and to highlight the theme of our project about innate antiviral immunity. Innate immunity is the 
first line of protection against infectious microorganisms. Early antiviral immune responses 
residing in innate immunity consist of (1) hindering viral entrance, (2) viral recognition and 
signal transduction, and (3) innate cell activation and synthesis of innate effector molecules to 
inactivate viruses. The evolution of adaptive immunity in vertebrate animals expands the ancient 
innate immunity into a more intricate defense system. Recent studies have highlighted the role of 
innate immune components in triggering adaptive immune defense. This dissertation focused on 
the second and third events of the innate immune cascade by functional characterization of some 
newly identified porcine innate molecules in a porcine viral disease model caused by PRRSV. 
Named “mystery disease” or “blue-ear disease” when it first appeared in the mid 1980's, PRRSV 
is the most devastating pathogen impacting the swine industry and a challenge for 
immunological studies and disease control. To date, few studies have reported on the role of 
porcine innate immunity in defense against PRRSV infection. 
Host defense peptides (HDPs), also known as antimicrobial peptides (AMPs), represent a 
large family of multifunctional innate immune effectors. Besides the well-known antimicrobial 
activity against a broad-spectrum of microorganisms, the new name reflects their role in 
immunomodulation, anti-endotoxins, wound healing and anti-cancer involvement. The antiviral 
activity of HDPs has been known for about two decades and was highlighted recently in effects 
against a series of human RNA and DNA viruses including herpes simplex virus (HSV), 
influenza virus and HIV. However, few studies have been conducted on porcine HDPs against 
porcine viral diseases. In Chapters 2 and 3, we focused on studies designed to complete the 
porcine HDP profile, and initially characterized their antiviral activity against PRRSV. 
Previously, only one porcine defensin had been identified. Using the combinational techniques of 
bioinformatics and molecular biology, we identified and characterized 11 novel porcine 
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defensins as described in Chapter 2. In Chapter 3, we evaluated the anti-PRRSV activity of eight 
selected HDPs which included porcine β-defensin-3 (pBD-3) and protegrin-4 (PG-4). Data 
showed that pBD-3 and PG-4 can effectively reduce PRRSV infectivity in a cell culture system. 
These findings demonstrate phylogenic conservation of multiple porcine β-defensins and suggest 
a potential role of porcine HDPs as a group of innate antiviral effectors.  
Another indication of the antiviral role of HDPs is their tissue distribution. HDPs are mostly 
synthesized or stored in internal and external mucosa, epithelial cells, skin cells, some leukocytes 
and intraepithelial immune cells. These tissue sites are often used by viruses to initiate their 
infection. Thus, upon viral presence at these sites, immediate innate recognition and well-
regulated expression of innate effectors (e.g. IFNs and HDPs) critically determine the 
effectiveness of local innate immune defense before the ramp-up of systemic adaptive immunity. 
Therefore, our other efforts in innate antiviral immunity have focused on the characterization of 
innate immune receptors, which function in perceiving viral molecules and mediating synthesis 
of innate immune effectors. TLRs are a main group of innate immune receptors. Particularly, 
TLR3, TLR7, TLR8 and TLR9 have been characterized for their role of recognizing viral nucleic 
acid and conveying antiviral signaling to mediate the expression of IFNs and probably HDPs. In 
Chapter 4, we cloned the full-length cDNA of porcine TLR3 and TLR7, examined their 
expression at RNA and protein levels, and functionally overexpressed them to show their 
capability in regulation of transcription factors of IRF. In Chapter 5, we concluded that porcine 
TLR3 is involved in anti-PRRSV innate immune responses. The conclusion was supported by 
the following evidence. First, PRRSV infection upregulated the expression of TLR3 in porcine 
alveolar macrophages (PAMs) and treating PAMs with TLR3 ligands, a synthetic dsRNA, 
suppressed PRRSV infectivity. We further demonstrated this by molecular manipulation of the 
TLR-3 gene in a cell culture system. Specific activation of porcine TLR3 overexpressed in 
MARC-145 cells elicited antiviral responses to PRRSV infection. Transfection of PAMs with 
small-interfering RNA targeting porcine TLR3, resulted in 50-80% suppression of TLR3 
expression and consequently increased PRRSV infectivity. In addition, porcine TLR3 is 
suggested to mediate cell responses including IFN-β production in anti-PRRSV process. In 
summary, Chapters 4 and 5 provide molecular information about porcine TLR3 and TLR7, and 
their mediation in PRRSV pathogenesis, which may provide new strategies to prevent this costly 
swine disease. 
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Studies included in this dissertation represent an initial exploration for the potential of 
applying innate immune mechanisms to aid in the prevention of an epidemic viral disease. The 
presented results were promising, but more questions were raised, such as: 
• What combinations of HDPs are most effective for controlling PRRSV in the lung, the 
primary infection site of PRRSV?  
• What are the mechanisms by which some HDPs inactivate PRRSV? 
• Besides TLR3, are other TLRs or non-TLR receptors involved in mediation of PRRSV 
pathogenesis?  
• What molecular patterns of PRRSV are recognized by TLR3 or other TLR? 
• In addition, considering the connection between TLRs and HDPs, how does viral 
recognition TLRs regulate HDP expression in PAMs or other innate immune cells? 
• PRRSV has been described for its ability to prevent optimal immune responses in pigs, 
thus PRRSV infection mostly results in a weak immune response and a persistent 
infection. Is it possible that PRRSV targets the components in TLR-mediated signaling 
transduction and prevents optimal immune responses?  
• Could PRRSV infection be controlled through modulating innate immune components 
including TLRs and HDPs?  
We welcome these questions, and will absolutely incorporate them into our future 
investigation in the area of innate antiviral immunity.   
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